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1 ABSTRACT 
Essential  hypertension  is  a  complex  multifactorial  condition  with  a  known  genetic 
component.  Several  lines  of evidence  suggest  a  contributory role  of adrenal  cortex 
function to the heritable component of  hypertension. 
In the human adrenal cortex, the enzymes 11 P-hydroxylase and aldosterone synthase are 
responsible for the final stages in the synthesis of cortisol and aldosterone respectively. 
The gene encoding 11 P-hydroxylase (  CYP 11 B  1) lies in tandem with the gene encoding 
aldosterone  synthase  (  CYP 11 B2)  on  chromosome  8.  The  two  genes  are  highly 
homologous  with the  main  differences  being  in  their  regulatory  regions,  as  ACTH 
primarily regulates CYP 11 B  1 whereas CYP 11 B2 is  under the control of angiotensin II 
and potassium. 
Variation  within  these  genes  has  been  implicated  in  certain  fonns  of hypertension. 
Mutations in CYP 11 B  1 and CYP 11 B2  account for the biochemical and haemodynamic 
abnormalities in the Dahl salt-sensitive rat.  In humans, mutations in CYP 11B2 and/or 
CYP 11B1  lead  to  the  rare  clinical  syndromes  of  glucocorticoid-suppressible 
hyperaldosteronism  and  11 P-hydroxylase  deficiency  that  are  associated  with 
mineralocorticoid  hypertension.  For these  reasons,  previous  studies  have  examined 
whether  polymorphisms  associated  with  CYP 11 B2  are  involved  in  hypertension. 
Several studies have reported that variation within the 5'UTR (-344 CIT) and intron 2 
(intron conversion (IC)) are associated with increased aldosterone levels and increased 
blood pressure. However, these findings have not always been confirmed and the  -344 
CIT  variation  seems  to  have  no  influence  on  aldosterone  biosynthesis  in  vitro. 
Paradoxically,  it  is  more  closely  associated  with  markers  of an  impaired  11 P-
hydroxylase  activity,  which draws  attention to  the  homologous  gene  CYP 11B1.  The 
studies  reported  in this  thesis  aimed  to  identify  the  pattern  of variation  across  the 
CYP 11 B1/CYP  11 B2 locus in order to determine the genetic variation responsible for the 
2 observed  impaired  11 ~-hydroxylation  and  its  link  with  aldosterone  levels  and 
hypertension. 
In  Chapter  3,  an  attempt  was  made  to  identify  polymorphisms  in  CYP 11 B1  that 
associate with hypertension and a raised aldosterone-to-renin ratio (ARR) and therefore 
might contribute to the genetic component of  these phenotypes.  No polymorphism was 
identified  that  could  account  for  either phenotype.  However,  eight  novel  missense 
mutations  were  identified  out  of 160  subjects  screened,  indicating  a  high  sequence 
variation. These were identified in exons 2 and 3 of the CYP 11 B  1 gene and alter the 
encoded amino acids; R43Q, L83S, H125R, P135S, Fl39L, L158P, L186V and T196A. 
These  variants  were  recreated  in  vitro  to  examine their effects  on enzyme  function. 
Enzyme activity was assessed by conversion of 11-deoxycortisol (S) to cortisol (F) and 
11-deoxycorticosterone (DOC) to corticosterone (B). 
The mutants L158P and L83S almost abolished enzyme function whilst R43Q, F139L 
and P135S and T196A enzymes resulted in product levels that were approximately 30% 
to  50%  that of wildtype  levels.  The  mutant enzymes  H125R and  L186V  resulted  in 
substrate-specific alterations in enzyme function.  H125R decreased conversion of S to 
F and L 186V increased S conversion.  Neither had an effect on the conversion of DOC 
to  B.  An attempt was  made to  assign these  residues  to  locations within the  protein 
molecule  using  homology-modelling  techniques.  This  confirmed  that  none  of the 
mutations are located within the putative active site.  The importance of these affected 
residues,  remote  from  the  active  site,  to  enzyme  function,  will  inform  subsequent 
studies of  structure/function relationships. 
The  study  in  Chapter  4  aimed  to  analyze  the  pattern  of variation  across  the 
CYP 11B2/B1 locus in detail. This confirmed that the overall sequence variation across 
the CYP 11 B locus is high and that there is tight linkage disequilibrium across the entire 
3 region with only 4 common haplotypes accounting for 68% of chromosomes in the data 
set.  The  detailed  sequencing  identified  several  candidate  polymorphisms  that  could 
account  for  the  observed  phenotypes,  including  increased  aldosterone  levels  and 
inefficient  11 ~-hydroxylase  function,  previously  associated  with  the  -344  CIT 
polymorphisms in CYP 11B2.  The polymorphisms identified within the coding regions 
of the  two  genes  were  either  synonomous  (CYP IIB2  Ser169Ser  and  Arg374Arg, 
CYP llBI  Leu75Leu  and  Asp82Asp)  or  are  known  to  have  no  affect  on  activity 
(CYP IIB2 Lysl73Arg).  The majority of variants were  identified in the  introns  and 
3'UTR ofCYP11B2 and CYPllBI and their functional effects remain to be determined. 
Of particular  interest,  due  to  their  potential  to  alter  gene  transcription,  was  the 
identification of2 in the 5' regulatory region of CYPllBI (-1889 G/T and -1859 A/G) 
and 7 within the 5' regulatory region of  CYP II  B2. 
In  Chapter  5,  the  frequency  and  phenotypic  associations  of the  newly  identified 
CYPllBI 5'UTR polymorphisms  -1889  G/T  and  -1859  A/G were  investigated in a 
hypertensive population.  The frequencies  were  found to  be  -1889  G-0.53,  T- 0.47;  -
1859 A-0.5, G-0.5.  Interestingly, the -1889 G/T and -1859 A/G polymorphisms were 
found  to  associate  with  an  impaired  11 ~-hydroxylase efficiency  in  a  hypertensive 
population.  The THS/total F ratio (index of liB-hydroxylase activity) was significantly 
higher  in -1889  TT  homozygotes  than  in  GG  homozygotes  (p  =  0.025).  A  similar 
pattern was seen with the -1859 SNP, with GG homozygotes tending to have a higher 
ratio than AA homozygotes (p = 0.056). 
These steroid data were  supported by the results from  Chapter 6 that examined the 
effects  of these  polymorphisms  in  vitro  using  luciferase  reporter  gene  constructs 
transfected  into  Yl  mouse  adrenal  cells.  There  was  no  significant  effect  on  basal 
expression  levels.  However,  the  construct  containing the  -1889  T  and  the  -1859  G 
alleles had a significantly reduced response to  stimulation with either 1  )..lM  ACTH (p < 
4 0.001)  or  lOJ.!M  Forskolin  (p  =  0.036)  when  compared  to  the  contrasting  allele 
combination. 
Evidence  of a  slightly reduced  11 P-hydroxylase  efficiency is  a  consistent finding  in 
subjects  with  essential  hypertension  when  compared  to  normotensive  controls. 
However, preliminary investigation of  the -1889 G/T and -1859 A/G polymorphisms in 
a hypertensive case-control population failed to show any association with hypertension 
(Chapter 5). 
In  summary,  these  studies  have  confirmed  that  the  CYP11B2  and  CYPllBI  genes 
contain  a  high  frequency  of genetic  variation.  Many  of the  variants  identified  in 
CYP llBI have been shown to  alter activity significantly.  There is  strong evidence to 
suggest that the impaired 11 P-hydroxylase efficiency previously associated with the  -
344 CIT and IC  variants in CYP11B2 is  due to linkage with the -1889 G/T and -1859 
AIG  polymorphisms  upstream  of  CYP  11 B I.  However,  the  causative  link  with 
hypertension and a raised ARR remains to be determined. 
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Angiotensin converting enzyme 
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+  -calmodulin-dependent protein kinase 
Congenital adrenal lipoid hyperplasia 
3 ', 5  '-Cyclic adenosine monophosphate 
CREB binding protein 
Complementary deoxyribonucleic acid 
Corticosteroid hormone induced factor 
Chloride ions 
Corticosterone methyl oxidase type I or II 
18 CNS 
COUP-TF 
CRE 
CREB 
CRH 
CYPIIAI 
CYPllBI 
CYPIIB2 
CYP17 
CYP21 
CYP450 
DAG 
DBD 
DBI 
DHEA 
DNA 
DMEM 
DNA 
DOC 
DOCA 
DMSO 
EDTA 
EMSA 
E 
ENaC 
EtOH 
F 
FAD 
FMN 
G protein 
GR 
GRE 
GSH 
GTP 
HDL 
HPA 
Central nervous system 
Chicken ovalbumin upstream promoter-transcription factor 
cAMP-response element 
cAMP-responsive element binding protein 
Corticotrophin-releasing hormone 
Gene encoding side-chain cleavage enzyme 
Gene encoding 11 P-hydroxylase 
Gene encoding aldosterone synthase 
Gene encoding 17-hydroxylase 
Gene encoding 21-Hydroxylase 
Cytochrome P450 enzymes 
1  ,2-Diacylglycerol 
DNA binding domain 
Diazepam-binding inhibitor 
Dehydroepiandrosterone 
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Cortisone 
Epithelial sodium channel 
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Glucocorticoid receptor 
Glucocorticoid response element 
Glucocorticoid suppressible hyperaldosteronism 
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RNA 
rpm 
RT-PCR 
s 
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TAE 
TBS 
TE 
THE 
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Pituitary homeobox 1 
Quantitative trait loci 
Renin-angiotensin system 
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Reverse transcription-polymerase chain reaction 
11-Deoxycortisol 
Steroidogenesis activator peptide 
Sterol carrier protein-2 
Steroidogenic factor 1 
Serum and glucocorticoid-regulated kinase 1 
Steroidogenesis-inducing protein 
Single nucleotide polymorphism 
Steroidogenic acute regulatory protein 
Tris-acetic EDTA buffer 
Tris-buffered saline 
Tris-HCl EDTA buffer 
Tetrahydrocortisone 
Tetrahydrocortisol 
Tetrahydrodeoxycortisol 
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22 1.1  Essential Hypertension 
Essential hypertension or hypertension of unknown cause  accounts  for  more  than 
90%  of cases of hypertension (Oparil  et a!  2003).  It is  a major clinical problem 
affecting  over 25%  of the  adult population worldwide  (Kearney  et a!  2005).  For 
diagnostic  purposes  hypertension  is  defined  as  resting  blood  pressure  levels 
repeatedly  above  140/90mm Hg  in  adults.  This  is  more  common in men than  in 
women and also in people aged over 65 than in younger people.  Blood pressure is a 
quantitative trait showing a continuous distribution within the population.  Therefore 
there  is  no  logical  sharp  boundary  between  'normal'  and  'abnormal'  values. 
Essential hypertension can be defined as the blood pressure value associated with an 
inceased risk of cardiovascular disease. At this elevated level of blood pressure, the 
risk of  myocardial infarction, stroke and heart failure is greatly increased (Mosterd et 
a!  1999) and the higher the blood pressure, the worse the  disease.  Cardiovascular 
diseases are responsible for approximately a third of all deaths (Kearney et a! 2005) 
and so  adequate control of blood pressure within the population is  a very important 
goal  both  clinically  and  economically.  The  current  understanding  of essential 
hypertension  is  that  it  is  a  complex  condition  resulting  from  the  interaction  of 
multiple genetic and environmental factors.  However, the identity of the genes that 
predispose to hypertension remains largely unknown. A better understanding of the 
contributing genetic factors would provide sites for targeted pharmacotherapy. 
In  the  following  sections  of this  review,  I  wish  to  explore  the  evidence  for  a 
contributory  role  of  adrenal  cortex  function  to  the  heritable  component  of 
hypertension.  I shall discuss briefly the general factors predisposing to hypertension 
including the evidence for a general genetic component.  The structure of  the adrenal 
23 gland and the biosynthestic pathways for the synthesis of its principal corticosteroid 
hormones,  cortisol  and aldosterone  will be  described.  The major effects  of these 
hormones and their mechanisms of action will be explained with particular attention 
to  the  ways  in  which  they  influence  blood  pressure.  A  description  of clinical 
syndromes of  corticosteroid deficiency or excess highlights their importance in blood 
pressure regulation.  However, to  address the  main aim of this review which is  to 
evaluate the  contribution of adrenocortical function to  the  heritable  component of 
hypertension requires  a detailed look at the  molecular genetics of aldosterone and 
cortisol  synthesis.  In  particular,  focusing  on  gene  and  enzyme  structure  and 
regulation of expression.  The  strong evidence  from  both animal  models and rare 
monogenic  forms  of human hypertension,  that modification of these  genes  affect 
blood pressure and cardiovascular function is presented.  Finally there is evidence to 
suggest that similar genetic  variation is  associated  with the  increasingly  common 
syndrome of  essential hypertension. 
From this review I will present the hypothesis that genetic variation within the genes 
responsible  for  aldosterone  and  cortisol  synthesis  act  not  only  independently  to 
increase risk but also interact in a previously unsuspected way.  This will form  the 
basis of  my experimental work. 
1.2  Environmental Risk Factors 
Evidence suggests that hypertension results from an interaction between genetic and 
environmental risk factors and that this accounts for the high prevalence of essential 
hypertension in industrialized countries (Kornitzer et al 1999).  The main modifiable 
risk  factors  are:  high salt intake,  alcohol  consumption,  obesity  and  low physical 
activity.  It seems likely that changes in these risk factors  have made an important 
24 contribution to the rapid rise in the frequency of  hypertension over recent years.  The 
evidence  for  the  contribution of each of the  main risk factors  is  reviewed briefly 
below. 
1.2.1  Salt Intake 
The  link  between  salt  intake  and  blood  pressure  seems  predictable  from  the 
relationship between salt and vascular volume homeostasis.  In 1972, Dahl found a 
correlation between urinary salt excretion and prevalence of hypertension in humans 
(Dahl  1972).  This  association  was  confirmed  by  the  large  international 
epidemiological  study,  INTERSALT,  which  revealed  an  association,  in  52 
populations, between sodium excretion and the increase in blood pressure with age. 
Sodium  excretion and  systolic  blood  pressure  were  also  found  to  be  related  after 
adjustment for  age,  gender, body mass index (BMI),  alcohol and potassium intake 
(Stamler  et  al  1989).  Several  meta-analyses  of randomized  clinical  trials  have 
confirmed  that  decreasing  salt  consumption  reduces  blood  pressure.  One  meta-
analysis comparing randomised clinical trials of hypertensive subjects with those of 
normotensive subjects concluded that salt reduction resulted in a significant decrease 
in  blood  pressure  in  hypertensive  individuals  and  a  small  non-significant  fall  in 
normotensives (Kornitzer et a/1999).  However, dietary sodium intake does not raise 
blood pressure in everyone, and distinction has  been made between 'salt sensitive' 
and 'salt resistant' individuals.  This phenotype is also observed in animal models of 
hypertension such as the Dahl salt sensitive hypertensive rat (Cicila et a/1993) (see 
section 1.15.1.1). 
25 1.2.2  Potassium Intake 
The  INTERSAL  T  study  also  showed  that  potassium  has  a  significant  inverse 
relationship  with  blood  pressure  in  individuals  after  correction  for  confounding 
factors.  Therefore, the  sodium/potassium ratio  is  significantly positively related to 
blood pressure (Stamler et al 1989).  This inverse relationship of potassium to blood 
pressure was confirmed in the Multiple Risk Factor Intervention trial (Stamler et al 
1997).  In an interventional study it was demonstrated that a diet of foods with high 
potassium content such as  fruit and vegetables significantly reduced blood pressure 
compared with a normal diet (Appel et a/1997). 
1.2.3  Alcohol Consumption 
The affect of alcohol intake on blood pressure depends on age and gender (Kornitzer 
et al 1999).  Long-term high alcohol consumption increases blood pressure but the 
precise nature  of the  relationship varies between studies.  The INTERSAL  T study 
found  an  association  between  high  alcohol  intake  (2:  300  ml/week)  and  the 
prevalence of  hypertension after adjusting for age, sex, BMI and urinary Na+ and K+ 
excretion (Stamler et al 1989).  In  a study of male  subjects,  alcohol intake could 
explain between 7 and  11%  of the  occurrence of hypertension (MacMahon 1987). 
Reducing alcohol intake has a favourable affect on both systolic and diastolic blood 
pressure in hypertensive subjects  (Puddey et a/1987). 
1.2.4  Obesity 
Many  population  studies  have  found  a  significant  association  between  BMI  and 
blood pressure (Kornitzer et al 1999).  The INTERSAL  T study found this to  be  an 
independent effect (Stamler  et al 1989).  Other studies  have  shown a favourable 
26 effect on blood pressure of  reduction of calorie intake or body weight in hypertensive 
subjects (Kornitzer et al 1999). 
1.2.5  Other Factors 
Many other environmental factors  can potentially affect a person's blood pressure. 
For example, a sedentary lifestyle, smoking and stress have all been associated with 
hypertension although the extent of their contribution is not always clear (Kornitzer 
et a/1999; Odermatt 2004).  In particular the contribution of stress to hypertension is 
unclear  as  it  is  hard  to  define  or  quantify  stress  and  there  is  a  high  degree  of 
variability between individuals. 
1.3  Evidence for a Genetic Component 
Heritability is defined as the total phenotypic variance in a trait that is due to additive 
genetic effects. Although environmental factors are known to play an important role 
in  the  pathogenesis  of  essential  hypertension,  evidence  from  family  and 
epidemiological studies  suggests that 30-60% of blood pressure variation within a 
population is genetic (Ward 1990). 
1.3.1  Family Studies 
Population studies such as  the one conducted in Tecumseh, Michigan, demonstrate 
that  there  is  a  greater  similarity of blood  pressure  within  families  than  between 
families  (Longini, Jr. et a/1984).  This is not simply due to a shared environment as 
there is a significant correlation of blood pressure between first-degree relatives but 
not between spouses who have been sharing the same environment for  1  0 years or 
more  (Havlik et al 1979; Miall et al 1967).  This  is  confirmed in adoption studies 
27 where there is a significant correlation of  blood pressure between parents and natural 
children or between natural  siblings  but  not  between these  and  adopted  children 
living in the same household (Biron et al1976).  The correlation of blood pressure is 
higher  between  monozygotic  than  dizygotic  twins,  strongly  suggesting  that  a 
proportion of the population variation of blood pressure  is  genetically determined 
(Feinleib et al 1977).  The genetic contribution can be quantified using the sibling to 
risk ratio (lambda-S).  This compares the prevalence of hypertension in sibships to 
the prevalence in the general population.  A lambda-S > 2 is  believed to  indicate a 
significant genetic component.  The lambda-S for hypertension is roughly 3.5 (Jones 
1999). 
1.4  Identifying the Genes Involved 
Having established that essential hypertension is  a complex quantitative trait with a 
strong genetic component, there are  several methods to  determine which genes  (or 
quantitative trait loci (QTL) contribute to  blood pressure).  The two  main methods 
for identifying the genes involved are genome wide scans and candidate gene studies. 
For human subjects, investigations are conducted either as  family studies consisting 
of affected members (usually sibling pairs) or as association studies where groups of 
hypertensive and normotensive subjects are compared. 
A genome wide scan uses random genetic markers spread over the entire genome to 
identify a QTL that associates with blood pressure.  This method allows the detection 
of novel susceptibility genes that a candidate gene approach would miss.  However, 
an identified QTL will typically consist of a large  chromosomal region containing 
100-300  genes  and further,  more  stringent linkage  mapping must be  performed to 
28 reduce the locus and focus on fewer relevant genes.  Each of these genes must then 
be examined for variants. 
The candidate gene approach is based on a prior knowledge of the pathophysiology 
of  hypertension, which will suggest potential causative genes. There are several lines 
of evidence  suggesting  a  contributory  role  of adrenal  corticosteroids  in  essential 
hypertension  and  therefore  that  the  genes  encoding  the  enzymes  for  their 
biosynthesis may be key candidates. 
1.5  Structure of the Adrenal Gland 
The adrenal glands are paired pyramidal-shaped organs situated above each kidney. 
Each comprises an inner medulla and a surrounding cortex (see figure  1.1).  The 
cortex  is  divided  into  3  layers: zona glomerulosa,  zona fasciculata  and  the  zona 
reticularis.  These  3  zones  are  histologically  and  enzymatically  distinct  with  the 
steroid hormones produced by each of the zones being dependent on which enzymes 
are present in the cells of  that zone. 
Capsule -1:: 
Capsule----...,.": 
Ad enal cortex 
Adrenal medulla { 
} 
] - zona glamerulosa 
Zona fascicular.a 
}-z,,,"  '"''"'" 
}Adrenal medulla 
Figure 1.1.  Cross section of the adrenal gland showing the distinct layers of the 
adrenal cortex 
(Taken from the McGraw-Hill online learning center; Ch20 Endocrine System 
http://highered. mcgraw-hill.  com) 
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Corticosteroids are  hormones produced by the  adrenal cortex that are  essential for 
life.  The  adrenal corticosteroids secreted by the  cortex are  divided into  two  main 
groups:  the  mineralocorticoids  and  the  glucocorticoids.  The  mineralocorticoid 
aldosterone is synthesised in the zona glomerulosa and affects water and electrolyte 
homeostasis. The glucocorticoids, cortisol in man and corticosterone in the rat, are 
synthesised  in  the  zona  fasciculata  and  control  carbohydrate,  fat  and  protein 
metabolism as well as contributing to the control of the immune response. The zona 
reticularis  is  the  site  of sex  steroid  synthesis  (mainly  the  androgen  precursors 
dehydroepiandrosterone (DHEA) and androstendione (A'dione)). 
Corticosteroids are a group of C21  steroids characterized by a double bond at C-4, a 
C-21  hydroxyl group and an oxo group at C-20.  A hydroxyl group or an oxo group 
may or may not be present at C-11. The presence or absence of a hydroxyl group at 
C-17  differentiates  the  17 -oxygenated  corticosteroids,  such  as  cortisol  or  11-
deoxycortisol (S)  from  the  17-deoxycorticosteroids such as  11-deoxycorticosterone 
(DOC),  corticosterone (B)  and aldosterone.  The  chemical and common names  for 
some  of the  adrenal  steroids  are  listed in table  1.1  and the  structure of the  more 
important  ones  are  shown in figure  1.2.  It is  possible  to  relate  these  structural 
features to their biological activities.  For example the presence of hydroxyl groups 
at C-17 and C-11  enhances glucocorticoid activity so that cortisol is the most active, 
whereas absence of a C-17 hydroxyl group results  in mineralocorticoid activity eg 
DOC.  Aldosterone  contains  a  hydroxyl  group  at  C-11  but  is  unique  in  that  it 
contains an aldehyde group on C-18.  The close proximity of these groups results in 
30 hemi-acetyl formation, reducing the influence of the C-11  hydroxyl group and hence 
decreasing glucocorticoid activity. 
All of  the adrenal steroids are synthesised from a common substrate, cholesterol, by a 
series  of enzymatic  conversions  performed  by two  types  of enzyme:  cytochrome 
P450 and hydroxysteroid dehydrogenase enzymes. 
Common name  Abbreviation  Systematic name 
cholesterol  c  cholest-5-en-3 ~-ol 
pregnenolone  PREG  3  ~-hydroxypregn-5  -ene-20-one 
progesterone  p  pregn-4-ene-3  ,20-dione 
17-hydroxypregenolone  17-0H-PREG  3  ~, 17a-dihydroxypregn-5-ene-20-one 
17-hydroxyprogesterone  17-0H-P  17a-hydroxypregn-4-ene-3,20-dione 
dehydroepiandrosterone  DHEA  3  ~-hydroxyandrost-5-ene-17  -one 
androstenedione  A'dione  androst-4-ene-3,17-dione 
11-deoxycortiso  I  s  17a,21-dihydroxypregn-4-ene-3,20-dione 
cortisol  F  11 ~' 17a,21-trihydroxypregn-4-ene-3,20-dione 
cortisone  E  17a,21-dihydroxypregn-4-ene-3, 11 ,20-trione 
11-deoxycorticosterone  DOC  21-hydroxypregn-4-ene-3  ,20-dione 
corticosterone  B  11 ~,21-dihydroxypregn-4-ene-3  ,20-dione 
IS-hydroxycorticosterone  18-0H-B  11 ~,  18,21-trihydroxypregn-4-ene-3,20-dione 
aldosterone  AI do  11 ~,21-dihydroxypregn-4-ene-3  ,20-dione-18-al 
Table 1.1.  Common and systematic names and abbreviations of some important 
adrenal steroids 
31 Cholesterol 
CH20H 
11-Deoxycorticosterone 
(DOC) 
Aldosterone 
(Aido) 
CH 20H 
0 
11-Deoxycortisol 
(S) 
IS-hydroxycorticosterone 
CH20H 
OH 
(F) 
Figure 1.2.  Steroid structures and common names 
32 1. 7  Cytochrome P450 Enzymes 
Cytochrome P450  (CYP450)  enzymes  form  a large  superfamily present in all  life 
forms  that  catalyze  the  mono-oxygenation  (hydroxylation)  of a  diverse  range  of 
substrates.  A total of nearly 4000 CYP450 genes have now been identified.  Their 
main functions  in humans  are  xenobiotic  metabolism  within the  liver and  steroid 
synthesis  within the  endocrine  glands  such  as  the  gonads  and  the  adrenal  cortex. 
Five CYP450s are involved in the synthesis of steroids in humans. 
CYP450 enzymes are mixed function oxygenases that catalyze the incorporation of 
one oxygen atom from an oxygen molecule into the substrate and reducing the other 
to  water.  All these enzymes possess a covalently bound haem prosthetic group to 
manipulate oxygen and electrons.  They are dependant on molecular oxygen (02) and 
electrons donated by NADPH in the following stoichiometry: 
R-H + NADPH + H+ + 02 ---7 R-OH = NADP+ +H20 
Each of the steroid hydroxylation reactions involves a two-electron reduction of one 
molecule  of oxygen  with  concomitant  oxygenation  of various  substrates.  The 
CYP450 enzymes, which are divided into 2 biochemical classes, mitochondrial and 
microsomal, are the terminal components of an electron transport system.  The type I 
enzymes (side chain cleavage (P450scc), liP-hydroxylase (P450u~) and aldosterone 
synthase  (P450aldo))  are  part  of a  system  located  on  the  inner  mitochondrial 
membrane,  comprising  NADPH,  adrenodoxin  reductase  (a  FAD-containing 
flavoprotein)  and  the  iron  sulphur protein (2Fe-2S)  adrenodoxin (see  figure  1.3). 
Two high-energy electrons are transferred from NADPH to the FAD of adrenodoxin 
reductase. Adrenodoxin accepts electrons from adrenodoxin reductase one at a time 
33 and transfers them to the haem iron of  the cytochrome P450 enzyme, which is bound 
to  the inner mitochondrial membrane (Bernhardt et al 1998). Type II enzymes (21-
hydroxylase  (P450c21)  and  17-hydroxylase  (P450c17))  are  located  within  the 
endoplasmic reticulum and rely on a single NADPH-specific P450 oxidoreductase 
for  the transfer of electrons (see  figure  1.3).  In some  cases, this transfer may be 
assisted by cytochrome b5. 
Mitochondrial 
2 e- DONOR 
NADPH+W 
NADP• 
Microsomal 
2 e- DONOR 
NADPH +W 
Figure 1.3.  Electron transport chains of mitochondrial and microsomal P450 
monooxygenases. 
Electrons  are  transferred  from  NADPH  through  NADPH-adrenodoxin  reductase 
(ADR)  and  adrenodoxin  (ADX)  to  mitochondrial  P450  or  through  P450 
oxidoreductase to microsomal P450 to exhibit the monooxygenase activity. 
RH and ROH indicate the substrate and the product, respectively. 
(Adaptedfi·om Kominami et al 1984) 
The  CYP450  reaction  involves  cyclic  oxidation/reduction of the  P450-containing 
haem iron in conjunction with substrate binding and oxygen activation.  The cycle is 
initiated by substrate binding which induces a conformational change that activates 
the  CYP450 from  its resting state to  form  a high-spin ferric  (Fe
3+)  complex on the 
haem  iron.  This  substrate-bound  complex  has  a  much  greater  +ve  reduction 
potential.  The  subsequent  reduction  of the  haem  iron  by  two  electrons  enables 
oxygen binding,  the  breaking  of the  0-0 bond  within molecular oxygen  and  the 
transfer of  one oxygen atom to the substrate to yield the oxidised product. 
34 Many CYP450s  can bind more than one  structurally distinct substrate due  to their 
ability to undergo conformational changes, making them an exception to the classic 
'lock and key' concept of enzyme function. 
Evidence  suggests  that adrenodoxin  does  not  form  a  static  ternary  complex  with 
adrenodoxin reductase and CYP450 but that it functions as a mobile electron shuttle. 
Each of  these associations is dependent on ionic interactions between complementary 
charged  residues.  Site-directed  mutagenesis  studies  have  shown  that  CYP450s 
interact with adrenodoxin at specific  amino  acid residues  and  that changes  in the 
primary sequence of the CYP450 or adrenodoxin can alter the interaction.  Factors 
affecting  this  interaction,  the  amount  of  adrenodoxin  or  its  electron  transfer 
properties can affect the level or pattern of adrenal steroid biosynthesis (Beckert & 
Bernhardt  1997).  The  electron  transfer  proteins  are  not  specific  to  individual 
CYP450s.  Therefore, adrenodoxin is able to interact with P450scc as well as P4501  1 ~ 
and  P450aldo·  Competition  for  electrons  from  the  adrenodoxin,  among  the  P450 
enzymes can also alter the pattern of  product yields. 
1.8  Corticosteroidogenesis 
The sequence of reactions which converts cholesterol to corticosteroids in the human 
adrenal cortex are illustrated in figure 1.4.  For steroidogenesis to occur, cholesterol 
must first be delivered to the mitochondrion. 
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Figure 1.4.  Major pathways of corticosteroid biosynthesis in human adrenal 
cortex. 
36 1.8.1  Cholesterol Uptake 
The  first  stage  in  the  biosynthesis  of all  adrenal  steroids  is  the  cleavage  of 
cholesterols  side  chain  by  the  cytochrome  P450  side  chain  cleavage  enzyme 
(P450scc),  encoded by CYPllAI, to  produce pregnenolone  (see  figure  1.4).  The 
rate-limiting  step of adrenal  steroidogenesis  is  the  uptake of cholesterol,  which is 
hydrophobic, across the aqueous intermembrane space of the mitochondrion to  the 
inner mitochondrial  membrane  where  P450scc  is  located  (Black  et al  1994)  (see 
figure 1.5). 
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The main supply of cholesterol to adrenal cells in man is from the circulation in the 
form oflow-density lipoprotein cholesterol (Gwynne & Strauss 1982) whereas in rats 
the main source is from high-density lipoproteins (Gwynne & Mahaffee 1989).  The 
cholesterol can then be  stored within the  cell  in lipid droplet stores  as  cholesterol 
37 esters.  A  low level  of de  novo  synthesis  of cholesterol from  acetate  also  occurs 
within  the  adrenal  cortex  (Borkowski  et  al  1967).  Upon  stimulation,  these 
intracellular cholesterol-containing vesicles are transported to the mitochondria along 
the  cytoskeleton fibres  of the  cells.  Free cholesterol is  then transported across  the 
intermembrane space to the inner mitochondrial membrane by mechanisms still not 
well  understood.  Several putative regulatory proteins have  been identified;  sterol 
carrier protein-2  (SCP-2)  (Vahouny  et al 1985),  steroidogenesis  activator protein 
(SAP)  (Frustaci  et  al  1989;  Pedersen  &  Brownie  1983),  the  mitochondrial 
benzodiazepine  receptor  (PBR)  and  its  endogenous  ligand  diazepam-binding 
inhibitor (DBI) (Papadopoulos 1993) and the steroidogenic acute regulatory (StAR) 
protein  which  has  been  the  most  widely  studied  and  has  the  most  compelling 
evidence for this role (Clark et al1994).  This is considered in more detail below. 
1.8.2  Steroidogenic acute regulatory (StAR) protein 
StAR  is  synthesised  as  a  37-kDa  cytosolic  precursor  with  an  N-terminal 
mitochondrial-signalling  sequence,  which  upon  hormonal  stimulation  can  be 
imported and modified by the  mitochondria to  a mature  30-kDa form  (Epstein & 
Orme-Johnson 1991 ).  Several studies have shown that the synthesis of the 30-kDa 
protein correlates  with the  synthesis  of steroids  (Epstein  &  Orme-J  ohnson  1991; 
Krueger  &  Orme-Johnson  1983).  In  vitro  studies  have  demonstrated  that 
transfection of either MA-10 murine Leydig tumour cells or COS-1  cells with the 
eDNA  of the  StAR  precursor  protein  increases  the  conversion  of cholesterol  to 
pregnenelone (Clark et al1994; Sugawara et al1995). 
Perhaps the most compelling evidence for the role of StAR in steroidogenesis came 
when  several  nonsense  mutations  within  its  gene  were  identified  as  causing  the 
38 disorder, congenital lipoid adrenal hyperplasia (lipoid CAH) (Lin et al 1995).  Lipoid 
CAH  is  a  lethal,  inherited  disorder  characterized  by  severely  impaired  steroid 
hormone  biosynthesis  and  enlarged  adrenal  glands  containing  high  levels  of 
cholesterol  and  cholesterol  esters  due  to  the  impaired  delivery  of cholesterol  to 
P450scc.  Targeted disruption of  the StAR gene to produce knock-out mice results in 
a similar phenotype to  that of congenital  adrenal  hyperplasia  (Caron et al  1997; 
Hasegawa et al2000). 
The  mechanism  by  which  StAR  regulates  cholesterol  transfer  to  the  inner 
mitochondria remains unclear.  It was thought that during the import of StAR into the 
mitochondria,  contact sites  form  between the  outer and inner membrane  allowing 
cholesterol  import  (Stocco  &  Clark  1996).  However,  studies  using  recombinant 
StAR proteins  lacking the  mitochondrial  import sequence  have  biological activity 
equivalent  to  wildtype  StAR,  demonstrating  that  mitochondrial  import  is  not 
essential  for  activity  (Arakane  et  al  1998;  Bose  et  al  2002).  Moreover, 
adrenocortical mitochondria have  characteristically tubular cristae,  which may not 
form such contact sites. 
1.8.3  Cholesterol side-chain cleavage enzyme (P450scc) 
This  first  step  in the  synthesis  of all  steroids  is  the  cleavage  of the  side-chain of 
cholesterol by the cholesterol side-chain cleavage enzyme (P450scc).  It is located on 
the inner mitochondrial membrane and catalyzes the conversion of C27 cholesterol to 
C21  pregnenolone  by 3  separate  reactions:  20a-hydroxylation,  22a-hydroxylation 
and  a  C20-22  bond  scission.  The  location  of  this  enzyme  highlighted  the 
mitochondria  as  an  important  site  for  cholesterol  delivery.  The  CYP IIAI  gene 
located on chromosome 15 encodes for P450scc. 
39 1.8.4  3f3Hydroxysteroid dehydrogenase (3/3-HSD) 
The  product  of  side  chain  cleavage  of  cholesterol,  pregnenolone,  exits  the 
mitochondria and is converted within the cytoplasm by the enzyme  3~-HSD  to form 
progesterone.  3~-HSD also  converts  17-hydroxypregnenolone,  which  is  formed 
from  pregnenolone by CYP 17 (see  section  1.8.5), to  17-hydroxyprogesterone, and 
dehydroepiandrosterone  (DHEA)  to  androstenedione.  3~-HSD is  a member of the 
microsomal short chain dehydrogenase family and the only non-P450 enzyme in the 
pathway. Two isoenzymes have been identified in the human (3~-HSD1 and 2).  The 
isoforms  are  encoded by separate genes that lie  in tandem on chromosome  1,  3  J3-
HSD1 and 3j3-HSD 2 respectively (Berube et a/1989; Lachance et a/1991).  It is the 
3~-HSD2  isoform that is found in the adrenals and gonads (Lachance et a/1991). 
1.8.5  17a-Hydroxylase(P450c17) 
Progesterone  and  pregnenolone  are  both  'hydroxylated'  by  the  enzyme  17a-
hydroxylase (P450c17), which is encoded by the CYP 17 gene on chromosome 10, to 
produce  170H-progesterone  and  170H-pregnenolone  respectively  (Sparkes  et al 
1991 ).  This  17 a-hydroxylation step  is  essential  for  glucocorticoid,  androgen  and 
oestrogen synthesis. 170H-Progesterone and 170H-pregnenolone are converted by a 
17,20 lyase reaction catalyzed by the same enzyme to  form  the adrenal androgens, 
androstenedione  and  dehydroepiandrosterone  (DHEA)  respectively.  The  zona 
glomerulosa,  where  pregnenolone  is  converted  to  produce  the  mineralocorticoid 
aldosterone,  does  not  express  P450c17.  Therefore,  P450c17  is  important  in 
determining the zone specific nature of  adrenal steroid synthesis. 
40 1.8.6  21-Hydroxylase (P450c21) 
The  enzyme  2I-hydroxylase  (P450c2I)  1s  encoded  by  the  CYP2I  gene  on 
chromosome 6 (White et ali9S6).  P450c2I performs 2I-hydroxylations to produce 
II-deoxycorticosterone  (DOC)  or  II-deoxycortisol  (S)  from  either  progesterone 
(zona glomerulosa) or 17-0H progesterone (zona fasciculata) respectively.  P450c2I 
is expressed in all three zones of  the adrenal cortex (Shinzawa et ali9SS). 
1.8. 7  Aldosterone Synthase (P450atdo) 
The  final  steps  in  the  synthesis  of  mineralocorticoids  (aldosterone)  and 
glucocorticoids  (cortisol)  were  originally  thought  to  be  performed  by  a  single 
enzyme encoded by a single gene locus (Miller I9S7).  This is indeed the case of  the 
bovine,  porcine  and  frog  enzyme(Nonaka  et  al  I99I;  Ogishima  et  al  I9S9). 
However  in man,  rat  and  mouse  the  final  stages  are  performed  by two  distinct 
enzymes.  The  three  terminal  stages  in  the  synthesis  of  aldosterone  (II-
hydroxylation,  IS-hydroxylation and dehydration) are all carried out by the enzyme 
aldosterone  synthase  (P450atct0),  which  is  encoded  by  the  CYP II  B2  gene  on 
chromosome  S (Curnow  et  al  I99I; Kawamoto  et al  I992;  Momet et al  I9S9). 
P450atdo is expressed exclusively in the zona glomerulosa of  the adrenal cortex where 
it performs the following reactions: 
I.  II  ~-hydroxylation of  DOC to form corticosterone 
2.  IS-hydroxylation of  B, producing IS-hydroxycorticosterone (lS-OHB) 
3.  IS-oxidation of IS-OHB, resulting in aldosterone 
41 In vitro studies have demonstrated that DOC is the preferred substrate ofP450aldo and 
that it remains  bound to  the  active  site throughout these reactions with B and  18-
0HB only being released as by-products (Denner et al 1995). 
1.8.8  11/3-hydroxylase (P45011p) 
The  final  stage  in the  synthesis of cortisol  (or corticosterone in the  rat)  is  an  11-
hydroxylation by the enzyme  11 P-hydroxylase (P450ll 13)  encoded by the CYP 11 Bl 
gene  on chromosome  8 (or  7 in the  rat)  (Momet et al  1989).  This  converts  11-
deoxycortisol  to  cortisol  within  the  mitochondria  and  is  specific  to  the  zona 
fasciculata-reticularis  (Ogishima  et  al  1992).  P450lll3  can  also  convert  DOC  to 
corticosterone (B)  highlighting the  functional  similarity with aldosterone  synthase. 
P450 11 13  can  also  perform  18- and  19- hydroxylations  of DOC,  resulting  in  18-
0HDOC  (18-hydroxy-11-deoxycorticosterone)  and  19-0HDOC  (19-hydroxy-11-
deoxycorticosterone  ), respectively as well as the conversion of corticosterone, to  18-
0HB (18-hydroxycorticosterone) (Okamoto & Nonaka 1992). 
1.9  Effects of Corticosteroids 
Corticosteroids are  involved in a wide  range  of physiological systems.  Some vital 
functions of glucocorticoids include the regulation of carbohydrate, protein and lipid 
metabolism, inflammatory, immunogenic and stress responses and the maintenance 
of blood pressure and cardiovascular function.  Mineralocorticoids are  essential for 
the  control  of electrolyte  and  water  balance.  Two  homologous  corticosteroid 
receptors  have  been identified,  the  mineralocorticoid receptor  (MR)  (Arriza et al 
1987) and the glucocorticoid receptor (GR)  (Hollenberg et al 1985).  The MR and 
GR receptors  both belong to  the  thyroid/steroid hormone  receptor  superfamily of 
42 transcription  factors  and  share  94%  ammo  acid  conservation  within their  central 
DNA binding domain (DBD) and approximately 57% within their C-terminalligand-
binding domain (Arriza et a/1987). Of particular interest here are the ways in which 
corticosteroids influence blood pressure. 
1.9.1  Mineralocorticoid Effects 
The  term  'mineralocorticoid'  is  derived  from  the  first  recognized  and  the 
physiologically  most  important  action  of aldosterone,  to  regulate  transport  of 
electrolytes across epithelial surfaces.  The main site of action is the kidney but the 
salivary  glands  and  the  colon  also  respond  (Orth  et  a!  1992).  Recent  work  has 
suggested  that  aldosterone  also  exerts  rapid  non-genomic  effects  via  membrane 
aldosterone  receptors  that  are  distinct  from  its  effects  on  gene  transcription  (see 
section 1.9.1.5). 
1.9 .1.1  Epithelial actions of  aldosterone 
Aldosterone  exerts  its  classic  genomic  effects  on epithelia by binding to  the  MR 
within the cytosol.  MR has high affinity for aldosterone, corticosterone and cortisol 
but is  specifically activated by aldosterone  in aldosterone target tissues  due  to  the 
inactivation of  the glucocorticoids by the enzyme 11 ~-hydroxysteroid dehydrogenase 
type 2 (11 ~-HSD2) (see section 1.9.3). In the absence of ligand, MR is maintained in 
an  inactive  state  by  association  with  a  complex  of chaperone  proteins  including 
hsp90.  Upon ligand-binding, these proteins dissociate revealing nuclear localization 
signals and allowing translocation of  the ligand-receptor complex to the nucleus (see 
figure 1.6). There it acts as  a transcription factor by binding to  a nuclear hormone 
response  element (HRE)  (with the  consensus  sequence AGAACAnnnTGTTCT) in 
43 the 5'UTR of aldosterone-responsive genes.  This results in activation or repression 
of expression of specific target genes.  Hormone-receptor complexes bind to DNA as 
dimers.  More recently it has been demonstrated that activated steroid receptors can 
also  affect  transcription  independent  of DNA  binding  by  direct  protein-protein 
interactions with other factors (Karin 1998; Reichardt et a/1998) (see section 1.9.2). 
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Figure 1.6.  Ligand mediated activation of the corticosteroid receptor (MR or 
GR).  (Adaptedfrom Weige/1996) 
In the  absence of hormone,  each receptor (R)  monomer is  associated with a heat-
shock protein complex (HSP).  Binding of steroid causes  a conformational change 
resulting in dissociation of  the heat  -shock complex and allowing dimerization of the 
receptor  and  DNA  binding  to  a  hormone  response  element  (HRE)  to  alter 
transcription of  target genes. 
The net effect of aldosterone within epithelia is to increase the reabsorption ofNa+ 
ions at the expense of K+ and H+ ions (White 1994) (see figure 1. 7).  The principal 
sites  of aldosterone  action  within  the  kidney  are  the  luminal  cells  of the  distal 
convoluted tubule and the collecting duct as reflected by the high expression levels 
44 of  MR at these sites. Aldosterone-responsive epithelia have high electrical resistance 
and  regulated  permeability to  water  and  electrolytes.  Sodium  reabsorption  at  the 
apical membrane is  facilitated by an electrochemical gradient and mediated by the 
amiloride-sensitive epithelial sodium channel (ENaC). The ENaC is the rate-limiting 
step and major determinant of  renal sodium reabsorption (Horisberger 1998). Sodium 
transport  out  of the  cell  is  by  means  of active  transport  across  the  basolateral 
membrane  mediated  by  the  sodium-potassium  ATPase  (Na+-K+-ATPase).  This 
drives the entry of sodium coupled to the excretion of potassium via the luminal K+ 
channel.  Sodium reabsorption is  accompanied by an influx of water. In addition to 
these main targets,  other potential mediators  of aldosterone  action are  the  luminal 
Na+1H+-exchanger  (NHE3)  in the  colon and the  luminal thiazide-sensitive Na+/cr 
cotransporter  in  the  distal  renal  tubule  (Cho  et al  1998;  Kim  et al  1998).  The 
principal mechanism of aldosterone-induced electrolyte transport appears to involve 
an increased activity of ENaC, the limiting step in the transport process. Evidence 
suggests  that  aldosterone  regulates  ENaC  activity  by  increasing  the  number  of 
channels at the apical membrane and/or by increasing their open-probability (Garty 
&  Palmer 1997; Verrey 1999).  The resulting gene products are  thought to mediate 
these effects and are termed aldosterone-induced protein(s) (AlP). 
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1.9 .1.2  Aldosterone-Induced Proteins 
AlP's  may  exert effects  on the  apical  membrane,  the  basolateral  Na+-K+-ATPase 
pump  and/or  cellular  energy  production  to  produce  an  increase  in  sodium 
reabsorption  with  a  concomitant  potassium  and  hydrogen  ion  excretion.  Several 
putative AlP's have been identified. 
Sgkl 
The  serum- and  glucocorticoid-regulated  kinase  1  (sgkl)  was  one  of the  first 
identified and perhaps is the best characterized of the AlPs.  Aldosterone increases 
46 expressiOn  of sgkl  in  the  kidney  and  the  distal  colon  in  vitro  and  in  vivo. 
Coexpression studies of sgkl with the ENaC in Xenopus larvis oocytes demonstrate 
strong activation of the  ENaC-mediated Na+  transport by sgkl; it also  appears  to 
activate the Na+1K+-ATPase and Na+/K+/Cr cotransporter (Henke et a/2002; Naray-
Fejes-Toth et al 1999; Shigaev et al 2000).  There is  some evidence that sgkl may 
phosphorylate the ENaC a-subunit to alter channel activity or that it can regulate the 
gene expression of  the subunits but the precise mechanism of action of sgkl remains 
unclear (Boyd &  Naray-Fejes-Toth 2005; Diakov &  Korbmacher 2004).  However, 
sgkl  modulates  the  activity  of the  ENaC  regulator  protein  Nedd4-2  (neuronal 
precursor  cell-expressed,  developmentally  down  regulated  protein  4-2).  The 
importance of this protein in the regulation of ENaC is highlighted by the pathology 
of Liddle's  syndrome.  Nedd4-2  is  a  ubiquitin-protein  ligase  that  regulates  the 
degradation rate  of ENaC.  Sgkl kinase interacts with Nedd4-2  and modulates its 
activity by phosphorylation to reduce its binding to ENaC (De bonneville et al 2001; 
Synder  et  al  2002).  This  results  in  a  reduced  ubiquitination  of ENaC,  with  a 
subsequent increase in channel density and stability at the apical membrane and an 
increased  capacity  for  sodium  reabsorption.  The  sgk1-knockout  mouse  has 
symptoms of  pseuedohypoaldosteronism, similar to that of  the MR knockout (Berger 
et al 1998; Wulff et al 2002).  However, the phenotype in the MR knockout is much 
more severe, suggesting there are other essential targets of  MR action. 
Corticosteroid hormone-induced factor (CHIF) 
Corticosteroid hormone-induced factor (CHIF) belongs to the FXYD family of small 
transmembrane  proteins  that  regulate  the  activity  of ion  channels  and  transport 
proteins.  The  y-subunit of Na  +  IK+ -ATPase  also  belongs to this  family  and shares 
47 >50%  sequence  homology  with  CHIF  (Geering  et  al  2003).  CHIF  is  expressed 
within the kidney and distal colon on the basolateral epithelial membranes.  In the 
distal  colon,  aldosterone,  dexamethasone,  Na+  restriction  and  K+  loading have  all 
been shown to increase the expression of CHIF (Brennan & Fuller 1999; Capurro et 
al 1996).  Na  + restriction increases CHIF protein levels in the kidney and the colon 
(Shi et al 2001).  The precise physiological function of CHIF is  unknown, but it is 
associated  with  the  Na+1K+-ATPase  in  renal  tissue  and  modulates  its  tranport 
properties  by enhancing the  affinity  of the  Na+/K+-ATPase  for  Na+  (Beguin  et al 
2001).  This may at least partly explain the  increase in Na+/K+-ATPase  activity in 
response to aldosterone. 
Kirsten Ras GTP-binding protein-2A (Ki-RasA) 
Ki-RasA  is  a  small  monomeric  GTP-binding  protein  that  appears  to  play  an 
important  role  in  mediating  aldosterone  action  in  renal  epithelia.  Aldosterone 
increases Ki-RasA expression and protein levels  during the  early phase  of action, 
with increases as early as 30 minutes after aldosterone administration. There is some 
controversy  surrounding  the  importance  of Ki-RasA  to  aldosterone  action  as  the 
levels of Ki-Ras or its induction by aldosterone appears to be very small (or absent) 
in some of aldosterone's target epithelia.  Evidence suggests that Ki-RasA increases 
the open probability of  the ENaC channel but decreases the number of  channels.  The 
mechanisms  for  these  apparently  conflicting  actions  remain  unclear  (Spindler  & 
Verrey 1999; Stockand 2002; Stockand & Meszaros 2003). 
PI3K 
The  enzyme,  phosphatidylinositide  3-kinase  (PI3K),  phosphorylates  inositol 
phospholipids to produce the second messengers, 3-phosphorylated inositides, which 
48 mediate diverse cellular signalling functions.  PI3K is  not an AlP  but aldosterone 
increases  its  activity,  perhaps  through induction of Ki-RasA.  Inhibition of PI3K 
affects both the early and late phases of aldosterone action, with a decrease in Na  + 
transport even in the presence of sustained aldosterone levels.  PI3K also appears to 
be important for the sodium transport changes mediated by insulin and vasopressin, 
indicating a point of convergence for the signalling pathways of these hormones to 
interact and regulate ENaC and Na+1K+-ATPase.  (Blazer-Yost et al1999; Stockand 
2002). 
1.9 .1.3  Nonepithelial aldosterone action 
As  well  as  the principal site of aldosterone action on epithelial cells  surfaces, MR 
have  also  been  identified  in  a  number  of nonepithelial  cells  including  vascular 
smooth muscle and endothelial cells (Christ et al1995; Takeda et al1996), neurones 
and  support cells  (Qin et al 2003),  circulating lymphocytes  (Wehling et al 1990), 
cardiomyocytes  (Stockand  &  Meszaros  2003;  Wang  et  al  2002)  and  cardiac 
fibroblasts  (Stockand  &  Meszaros  2003).  It is  now accepted that aldosterone  has 
physiological  and pathophysiological  effects  in nonepithelial tissues,  especially  in 
the central nervous system (CNS) and cardiovascular system.  Of particular interest 
to this study are the effects on the cardiovascular system. 
1.9.1.4  Cardiovascular effects of aldosterone 
Within the cardiovascular system, aldosterone is thought to exert effects on both the 
vasculature  and  the  heart,  causing vascular  inflammation  and  damage  as  well  as 
cardiac hypertrophy and fibrosis,  by pathways independent of its  effects  on  blood 
pressure.  However, all these changes may themselves contribute to an altered blood 
pressure regulation. 
49 Aldosterone effects on the vasculature 
In  the  vascular  system,  aldosterone  promotes  smooth  muscle  hypertrophy  and 
endothelial dysfunction.  Activation of  MR in vascular smooth muscle cells increases 
the  contractile  response  to  adrenergic  stimulation  and  impairs  the  vasodilatory 
response  to  acetylcholine  (Farquharson  &  Struthers  2002;  Jazayeri  &  Meyer,  III 
1989; Komel et al 1988; Taddei et al 1993).  Aldosterone also stimulates an increase 
in  the  Ang  II  receptor  (ATl)  density  in  cardiovascular tissues,  which  may  also 
modulate vascular tone (Robert et all999).  Aldosterone decreases the availability of 
the  vasodilator  nitric  oxide  (NO)  and  enhances  vascular  and  systemic  oxidative 
stress.  These effects are thought to contribute to the vascular alterations observed in 
the  spontaneously hypertensive rat (Sanz-Rosa et al 2005).  In patients with heart 
failure  spironolactone, a non-specific MR antagonist (which also  acts  on androgen 
receptors),  greatly  increases  NO  bioactivity,  with  a  concomitant  improvement  in 
endothelial  function  (Farquharson  &  Struthers  2000).  Excess  aldosterone  is  also 
thought  to  cause  vascular  remodelling  through  collagen  deposition  in  the  blood 
vessels with a resulting decrease in compliance.  In support of  this, there is evidence 
to  suggest  that  aldosterone  levels  are  inversely  related  to  arterial  compliance  in 
essential hypertension (Blacher et al1997). 
Aldosterone effects on the heart 
Aldosterone  promotes  cardiac  hypertrophy  as  well  as  perivascular  and  interstitial 
fibrosis (Brilla et al 1990). Hypertension is known to cause cardiac hypertrophy and 
fibrosis through hemodynamic changes, but the aldosterone-induced hypertrophy and 
fibrosis, although dependent on salt status, have been shown to occur independently 
of blood pressure.  In support of this, patients with primary aldosteronism are more 
50 likely  to  have  left  ventricular  hypertrophy  (L VH)  or  stroke  than  in  age  and  sex 
matched subjects with essential hypertension of similar severity (Rossi et al  1997; 
Tanabe et a/1997). 
The  importance  of MR  activation  m  promoting  cardiovascular  injury  has  been 
recently  further  highlighted  by  several  clinical  trials,  including  The  Randomized 
Aldactone  Evaluation Study  (RALES)  (Pitt  et a!  1999)  and the  Eplerenone  Post-
Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) 
(Pitt  et al  2003).  Addition  of low  doses  of MR antagonist  to  standard  therapy 
reduced cardiac moribidity and mortality in heart failure patients and in patients after 
an  acute  myocardial  infarction.  This  effect  was  independent  of blood  pressure 
reduction or fluid  loss,  suggesting that antagonism of the  non-classical  actions  of 
aldosterone  at  non-epithelial  sites,  such  as  the  heart  and  vasculature,  may  be 
responsible  for  the  beneficial  effects.  A  substudy  of RALES  demonstrated  that 
markers of collagen synthesis, which associate with cardiac fibrosis, correlated with 
disease  severity  and  increased  risk.  Low  doses  of spironolactone  decreased  the 
levels  of collagen,  with an  associated  decrease  in  risk.  This  supports  a role  for 
aldosterone and cardiac fibrosis in the pathology of  heart failure (Zannad et a/2000). 
The mechanisms of these aldosterone-induced effects is unclear but are thought to 
involve the regulation of collagen deposition in cardiac tissue (Brilla et al 1990).  In 
the presence of a high sodium intake, aldosterone exerts a direct pro-fibrotic action 
by stimulating the accumulation of fibrillar type  1 collagen in the myocardium with 
associated hypertension and L  VH  (Brilla & Weber 1992). 
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aldosterone-induced fibrosis.  After several weeks, aldosterone/salt treatment of rats 
induces  coronary  inflammation,  characterized  by  macrophage,  monocyte  and 
fibroblast  inflitration  of the  perivascular  space  and  increases  in  mRNA  for  pro-
inflammatory  mediators  and  cytokines  (Farquharson  &  Struthers  2002;  Rocha  & 
Funder  2002).  This  inflammatory  response  appears  to  be  necessary  for  the 
accumulation of  fibrillar collagen and fibrous tissue within the heart. 
Aldosterone  also  increases  the  expressiOn  of NADPH  oxidase,  which  in  tum 
catalyses the  formation of the  superoxide anion.  The  superoxide anion reacts  with 
NO  to  form  peroxynitrite,  reducing  NO  bioavailability  with  a  resulting 
proinflammatory and fibrogenic  phenotype.  All these responses can be  blocked by 
MR  antagonists  or  antioxidant  agents  such  as  N-acetylcysteine,  suggesting  that 
oxidative  stress  is  at  least partly  responsible  for  the  pro-inflammatory  phenotype 
induced by aldosterone (Rocha & Funder 2002; Sun et al2002). 
A role for the classic MR in mediating these cardiac effects is suggested as  most of 
the  observed  phenotypes  take  several  weeks  to  develop  and  the  antagonist 
spironolactone is  able to prevent aldosterone-induced fibrosis (Brilla et al 1993).  It 
has recently been demonstrated that the vascular inflammation and cardiac fibrosis 
stimulated in rats by 4 weeks of DOC treatment, can be completely reversed by the 
eplerenone  but not  mineralocorticoid  withdrawal  alone  (Young  &  Funder  2004). 
MRs have been detected in all four chambers of the heart, within cardiac myocytes, 
endocardium,  VSMC  and  endothelial  cells  (Pearce  &  Funder  1987).  However, 
whether  the  MR protector  11 ~HSD2 is  expressed  here  remains  controversial.  If 
expression occurs, it may only be  at  low levels  and within specific cell types  (  eg. 
52 VSMC) (Funder 2005).  This implies that within the heart, MR is  essentially a high 
affinity GR due to the much higher circulating levels of cortisol.  This effect would 
be  further enhanced if lll3HSD  1 (converting cortisone to  cortisol) is  expressed.  It 
has  been identified in  vitro in cardiac fibroblasts  (Sheppard &  Autelitano 2002).  It 
has been suggested that local production of aldosterone in the heart could generate 
high local intracardiac levels, enabling MR activation by aldosterone but the lack of 
cardiac  remodelling  in  adrenalectomized  rats  suggests  this  is  unlikely  (Rocha  & 
Funder 2002).  However, co-infusion with corticosterone antagonizes the actions of 
aldosterone  in the  heart,  preventing  a rise  in blood pressure  and  cardiac  fibrosis. 
Glucocorticoids may have a protective role within the heart (Young & Funder 1996). 
1.9 .1.5  Non-genomic actions of  aldosterone 
In  addition to  the  classic  genomic  mechanism  of aldosterone  action,  there  is  also 
increasing evidence that aldosterone can also  exert rapid,  non-genomic effects that 
involve the activation of second messenger pathways (Wehling et a!  1992; Wehling 
1995).  The  genomic  effects  mediated  through  the  MR involve  steroid-receptor 
regulation  of gene  expression  and  involve  a  latent  period  of 1-2  hours.  These 
genomic  effects  can be  blocked by inhibitors  of transcription (actinomycin D)  or 
translation (cycloheximide)  as  well  as  by MR antagonists  such as  spironolactone. 
Several  recent  studies  have  reported  rapid  effects  that  occur  within  15  minutes. 
These are believed to be independent of gene transcription and translation as they are 
not blocked by actinomycin D or cycloheximide (Falkenstein et a/2000; Harvey et al 
2001).  These  rapid  effects  have  been  predominantly  demonstrated  outwith  the 
kidney in cells  such  as  vascular smooth muscle  cells  (Christ et a!  1995)  skeletal 
muscle cells (Passaquin et a!  1998) and myocardial cells  (Barbato et a!  2002).  A 
53 rapid (within 4 minutes) vasoconstrictor response to a modest infusion of aldosterone 
has been recently demonstrated in vivo (Romagni et al 2003).  Whether these effects 
are  mediated  through  the  classic  MR or  a  novel  non-genomic  receptor  remains 
controversial.  Wehling et al demonstrated a rapid response (1-2mins) to aldosterone 
on the Na  +  IH+ -exchanger and inositoltrisphosphate generation in human lymphocytes 
and vascular smooth muscle cells.  This effect was not mediated by cortisol and was 
not  blocked  by  the  MR antagonist  spironolactone,  supporting  the  existence  of a 
distinct, novel receptor (Wehling 1995).  A similar pattern was observed in kidney 
cells where aldosterone induced a rapid rise in cytosolic calcium that could not be 
blocked by the classic MR antagonists  (Gekle et al 1997).  This rapid response of 
calcium to aldosterone can also be induced in MR knockout mice, further supporting 
the  possibility  of distinct  receptors  for  rapid  signalling  (Haseroth  et  al  1999). 
However,  in  vascular  tissue  the  rapid  nongenomic  effect  of  aldosterone  on 
intracellular Ca
2+ levels, the Na  +  IH+ exchanger and vasoconstriction are  blocked by 
the  MR antagonist eplerenone,  suggesting a role for the  classic MR (Michea et al 
2005).  In rat smooth muscle cells, the  rapid,  aldosterone-mediated sodium efflux, 
which is not blocked by actinomycin, also appears to be MR-dependent.  However, 
the  recent  identification  of  membrane  bound  G-protein-coupled  receptors  for 
progesterone and oestrogen supports the possibility that a similar receptor exists for 
aldosterone.  A  candidate  aldosterone  membrane  receptor  of 50kDa was  isolated 
from  human  lymphocytes  using  binding  assays  but  the  complete  structural 
characteristics are yet to be determined (Eisen et a/1994). 
These nongenomic effects of aldosterone (Wehling et al 1998) have been linked to 
the development of increased systemic vascular resistance and so could contribute to 
hypertension and cardiovascular disease (Armanini et al 1991 ). 
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Cortisol has  a wide  range  of effects  throughout many tissues  (brain,  heart,  blood 
vessels  and  kidney)  (Sapolsky  et al  2006)  as  indicated  by the  almost  ubiquitous 
expression of its receptor (GR)  (Ballard et al 1974).  Glucocorticoids  are  known to 
acutely  increase  blood pressure  and  long-term  administration  has  been  shown  to 
induce hypertension in humans (Whitworth et al 2000). The precise mechanisms by 
which cortisol regulates  blood pressure  are  complex and not fully  understood but 
appear  to  involve  several  actions  on  the  vasculature  and  kidney.  Cortisol 
administration results in an increased pressor responsiveness  of the  vasculature to 
catecholamines and to  a lesser extent Ang II (Whitworth 1994).  This may at  least 
partly  occur  through  upregulation  of the  receptors  for  these  vasoconstrictors, 
including AT1A.  There is also increasing evidence that cortisol inhibits the response 
of  the vasodilator, nitric oxide, by inhibiting the enzyme nitric oxide synthase (NOS), 
by preventing transport of  the precursor arginine or by inhibiting the synthesis of  the 
NOS cofactor, tetrahydrobiopterin (Mitchell & Webb 2002; Whitworth et al2000). 
Cortisol  also  has  indirect  effects  on  the  kidney  by  stimulating  angiotensinogen 
(AGT)  expression in the  liver via two  glucocorticoid  response  elements  (GRE's) 
(one  full  and  one  half),  on  the  AGT  gene.  The  resulting  increase  in  AGT 
concentration  affects  intravascular  RAS  activity,  resulting  in  Ang  II-dependent 
changes in blood pressure (Braiser &  Li  1996).  Another possibility is that cortisol 
activates the MR within the kidney to promote sodium and water retention.  Indeed, 
kinetic  properties  of the  enzyme  11 ~HSD2 (the  MR protector,  see  section  1.9.3) 
suggest that even high normal physiological cortisol concentrations could saturate 
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altering both intravascular volume and vascular resistance. 
The cytosolic GR receptor is homologous to  and functions in a similar way to MR 
(Gustafsson  et  al  1987).  However,  GR  has  moderate  affinity  for  cortisol  and 
corticosterone with low affinity for  aldosterone and DOC.  Ligand binding induces 
GR to dissociate from the complex of heat shock proteins that maintain it in a stable 
state and to  form  homodimers. This dimerization is  thought to occur prior to DNA 
binding.  The GRJsteroid dimer complex binds to specific regions within target genes 
called  glucocorticoid-responsive  elements  (GRE)  with  the  consensus  palindromic 
DNA sequence 5'-GGTACAnnnTGTTCT-3'.  There  is  also  evidence that GR can 
form  heterodimers with other transacting factors  including MR.  The  interaction of 
GR with GRE inititates or represses transcription with the help of  various coactivator 
or corepressor proteins.  There is also evidence that GR can exert its effects on gene 
transcription independent of DNA binding through protein-protein interactions with 
other factors  (Beato  &  Sanchez-Pacheco  1996;  Karin  1998;  Reichardt et al  1998; 
Stocklin  1996).  The  following  molecular  mechanisms  of glucocorticoid/receptor 
action on gene transcription have been observed (see figure 1.8): 
1.  Trans-activation - Steroid/GR complex binds GRE and increases expression of 
target genes (Strahle et al 1987). 
2.  Trans-modulation- Steroid/GR complex binds composite GREs comprised of  half 
GRE  and  a  half binding  site  for  another  transcription  factor  (  eg.  AP-1)  - alter 
transcription of  other TF'  s (Diamond et al1990; Pearce & Yamamoto 1993). 
3.  Trans-repression - Steroid/GR complex binds negative GRE  sequences (nGRE) 
and repression of  transcription of  target genes (Beato et al1989). 
56 4.  Transcription  synergy  - Protein-protein interaction with factors  such  as  Stat-5 
(Stocklin 1996). 
5.  Transcription repression - Protein-protein interaction with factors  such as  AP-1, 
CREB or NF -KB (De Bosscher et al2003). 
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Figure 1.8.  Mechanisms of transcriptional regulation by the glucocorticoid 
receptor 
TF =  transcription factor 
(Adapted from Karin 1998; Reichardt & Schutz 1998) 
As mentioned previously, the GR is  almost ubiquitously expressed compared to the 
relatively selective expression of MR. Due to the high degree of homology between 
MR and GR, it is perhaps not surprising that there is some overlap of ligand binding. 
In  particular,  the  MR has  been  shown  to  have  the  same  affinity  for  aldosterone, 
corticosterone  and  cortisol  in  vitro  (Krozowski  &  Funder  1983).  In  combination 
with the  much higher circulating levels  of cortisol  (1 00  - 1000 fold)  compared to 
aldosterone within the body, a mechanism is  clearly required to  ensure the specific 
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section. 
1.9.3  llfi-hydroxysteroid Dehydrogenases 
The  enzyme  11 ~-hydroxysteroid  dehydrogenase  type  2  (11 ~-HSD2)  confers 
specificity on the  MR by  inactivating  cortisol  (Edwards  et al  1988;  Funder et al 
1988)  (see  figure  1.9).  This NAD-dependent  enzyme  is  coexpressed with MR in 
aldosterone target tissues (kidney,  colon and salivary glands) and converts cortisol 
into the inactive 11-keto metabolite, cortisone. Disruption of this enzyme-protective 
system, due to mutations in the  11 ~-HSD2 gene, results in the syndrome of apparent 
mineralocorticoid  excess  (AME)  in  which  cortisol  is  free  to  act  like  a 
mineralocorticoid  and  activate  MR  (Mune  et  al  1995)  (see  section  1.15.2.2). 
Another distinct  11~-HSD isoenzyme  (11~-HSD1) is  expressed mainly in the liver 
and visceral adipose tissue, as well as the brain, gonads, muscle, lung and other GR-
expressing tissues (Moisan et al 1990; Monder &  White  1993; Walker et al 1992) 
(see  figure  1.9).  This  isoform requires  NADP(H) which is  supplied by hexose-6-
phosphate  dehydrogenase  (H6PDH).  11~-HSD1  can  function  bidirectionally 
(Monder &  White 1993) but has been shown in vivo to  act as  an  11-oxo-reductase, 
particularly  in  hepatocytes  and  adipocytes,  thereby  enhancing  GR-dependant 
functions  at  these  sites  including  gluconeogenesis  and  adipocyte  differentiation 
(Seckl &  Walker 2001). Therefore, inhibition of 11~-HSD1 is a potential target for 
treatment of disorders that might be ameliorated by local reduction of glucocorticoid 
action, such as type 11  diabetes and obesity. 
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Figure 1.9.  Schematic role of 11~-HSD isozymes and their main sites of action 
(Adapted  from Arlt & Stewart 2005) 
The  11 ~-HSD enzymes  function  to  provide  tissue-specific  mineralocorticoid  and 
glucocorticoid effects in the appropriate tissues throughout the body. 
1.9.4  Extra-adrenal Corticosteroid Production 
Within  the  vasculature  and  the  brain,  all  the  enzymes  required  for  the  de  novo 
synthesis  of  corticosteroids  from  cholesterol  have  been  identified  (Davies  & 
MacKenzie  2003).  Therefore,  locally  produced  aldosterone  could  act  in  an 
autocrine/paracrine manner to  exert the non-classical effects mentioned previously. 
However, the level of  transcription to mRNA suggests that local steroid production is 
small  in  comparison  with  adrenal  production  and  so  whether  extra-adrenal 
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intracerebroventricular (icv) infusion of aldosterone, at doses far too low to  have an 
effect  when  administered  subcutaneously,  significantly  increases  blood  pressure 
(Gomez-Sanchez  1986).  Therefore small local  amounts  can have an effect.  Local 
concentration,  proximity  to  target  cells  and,  possibly,  tissue-specific  control 
mechanisms may all be determining factors.  In theory, local aldosterone production 
in the heart would provide an important therapeutic target for cardiovascular disease, 
especially  considering  the  suggestion  that  aldosterone  synthase  expression  is 
increased  in heart  failure  (Yoshimura  et al 2002).  However,  research  into  local 
aldosterone production within the heart has yielded contradictory results (Davies & 
MacKenzie  2003;  Funder 2004;  Gomez-Sanchez  et al 2004;  Silvestre  et al 1999; 
Silvestre et al 1998; Young et al 2001). There have been reports of a high relative 
aldosterone concentration in perfused hearts  or homogenates (Silvestre et al  1999; 
Silvestre  et al  1998)  and  yet  recent  work  using  a  highly  sensitive  and  specific, 
quantitative  RT-PCR method  failed  to  detect  CYP JJB2  expression  in  several  rat 
models  of cardiovascular  pathology  or  in  isolated  cardiac  myocytes  treated  with 
angiotensin II and ACTH (Y e et al 2005).  It is at least possible that the high relative 
aldosterone concentrations within the heart are due to  sequestration of the hormone 
from the bloodstream or to slower degradation rather than local synthesis.  In favour 
of this,  the  levels  of aldosterone  detected  in  the  heart  appear  to  reflect  normal 
circulating plasma levels (Gomez-Sanchez et al2004). 
1.10  Abnormal Corticosteroid Production 
Abnormalities in corticosteroid production highlight their importance in influencing 
blood  pressure.  At a  gross  level,  corticosteroid  excess  as  occurs  in  Cushing's 
60 syndrome (cortisol excess) or primary aldosteronism (aldosterone excess) are  often 
associated  with hypertension whilst  Addison's  disease  (the  deficiency  of adrenal 
steroids)  is  invariably associated with hypotension (White  1994;  White  &  Speiser 
1994). 
1.1 0.1  Cortisol Excess 
Cushings disease is the result of excess cortisol production due to pituitary adenomas 
that secrete excess amounts of ACTH.  A similar phenotype or syndrome can occur 
as the result of ectopic ACTH production or adrenal cortisol secreting tumours.  The 
syndrome  IS  characterized  by  truncal  obesity,  glucose  intolerance  and 
hyperglycaemia,  osteoporosis,  hyperlipidaemia  and  hypertension.  Hypertension 
occurs in 70 - 80% of cases.  The increased cortisol levels cause saturation of the 
enzyme  11 ~HSD2, resulting  in  cortisol  activation  of the  MR  by  the  kidney. 
Evidence of impaired  11 ~HSD2 in patients with Cushings, is  demonstrated by the 
ratio of  urinary cortisol:cortisone metabolites (Stewart et al1995; Ulick et al1992a). 
A  similar finding  has  also  been reported  in EH (Soro  et al 1995).  However,  in 
subjects with cortisol-induced hypertension, treatment with spironolactone to  block 
the  sodium  and  water retention,  have  failed  to  reduce  the  induced  rise  in  blood 
pressure suggesting other mechanisms are involved (see section 1.9.2) 
Excess  glucocorticoids,  either  endogenous  (Cushings  syndrome)  or  exogenous 
(glucocorticoid  therapy),  can  result  in  hypertension.  With  cortisol-induced 
hypertension,  the  risk  of cardiovascular  morbidity  and  mortality  is  high  with an 
increased  incidence  of left  ventricular  hypertrophy  compared  to  other  forms  of 
hypertension.  The  hypertension  is  associated  with  an  increased  cardiac  output, 
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increased vascular responsiveness. 
1.1 0.2  Aldosterone Excess 
Aldosterone  excess  can  occur  from  rare  genetic  causes  (such  as  Glucocorticoid 
suppressible hyperaldosteronism) or primary aldosteronism (PA).  PA can be defined 
as  excessive production of aldosterone independent of its normal regulator, Ang II, 
which is  produced by renin (Gordon et al 1994a). This relationship is  described in 
detail  in section  1.12.2.  Briefly,  autonomous  excess of aldosterone  will  suppress 
renin  levels  so  that  the  aldosterone-to-renin  ratio  (ARR)  is  elevated.  PA  is 
characterized by increased extracellular fluid  volume,  hypokalaemia,  alkalosis  and 
hypertension as  a result of the marked sodium and water retention.  Jerome Conn 
first described the symptoms in 1954 as a syndrome related to the hypersecretion of 
aldosterone by an adrenal adenoma, now known as Conn's syndrome (Conn & Louis 
1956).  For many years this was thought to be the primary cause ofPA, but recent 
studies  suggest  that  bilateral  adrenal  hyperplasia  (idiopathic  hyperaldosteronism) 
may  be  a more  common cause  of P  A than previously realised  (Lim  et al 2002a; 
Montori & Young, Jr. 2002). 
1.1 0.2.1  ARR as a screening tool for P  A 
Until  recently,  PA  has  always  been  considered  to  be  a  rare  cause  of secondary 
hypertension, accounting for less than 1% of cases.  However, recent use of the ARR 
as  a  reliable  marker of inappropriate  aldosterone  activity has  led to  an  increased 
frequency of the  diagnosis of P  A among hypertensive patients.  Generally an ARR 
>750  (when  aldosterone  is  expressed  in  pmol/L  and  renin  as  renin  activity  in 
62 ng/ml/hour) is accepted as higher than the normal range.  A number of independent 
studies worldwide, including Scotland (Lim et al1999b; Lim et al 2002a), Australia 
(Gordon et al1994b), South East Asia (Loh et al2000) and South America (Fardella 
et al 2000), demonstrate the prevalence of P  A using a high ARR as  a marker to  be 
between 5 to  15% in unselected individuals with hypertension, with a much higher 
proportion of bilateral adrenal hyperplasia (BAH) (Mulatero et al 2004). In most of 
these studies, less than half of  the identified patients were hypokalemic, the previous 
prerequisite  for  diagnosis  of mineralocorticoid  hypertension.  The  idea  that  a 
normokalemic form of  P  A may account for as many as 20% of  patients with essential 
hypertension was first suggested by Conn in 1965 but has largely been forgotten until 
now (Conn et al1965). 
The ARR measurement itself is not conclusive and further confirmatory tests such as 
fludrocortisone  suppression  test  or  salt  loading  are  required  to  demonstrate 
inappropriate regulation of aldosterone levels.  Much of  the controversy surrounding 
the use of the ARR as  a diagnostic tool for P  A is  due to the plasma renin activity 
dominating the ratio.  In many cases, the elevated ratio is due to low renin levels and 
aldosterone  levels  are  often  within  the  'normal'  range  and  so  would  not  be 
traditionally  diagnosed  as  P  A.  It is  unclear  how these  subjects  differ  from  the 
previously well-defined subgroup of low renin essential hypertension, which is  also 
characterized by aldosterone levels that are  inappropriately high for the  prevailing 
renin level.  Padfield et al  proposed some  years  ago  that patients with P  A due  to 
BAH are no different to the subgroup of  low renin essential hypertension (Padfield et 
al 1981 ).  Indeed the presence of adrenal nodules with or without hyperplasia that is 
characteristic  of  BAH  can  also  occur  in  essential  hypertension,  low  renin 
hypertension or even in normotensive subjects  (Kaplan 1967) suggesting there may 
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demonstrating  that  subjects  with  aldosterone-producing  adenomas  often  have 
hyperplasia within the rest of the adrenal, suggesting that solitary adenomas arise on 
the background of an already abnormal gland (Neville & MacKay 1972). Therefore, 
with the new diagnostic criteria, P  A may be  considered a subtype of hypertension 
with  dysregulated  renin-angiotensin-aldosterone  dynamics  that  may  show 
progression from hypertension with a raised ARR to BAH and finally to classical P  A 
with truly autonomous aldosterone secretion. 
There is still much controversy surrounding the use of the ARR as  a screening tool 
for P  A and the classification of hypertensive patients.  However, the use of  the ARR 
has  lead to  an  increase  in the  diagnosis  of aldosterone-secreting adenomas,  many 
cases of  which can be cured completely by surgery.  Also, whatever the classification 
of subjects  with  a  high  ARR  as  BAH,  PA  or  low  renin  essential  hypertension, 
although  the  aldosterone  levels  may  not  be  particularly  elevated,  they  are  still 
innappropriate for the prevailing levels of  renin and Ang II. This highlights a role for 
altered  aldosterone  production  or  control  as  a  key  phenotype  in  essential 
hypertension.  In support of this is  the  observation that patients with a raised ARR 
respond  particularly  well  to  treatment  with  selective  MR  antagonists  such  as 
spironolactone (Lim et al1999a). 
It is clear from the clinical syndromes of  Cushing's disease and P  A that abnormalities 
in  corticosteroid  production  can  be  associated  with  hypertension.  However,  to 
further  explore  the  contribution  of corticosteroids  to  the  genetic  component  of 
essential hypertension, a review of  the molecular genetics of aldosterone and cortisol 
synthesis is required. 
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As  mentioned  previously,  in  man  the  three  terminal  stages  in  the  synthesis  of 
aldosterone (lip-hydroxylation, IS-hydroxylation and 18-oxidation) from DOC are 
all  catalyzed  by  aldosterone  synthase  (encoded  by  CYP II  B2).  Cortisol  is  also 
synthesized by liP-hydroxylation, in this case of li-deoxycortisol, and catalyzed by 
the  enzyme  Up-hydroxylase  (encoded  by  CYP 1J B  1).  In  other  species  such  as 
bovine, pig and bullfrog, there is  only a single CYP II  B I  gene for the synthesis of 
cortisol and aldosterone (Nonaka et a/1995). 
CYP IJB2  and  CYP JJBI  are  situated  approximately  40  kilobases  apart,  on 
chromosome 8 in man.  They are  both approximately 6.5kb long from  the  start of 
transcription to the polyadenylation site and contain 9 exons and 8 introns (see figure 
1.10).  They are 95% homologous in their coding regions with the main differences 
in  their  sequences  being  in  their  5'UTR  regions  that  are  responsible  for  the 
differences in their transcriptional regulation and zonal distribution (Chua et a/1987; 
Momet et a/1989; Zhang & Miller 1996). 
S'UTR  -8Kb  3'UTR 
Figure 1.10.  Schematic diagram ofthe exonic-intronic arrangement of the 
CYPJJBJ!B2 genes 
65 1.12  Regulation of CYPJJBJ and CYPJJB2 Expression 
Adrenal  steroidogenesis  is  under  both  acute  and  chronic  regulation  by  tropic 
hormones.  The acute response occurs within minutes and involves the mobilization 
of cholesterol from  intracellular stores to the mitochondrial membrane (see section 
1.8.1)  in  response  to  ACTH,  Angiotensin  II,  K+  and  their respective  intracellular 
messenger pathways (see following sections) (Clark et al1995b; Clark et al1995a). 
Of particular interest to this review is the chronic response that takes several hours 
and involves the transcription of  the genes encoding the steroidogenic enzymes. 
1.12.1  ACTH 
Corticotrophin releasing hormone (CRH) release is  controlled by input from 'higher' 
centres that respond to  physiological and psychological stressors (see  figure 1.11). 
CRH  is  released  from  the  hypothalamus  and  passes  into  the  hypophyseal  portal 
circulation  to  stimulate  the  release  of ACTH  from  the  corticotroph  cells  of the 
anterior  pituitary.  ACTH  activates  its  receptor  on  adrenal  cells  to  stimulate 
steroidogenesis  and  mcrease  glucocorticoid  (cortisol)  synthesis.  Glucocorticoid 
synthesis  is  controlled  by  classical  endocrine  feedback  loops  whereby  cortisol 
inhibits  secretion of CRH from  the  hypothalamus  and  ACTH  from  the  pituitary. 
ACTH  IS  synthesised  as  part  of  a  large  presursor  molecule  pro-
opiomelanocorticotrophin  (POMC),  which  also  contains  the  other  peptides 
melanocyte stimulating hormone (MSH) and  ~-endorphin. 
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Figure 1.11.  Hypothalamic pituitary axis regulation of cortisol secretion 
ACTH itself is  a 39  amino acid peptide; the  first 24  of which are  conserved in all 
species and the first 18 confer its biological activity (Smith & Funder 1988).  Normal 
ACTH release from the  anterior pituitary is  pulsatile and follows  a diurnal rhythm 
with the highest levels occurring first thing in the morning and the lowest at night 
(Veldhuis et al1990).  ACTH exerts its effects by binding to its receptor (ACTH-R), 
67 a G-protein coupled receptor, which is a member ofthe melanocortin receptor family 
(Mountjoy  et al  1992).  After  binding to  its  receptor,  ACTH  activates  adenylate 
cyclase, resulting in an increased intracellular cAMP concentration and activation of 
protein  kinase  A  (PKA)  (Buckley  &  Ramachandran  1981;  Sala  et al  1979)  (see 
figure 1.12).  ACTH plays an essential role in regulating CYP IIBI gene expression 
(Sewer  &  Waterman 2003).  Each of the ACTH-responsive  genes  contain unique 
cAMP-response  sequences  (CRS)  within  their  5'  regulatory  regions  that  bind  a 
variety of transcription factors,  including homeodomain proteins, SP  family,  CREB 
and SF-I (Waterman & Bischof 1996).  ACTH stimulates CYP IIBI transcription via 
cAMP  and  the  orphan  nuclear  receptor,  SF-1.  The  cAMP-mediated  increase  in 
steroidogenic gene transcription takes hours and is inhibited by the protein synthesis 
inhibitor, cycloheximide. This suggests that synthesis of  a common, unknown protein 
factor(s)  is  required.  Several  other  cAMP-independent  intracellular  signalling 
pathways appear to be induced by ACTH, including protein kinase C (PKC) (Arola 
et al  1994),  calcium  influx via calcium  channels  (Yamazaki  et al 1998)  and  the 
lipooxygenase pathway (Yamazaki et al1996). 
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Figure 1.12.  Intracellular mechanisms of Ang II, K  + and ACTH influencing 
gene expression  (Adaptedfrom Cooke 1999; Rossier 1997) 
ACTH has  a  modest effect  on the  secretion of aldosterone  but the  physiological 
relevence  is  unclear.  ACTH  acutely  stimulates  aldosterone  secretion  (probably 
through activation of StAR protein production but in the long-term, has an inhibitory 
effect on CYP  11 B2 gene  expression and  aldosterone  levels.  (Aguilera et al 1996; 
Mitani  et al 1996).  It is  not  completely  clear how ACTH  inhibits  expression of 
CYP  11B2.  Cyclic  AMP  (cAMP),  the  second  messenger  for  ACTH,  desensitizes 
adrenocortical cells to  Ang  II  by causing a reduction in the  expression of Ang II 
receptors  (Bird  et  al  1994;  Yoshida  et  al  1991).  ACTH  may  also  decrease 
aldosterone  production  by  stimulating  the  expression  of CYP  11 B 1  and  CYP  17, 
69 resulting in a removal of precursors from the aldosterone pathway and using them to 
synthesize cortisol.  ACTH receptors are present in both the zona glomerulosa and 
fasciculata.  Under  normal  circulating  ACTH  levels,  the  glomerulosa  maintains 
CYP II  B2 expression by at least two mechanisms.  Firstly, Ang II will inhibit ACTH-
stimulated cAMP production in glomerulosa but not fasciculata cells (Begeot et al 
1988; Hausdorff et a/1987).  Secondly, the glomerulosa expresses a type of  adenylyl 
cyclase that is  inhibited by increasing intracellular Ca
2
+, the second messenger for 
both Ang II and K+ (Shen et al1997). 
Long-term  ACTH  exposure  stimulates  adrenal  growth  both  in  vitro  and  in  vivo 
through  promoting  hypervascularization  as  well  as  cellular  hypertrophy  and 
hyperplasia (Arola et al 1993;  Bomstein et al 1992;  Bomstein &  Chrousos  1999; 
Vinson 2003).  This results in an increase in the number of cells with the potential for 
steroidogenesis  (Arola  et  al  1993;  Dallman  et  al  1980).  ACTH  appears  to 
specifically induce the  proliferation of zona fasciculata  cells  whilst recruiting and 
transforming glomerulosa cells into fasciculata-like cells (Aguilera et al 1981; Arola 
et al 1993; Mazzocchi et al1986) 
1.12.2  Angiotensin II and Potassium 
Ang II and circulating potassium concentration are the most influential regulators of 
aldosterone secretion.  They act through common intracellular signalling pathways to 
increase transcription of  CYP  II  B2 in the zona glomerulosa. 
Ang II is an octapeptide hormone generated by the renin-angiotensin-system (RAS) 
(see figure 1.13).  The rate-limiting step in the RAS  is the secretion of the protease 
renin from the kidney, which is controlled through a negative feedback loop.  Renin 
70 is  released  from  the  juxtaglomerular  cells  in  the  renal  tubule  in  response  to  a 
decrease  in renal  perfusion pressure  and  filtrate  sodium  content and  an  increased 
sympathetic tone.  It converts angiotensinogen, which is  constitutively secreted by 
the liver, into angiotensin I (Ang I).  Ang I,  which has no apparent activity, is  then 
converted  by  angiotensin-converting-enzyme  (ACE)  into  Ang  II,  the  active 
component of the RAS.  Ang II  causes an elevation in blood pressure by  directly 
constricting  blood  vessels,  increasing  sympathetic  nerve  activity,  increasing 
myocardial contractility, enhancing renal salt and water retention both directly and 
indirectly through stimulating aldosterone release from the adrenal (Carpenter et al 
1961; Gavras et a/1976).  The resulting increase in Na+ and water retention as well 
as  blood pressure  inhibit renin release.  Ang  II  also  has  a proliferative  effect on 
tissues, inducing cardiac and vascular hypertrophy, partly through the stimulation of 
growth factors and cytokines (McConnaughey et al 1999).  Ang II has been shown to 
activate NADPH oxidase, resulting in increased production of the superoxide anion 
(·02-),  which  can  react  with  nitric  oxide  (NO)  to  produce  the  harmful  oxidant 
peroxynitrite (ONOO-).  This may contribute to the vasoconstrictive response to Ang 
II by decreasing the availability of  the vasodilator NO (Rajagopalan et al 1996). 
There are two main receptors for Ang II, AT1  and AT2.  AT1  occurs as two subtypes 
AT1A and  AT1B (Kambayashi  et  al  1993;  Mukoyama et al  1993).  Most of the 
known biological actions of Ang II are mediated through AT1, in particular AT1A, 
except for the control of aldosterone secretion from the adrenal cortex, which appears 
to  be  mediated by ATlB (Gigante et al  1997).  The  AT1  receptor is  a G-protein-
coupled receptor (GPCR) that exhibits zonal distribution within the adrenal cortex. 
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Ang  II  is  thought to  stimulate  aldosterone  synthesis  through various  intracellular 
signalling pathways including the src family of  tyrosine kinases (Sirianni et al2001) 
and  the  12-lipoxygenase  (12-LO)  pathway  (Gu  et al 2003).  However,  the  best-
characterized pathway is  the activation of phopholipase C (see figure 1.12).  Once 
activated, phospholipase C hydrolyses phosphatidyl inositol 4,5-biphosphate (PIP2) 
to  1,4,5 inositoltriphosphate (IP3) and diacylglycerol (DAG) resulting in release of 
Ca
2+ from intracellular stores and activation of protein kinase C (PKC) respectively. 
At  the  same  time,  the  membrane's potassium  permeability  decreases  resulting  in 
72 depolarization of  the cell and stimulation of  voltage-gated calcium channels, causing 
entry of extracellular calcium (Ca
2+).  The increased intracellular Ca
2+ concentration 
activates  calmodulin  and  regulates  CYP 11 B2  transcription  through  various 
calmodulin-dependent kinases (Condon et al 2002).  PKC has no  apparent effect on 
CYP 11 B2  transcript levels but does inhibit expression of CYP 17 (Bird et al 1996), 
perhaps contributing to the zonation of  the adrenal cortex. 
The RAS  is very sensitive to changes in circulating potassium levels.  The level of 
potassium  affects  renin  secretion as  well  as  having  a  direct effect on the  adrenal 
cortex  to  increase  aldosterone  secretion.  Potassium  (like  Ang  II)  stimulates 
aldosterone secretion by increasing expression of CYP 11 B2 through an increase in 
intracellular  Ca
2+ and  activation  of calmodulin  kinases.  Potassium  signalling  is 
mediated through membrane depolarization, leading to an influx of calcium through 
T and L-type  channels  (see  figure  1.12).  K+  and partially Ang II  stimulation of 
CYP 11 B2 mRNA can be blocked by calcium channel blockers such as nifedipine. 
1.13  Transcriptional regulation of the CYPJJB Genes 
As  mentioned  previously,  chronic  regulation  of  steroidogenesis  involves 
transcription of the  genes  encoding the  necessary  steroidogenic enzymes.  This  is 
mediated by alteration of trans-acting factors that bind to the cis-regulatory elements 
within the 5' regulatory regions of  the target genes. 
Investigation of the  5'  regulatory regions of the  bovine CYP 11 B gene revealed six 
cis-acting  elements  (Ad1-6)  (Kirita  et al  1990)  (see  figure  1.14).  Deletion  and 
mutation analysis confirmed that Adl and a region containing Ad3  and Ad4 were 
essential  for  the  ACTH/cAMP-induced  expression  of the  gene  (Hashimoto  et  al 
73 1992;  Kirita et al 1990;  Takayama et al 1994).  These  sites  are  highly conserved 
within the CYP  JIB genes of all species studied so  far,  including hCYP  IIBI (Wang 
et al2000) and hCYP  IIB2 (Clyne et al1997), with the exception of  the rat CYP IIBI 
gene (Rainey 1999). 
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Figure 1.14.  Schematic diagram of  the bovine CYPJJB promoter with the 
cis-elements (Adl to Ad6) that are conserved among all the CYPJJB genes 
(Morohashi et al 1993) 
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The  Ad1  element closely resembles  a consensus  cAMP regulatory element (CRE) 
site.  CRE's  play an essential role  in cAMP-dependent gene  expression of a wide 
variety of genes.  Proteins, such as the CRE-binding protein (CREB) (Montminy & 
Bilezikjian 1987) and the highly related activating transcription factors (A TF) (Hai et 
al 1989; Hurst et al 1990), bind to CRE sites to initiate transcription. CREB binds to 
DNA  as  a  dimer  (Yamamoto  et al  1988)  and  has  a  conserved  region of leucine 
residues  (leucine zipper) at its  C terminus that enables dimerization and sequence-
specific DNA binding (Dwarki et al 1990; Yun et al 1990).  CREB binds to  DNA 
through  a  domain  of basic  residues  near  the  leucine  zipper.  These  regions  are 
characteristic of the bZIP family of transcription factors  and are  highly conserved 
74 between CREB and ATF1  (Rehfuss et a/1991).  CREB functions as a component of 
a  variety  of signalling  pathways,  particularly  PKA  (Montminy  1997),  but  also 
mitogen-activated protein kinases (MAPKs) (Xing et a/1996) and CaMKs (Sheng et 
a/1991; Sun et a/1994).  All these pathways mediate CREB-induced transcription 
by phosphorylating  CREB  at residue  serine  133  (Ser133)  (Gonzalez  et al  1989). 
Mutation of this  Ser133  residue  abolishes the transcriptional response to  cAMP  in 
vitro  (Gonzalez  et  al  1989).  The  phosphorylated  Ser133  binds  another  protein 
referred to as  the CREB-binding protein (CBP) (Chrivia et al 1993). Co-expression 
of CBP  in vitro increases the stimulus-induced CREB transcription of CRE reporter 
gene constructs (Kwok et a/1994). CBP is a 265-kDa nuclear protein, which binds to 
phosphorylated  CREB  and  allows  recruitment  and  stabilization  of  the  RNA 
polymerase  II  transcription  complex  on  the  promoter  of  CREB  target  genes 
(Nakajima et a/1997; Shikama et a/2000).  CBP is also able to alter the chromatin 
structure, making the DNA template more accessible to the transcriptional machinery 
due to its histone acetyltransferase (HAT) activity and ability to recruit other proteins 
with similar functions (Bannister & Kouzarides 1996; Ogrysko et a/1996). 
1.13.2  AD4 (SF-1) 
The Ad4 site  (CCAAGGTC) is  also found to  be important in the regulation of the 
bovine CYP II  B gene.  This Ad4 site or homologous sequences have been identified 
in the regulatory regions of all other steroid P450 genes (CYPJJAI, CYP2I, CYPI7, 
CYPJJBI,  CYPJJB2,  CYPI9)  (Morohashi  et  al  1992),  suggesting  an  important 
functional  role  in  steroidogenesis.  An  AD4-binding  protein  (AD4BP)  has  been 
identified and cloned from  bovine adrenal  cortex nuclear extract (Morohashi et al 
1992).  AD4BP is  a homolog of the  steroidogenic factor  1 (SF-1) identified in the 
75 mouse  (Ikeda  et al 1993;  La1a  et al  1992).  SF-1  is  an orphan member,  with an 
unknown  or  possibly  non-existent  physiological  ligand,  of the  nuclear  hormone 
receptor  superfamily,  with  potential  phosphorylation  sites  for  cAMP-dependent 
kinases, CaMK or PKC, suggesting a role for SF -1  in cAMP-dependent transcription. 
SF-1  is  a  53kDa  protein  comsisting  of  a  zinc  finger  domain  and  ligand 
binding/dimerization  domain.  These  functional  domains  are  conserved  between 
species (human, bovine, rat and mouse)  supporting the existence of a ligand.  The 
oxysterols  (25-,  26- or  27 -hydroxycholesterol)  enhance  SF -1-dependent 
transcriptional activity in  vitro,  suggesting that SF-1  is  a ligand-activated receptor 
(Christenson et al 1998; Lala et al 1997).  However, this is  a controversial finding 
(Mellon & Bair 1998) and needs further clarification. 
SF -1  is  expressed  exclusively  in  steroidogenic  tissues  and  the  brain.  Important 
information about the role ofSF-1 came from the development ofthe SF-1  knock-out 
mouse (Luo et al 1994).  These mice survive the in utero stage of development but 
all die within 8 days of birth due to adrenocortical insufficiency.  They lack adrenal 
glands  or gonads.  Therefore  SF -1  plays an  essential role  in the  development and 
function of  the primary steroidogenic tissues.  Naturally occuring SF-1  mutants have 
also been identified in patients with primary adrenal failure (Ozisik et al 2002).  In 
males, these mutations are also characterized by complete sex reversal.  Within the 
adrenal,  SF -1  has been found to play a key role in the transcriptional regulation of 
most of the  steroid hydroxylase  genes  (CYPllAI,  CYP21,  CYPllBI, CYP17 and 
CYP 19) as well as 3  fJHSD and StAR.  SF -1  regulation of  transcription is mediated by 
interaction with various co-activator proteins, including steroid receptor coactivator I 
(SRCI) (Ito et a/1998), glucocorticoid receptor interacting protein (GRIPI) (Hammer 
et a!  1999) and CBP /p300  (Monte et a!  1998) and also through repressors such as 
76 DAXl that inhibits SF -!-mediated steroidogenesis  (Babu et a! 2002; Ito et a/1997). 
SF-1  is  homologous to  the  Drosophila fushi  tarazu factor  1 (FTZ-Fl) (Lala  et al 
1992),  indicating conservation of the  gene  between vertebrates  and  invertebrates, 
again emphasizing the importance of  its role in development. 
1.13.3  Transcriptional Regulation ofCYP11B2 
Determination of  the important cis-elements within the upstream regulatory region of 
CYP  11 B2 (20 17bp) has been carried out using transient transfection of reporter gene 
constructs in both mouse (Yl) and human (H295R) adrenocortical tumour cell lines. 
These CYP  11B2-reporter gene studies confirm that Ang II, K+, Ca
2+ channel agonists 
and  cAMP  analogues  upregulate  gene  expression (Clyne  et al 1996;  Clyne  et al 
1997).  Deletion analysis of this construct has revealed that 3 functionally important 
cis  elements  are  required  for  basal  expression  and  response  to  Ca
2+  and  cAMP. 
These are a near consensus CRE at -71/-64 (Adl) and an element at -129/-114 (Ad5) 
which are homologous to sites previously identified in the bovine CYP JIB gene, Ad1 
and Ad5  respectively,  and also  a NBRE-1  site  at  -766/-759  (Bassett et al 2004b; 
Clyne et a/1997) (see figure 1.15). 
CYP1182 
-766/-759  -344/-336 
NBRE-1  Ad4 
-129/-114 
COUP/SF1 
NGFIB/NURR1 
Ad5 
-71/-64 
Ad1 
(CRE) 
Figure 1.15. Schematic diagram of the transcription factor binding sites in the 
hCYPJJB2 5'UTR (Bassett et al2004b). 
77 The  CRE  at  -71/-64  (TGACGTGA)  is  common to  both human  (h)CYP11B2  and 
(h)CYP 11B1, and is also present in other species such as the rat, mouse and hamster 
as  well as  the bovine CYP  11 B gene (Rainey 1999).  The CRE can be regulated by 
both PKA and CaMK mechanisms (Bassett et al 2000; Condon et al 2002).  Studies 
of CYP  11 B2 CRE binding by electrophoretic mobility shift assay (EMSA) revealed 
that it binds members of the CREB and ATF (ATF1  and ATF2) families (Bassett et 
al  2000).  As  mentioned  previously,  these  proteins  bind  to  the  CRE  following 
activation  by  phosphorylation.  One  possibility  is  that  this  phosphorylation  is 
mediated,  at  least  partly,  by  CaMK  I  or  IV  that  are  induced  by  Ang  II  or  K  + 
stimulation (Bassett et al2004b  ).  CaMK I and IV have been shown to phosphorylate 
CREB  and ATF-1, increasing the expression of target genes (Matthews et al 1994; 
Ueda et al 1999).  Mutations of the CRE site decreased basal reporter gene activity 
by approximately 50%  as  well  as  dramatically reducing the  response  to  Ca
2
+ and 
cAMP  stimulation (Clyne et al 1997).  However, further deletion studies produced 
further  decreases  in  transcription  suggesting  that  further  sites  are  neccessary  to 
account for maximal CYP  11 B2 expression. 
Electrophoretic mobility shift assay (EMSA) analysis ofthe -129/-114 (Ad5) element 
(CTCCAGCCTTGACCTT)  has  shown  that  it  binds  several  nuclear  proteins, 
including  SF-1  and another orphan nuclear receptor,  chicken ovalbumin upstream 
promoter transcription factor (COUP-TF) (Clyne et al 1997).  On the bovine CYP  17 
and the mouse CYP21  gene,  COUP-TF and SF-1  bind competitively to  a common 
site (Lund & Bakke 1995; Rice et al1991).  It is not clear at present whether they act 
competitively or synergistically on the human CYP  11 B2 gene.  Deletion of this site 
decreases  basal  activity  by  approximately  80%  and  also  reduces  the  maximal 
response to Ca
2+ and cAMP stimulation (Clyne et al1997). 
78 The transcription factors NGFIB (nerve growth factor-induced clone B) and NURRl 
(NUR-related  factor  1)  are  members  of the  NGFIB  family  of orphan  nuclear 
receptors that bind to  a consensus sequence NBRE (AAAGGTCA) (Giguere  1999) 
(Davis  et al 1991;  Wilson  et al 1991 ).  These  factors  can  also  bind to  the  Ad5 
element (on the  non-coding strand)  as  well  as  a novel NBRE-1  site  at -766/-759 
(Bassett et al2004a).  Both these transcription factors increase CYP  IIB2 expression 
when co-tansfected in human adrenal H295R cells  (Bassett et al 2004a). They are 
both expressed in the zona glomerulosa and their mRNA levels can be  upregulated 
by Ang II  or K+  stimulation.  There  is  also  evidence of upregulated expression of 
NURRl  mRNA that  correlates  very well  with that of CYP II  B2 in  subjects  with 
aldosterone  producing  adenomas  (Lu  et al 2004).  Mutation of the  NBRE-1  site 
decreases basal expression as  well as  the response to  Ang II  and K+ (Bassett et al 
2004a).  There are subtle differences in the function ofNGFIB and NURRl and there 
is  evidence to  suggest that NURRl plays  a more specific role in the regulation of 
CYP II  B2 (Bassett et al 2004a).  Therefore the CRE, Ad5 and NBRE-1  sites interact 
to  regulate  basal transcription as  well  as  the  response  to  each signalling pathway 
(cAMP or Ca
2+). 
The Ad4 or SF -1  site identified in the bovine gene has now been identified in all the 
steroid  P450s  based  on  sequence  alignments,  including  at  position  -351/-343 
(AGGTCC) of CYP  IIB2.  Although this site binds strongly to SF-1, deletion studies 
suggest  it  is  not essential  for  basal  or  stimulus-induced  expression  of CYP II  B2 
(Bassett et al 2002).  In fact co-expression of  CYP II  B2 reporter gene constructs with 
SF -1  has a negative effect on gene transcription, making the regulation of CYP II  B2 
different to the other steroidogenic genes, StAR, CYPllA, CYP II  BI and CYP  17 that 
are  all  induced  by  SF-1.  The  effects  of both  NGFIB  and  NURRl  on  CYP11B2 
79 expression can be inhibited by SF -1  supporting a negative effect of SF -1  (Bassett et 
al2004a). 
1.13.4  Transcriptional Regulation ofCYPJJBJ 
Reporter gene  studies and deletion analysis of the regulatory regions  of CYP II  BI 
showed  that  two  cis-elements  (Adl  and  Ad4)  are  required  for  basal  and 
ACTH/cAMP  induction of CYP 11BI  transcription  (Wang  et al 2000).  The  Adl 
element at position -71/-64 (TGACGTGA) is a near-consensus CRE also required for 
the regulation of CYP 11 B2 expression.  In contrast to  CYP 11 B2, the expression of 
CYP 11BI is also dependant on the Ad4 or SF-I binding site (Wang et al2000) (see 
figure 1.16). 
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Figure 1.16.  Schematic diagram of the transcription factor binding sites in  the 
hCYPJJB2 S'UTR (Wang et al2000; Wang et al2001). 
Liver  receptor  homologue-!  (LRH-1)  is  another  member  of the  orphan  nuclear 
receptor  superfamily  that  has  been  shown  to  stimulate  CYP 11BI  reporter  gene 
expression (Wang  et al 2001).  LRH-1  is  closely related to  SF-I  and produces  a 
similar stimulatory effect on CYP 11BI expression.  LRH-1  is  mainly expressed in 
80 the  liver, intestine, colon and pancreas (Nitta et al  1999) but low levels have been 
identified in steroidogenic tissues including adrenal tissue as well as in H295R cells 
(Sirianni et al 2002;  Wang et al 2001).  Further analysis revealed that it exerts its 
positive regulatory effect on CYP 11 B I by binding to the same cis-element as  SF -1 
(Ad4).  Whether LRH-1  acts  independently  or  in parallel  with  SF-1  is  yet to  be 
determined. 
A similar effect has  been observed with the homeodomain-containing transcription 
factor pituitary homeobox 1 (Ptx1/Ptx1) (Hiroi et al2003).  This factor interacts with 
SF-1  to  mediate pituitary development.  Ptx1/Ptx1  has  recently been found  to  be 
expressed within the adrenal gland and to stimulate CYP IIBI expression to a similar 
level  as  SF-1  after  transfection  in  Y1  cells.  Co-expression  with  SF-1  does  not 
produce a synergistic effect, suggesting independent mechanisms (Hiroi et al 2003). 
The  effect  of Ptx1/Ptx1  is  mediated  through  the  hCYPJJBI  Ptx1/Ptx1  binding 
element at position -377/372.  Mutation of this  element decreases  the  response to 
Ptx1/Ptx1 but has no effect on basal levels of expression. 
These  studies  highlight  specific  cis-elements  that  could  account  for  the  different 
transcriptional regulation of CYPJJBI and CYPJJB2.  Neither the Ad5  or NBRE-1 
elements  required  for  CYP II  B2  regulation  are  present  in  CYP II  B I  whereas  the 
-377/372 Ptx1/Ptx1  site  appears to  be specific to  CYPJJBI.  Also  SF-1,  which is 
important for  basal  and  stimulated  levels  of CYP JJBI  expression,  actually  has  a 
negative  effect on CYP II  B2  expression  suggesting  a possible  mechanism  for  the 
zonal expression of  these isozymes within the adrenal cortex. 
81 As well as being homologous at the nucleotide level, aldosterone synthase (P450a1 cto) 
and  11 ~-hydroxylase (P450n~) are also homologous at the protein level, with only a 
few amino acids accounting for their differences in structure.  The following sections 
will describe some of  the features of  cytochrome P450 enzymes highlighting some of 
the similarities and differences between P450aldo and P450n~-
1.14  Cytochrome P450 Protein Structure 
The P450aldo  and P450n~ proteins both consist of 503  amino acids, including a 24-
residue  N-terminal  mitochondrial  targeting  sequence.  Their  apparent  molecular 
masses are 48.5 and 50 kDa respectively (Ogishima et al1991).  At the protein level, 
the two enzymes are 93% homologous with only 37 amino acids that differ between 
them  (Kawamoto  et al  1992;  Momet  et  al  1989)  to  account  for  their  different 
functions.  Although the precise 3-dimensional structures of  mammalian P450aldo and 
P450n~ are yet to be determined, some information can be deduced from the known 
structures of  other cytochrome P450 enzymes. 
1.14.1  Bacterial/Microsomal P450 homologues 
To  date, no  structure of a mitochondrial cytochrome P450 has been experimentally 
determined.  The  tertiary  structures  of several  bacterial  P450s  have  been  well 
studied,  including  P450cam  (CYP101),  P450BM3  (CYP102)  and  P450terp 
(CYP 1  08).  More  recently the  structures  of three  mammalian microsomal  P450s, 
CYP2C5  (Williams  et  al  2000),  CYP2C8  (Schoch  et  al  2004)  and  CYP2C9 
(Williams et al 2003) were also resolved.  Studies of bacterial homologues suggest 
that P-450 enzymes consist of a number of helices (A-L) (Ravichandran et a/1993). 
The haem in cytochrome P-450 enzymes is located between helices I and L. 
82 1.14.2  Regions of  Conservation 
Although the sequence homology among the P450s is limited to  10-30% (Hasemann 
et al 1995) (Denisov et al 2005), they all appear to have a similar tertiary structure 
with a conserved structural core (Peterson &  Graham 1998).  This comprises a four-
helix bundle of helices D, E, I and L,  as  well as  regions of helices J and K and the 
structurally conserved  ~-sheets 1 and 2.  CYP450 enzymes contain haem prosthetic 
groups and use iron-oxo intermediates for oxidative reactions (see section 1. 7).  The 
inner  helices  form  a  'pocket'  around  the  haem,  enabling  substrate  binding  and 
activation.  This haem-binding domain is  a region of conserved non-polar residues 
that establish a hydrophobic environment surrounding the haem that is  important in 
maintaining its full redox potential.  It consists of the B'-C loop, the central I helix, 
the L-helix and the cys pocket (Hasemann et al 1995).  The cys pocket is the  ~ bulge 
region that surrounds the  cysteine residue that is  absolutely conserved in all P450 
enzymes.  This conserved cysteine residue forms  the proximal or fifth ligand to the 
haem  iron and is  responsible for  the  characteristic name;  the  ferrous-CO  complex 
gives 450nm Soret absorbance (Denisov et al 2005). The structurally conserved sets 
of~ sheets form the hydrophobic substrate access channel. All of  the P450 structures 
also  have  highly conserved coil,  termed the  meander,  of approximately 20  amino 
acids that runs between the K' helix and the cys pocket.  It interacts with the ERR 
triad (Glu(439)-Arg(442)-Arg/His/Asp(498)) located within the K helix forming a set 
of salt  bridges  that  are  thought to  be  important  in  stabilizing  the  core  structure. 
Disruption ofthis motif results in a loss of  haem binding (Hasemann et al1995). 
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The regions of  the highest sequence variability among the CYP450s are thought to be 
important  for  substrate  recognition  or  redox  partner  association.  These  variable 
regions tend to form theN terminal part of  the protein and include helices A, B, B', F 
and G and their interconnecting loops.  Gotoh determined several regions thought to 
be  important  for  substrate  binding  through  analysis  of the  known  structure  of 
P450cam and sequence alignment with members  of the  mammalian CYP2  family. 
He called these regions substrate recognition sites (SRS) 1-6 (Gotoh 1992). 
SRS  Secondary structure  Residues 
SRS-1  B' helix and B '-C loop  103-106 
SRS-2  C terminus of  helix F  209-216 
SRS-3  N terminus of  helix G  248-255 
SRS-4  N terminus of  helix I  302-320 
SRS-5  ~sheet  3 (p3)  375-385 
SRS-6  ~sheet 5 (~5)  485-493 
The positioning of  these SRSs is supported by the identification of residues essential 
for CYP2 substrate recognition that map to the identified sites (Gotoh 1992). 
1.14.4  Homology Modelling 
Homology  modelling  of  aldosterone  synthase  (P450aldo)  and  11 ~-hydroxylase 
(P450 11 ~) using the known structures of the bacterial enzymes P450BY-3 (CYP 102) 
84 and P450terp (  CYP 1  08)  produced models with a very similar overall structure but 
with differences in the position of the haem (see figure 1.17).  The positions of the 
various a-helices and  ~-sheets within these models are shown in table 1.2. (Belkina 
et al200I). 
Figure  1.17.  Superposition  of the  homology  models  of  P450u~ (black)  and 
P450atdo  (grey).  The  positions  of each of the  a-helices  are  marked.  While  the 
overall structure is similar the position of  the haem differs between the two proteins. 
(Taken from Lisurek & Bernhardt 2004) 
85 Name  I P450us  I P450aldo  Name  1  P450us  I P450aldo 
A-helix  30-44  30-40  F-helix  223-237  224-243 
A1-helix  46-50  46-50  G-helix  247-282  249-281 
~1-1  55-59  55-57  H-helix  289-296  290-296 
~1-2  64-67  65-67  !-helix  301-331  301-331 
B-helix  70-75  71-76  J-helix  334-354  334-351 
B'-helix  94-102  94-102  K-helix  364-376  365-376 
B3-helix  115-118  115-118  ~1-3  401-405  401-408 
C-helix  127-140  127-140  ~1-4  383-386  380-386 
C'-helix  145-150  145-150  ~2-1  389-392  389-393 
D-helix  158-175  157-175  ~2-2  395-398  395-398 
E'-helix  185-192  185-192  K'-helix  406-410  406-416 
E-helix  196-206  195-204  L-helix  450-468  451-466 
D3-helix  209-214  207-213 
Table  1.2.  Secondary  structures  of the  P450 11 ~  and  P450atdo  3D  homology 
models (Belkina et al 2001) 
Following  targeting  to  the  mitochondrion,  P450atdo  and  P450ll~ bind to  the  inner 
membrane through interactions that are  not yet well  defined.  However,  from  the 
homology models, there appear to  be hydrophobic patches on the protein surfaces, 
that  encompass  helices  A  and  A'.  These  are  thought  to  be  involved  in  protein-
membrane interactions. 
The I helix, the  largest helix running through the  centre of the molecule,  contains 
many hydrophobic amino acids and forms the major part of the putative active site, 
essential  for  substrate  binding and  specificity (Belkina et al 2001 ).  Excluding the 
mitochondrial  targeting  peptide,  only  29  amino  acids  differ  between  aldosterone 
synthase and 11 ~-hydroxylase out of a total of 4  79.  Several of these distinguishing 
amino acids are  located within the I,  helix including amino  acids at positions 301, 
302 and 320.  Replacing these amino acids within P450atdo with the corresponding 
P450ll~  equivalents  (L301P,  E302D,  A320V)  individually,  enhances  the  11~-
hydroxylation activity of P450atdo by approximately 2 fold.  When all 3 mutations are 
86 present  as  a  triple  mutant,  there  is  a  synergistic  effect  with  an  increase  in  11 ~­
hydroxylase activity to  85%  of wildtype  P4501 1 ~ and a suppression of aldosterone 
synthase  activity to  10%  of wildtype  P450aldo  (Bortner  &  Bernhardt  1996).  In  the 
opposite  scenario,  exchanging  amino  acids  within  P450 11 ~ for  the  P450aldo 
equivalents to  produce the  mutants  Val320Ala,  Ser288Gly and  Asn335Asp  (either 
alone  or in combination)  confers  aldosterone  synthase  activity to  P450 11 ~ with no 
apparent affect on its 11 ~-hydroxylase function (Bortner & Bernhardt 1996; Curnow 
et al1997; Mulatero et al1998).  Therefore, the differences in amino acid sequence 
within  the  I  helix  may  largely  explain  the  differences  in  specificity  of the  two 
enzymes. 
The I helix within P450aldo or P450 11 ~ is encoded by residues from exon 5 and exon 6 
of the  genes.  Studies  on  the  monogenic  hypertensive  disorder,  glucocorticoid 
suppressible  hyperaldosteronism  (GSH)  support  an  essential  role  of this  protein 
region for enzyme function (see section  1.5.2.1).  GSH is  the result of a chimeric 
gene consisting of the 5' region of CYP II  B I attached to part of CYP II  B2, resulting 
in the synthesis of aldosterone synthase being under the control of  ACTH.  However, 
if the cross-over point between the genes is after codon 302 (half way through ex on 
5), aldosterone synthase activity is undetectable, suggesting that regions upstream of 
this are indeed essential for enzyme function (Pascoe et al1992a). 
Homology modelling has  suggested that the main difference between P450aldo  and 
P450 11 ~ is  the  orientation of the  haem.  This  affects  the  way in which the  haem 
interacts with the side chains of adjacent amino acids.  In P45011 f3,  the haem interacts 
with Arg448 and Arg384 whereas in P450alcto, the haem forms two interactions with 
Arg448.  Mutations in both Arg448 and Arg384 have been identified as the cause of 
87 congenital  adrenal hyperplasia (11 ~-hydroxylase deficiency)  (see  section  1.15.2.3) 
with all known mutations completely abolishing enzyme activity (Curnow et al1993; 
Geley et al1996; Nakagawa et al1995; White et al1991), supporting a key role for 
these  amino  acids  in  haem  stabilization.  Due  to  these  differences  in  haem 
interactions, the active site of  P450II~  is  predicted to  be  larger than that of P450aldo 
(Belkina  et  al  2001).  This  would  seem  appropriate  as  the  main  substrate  for 
P450u~  (S)  is  larger  than that  for  P450aldo  due  to  the  presence  of an  extra  17a-
hydroxy group. 
Other studies  clearly demonstrate  that residues  relatively remote  from  the  known 
active  site  of P450aldo  or  P450u~  can  also  markedly  alter enzyme  function.  Their 
location provides  further  insights  into  the  function  of cytochrome P450  enzymes. 
Fisher et al  (2000) showed that substituting the  aldosterone-specific residue D147, 
that is distant from the active centres, for the 11 ~-hydroxylase equivalent (E 14 7) and 
vice versa, significantly alters activity (Fisher et al 2000). 
1.15  Evidence for a Role of the CYPJJB locus in  Essential 
Hypertension. 
As early as  1956, functional abnormalities of the adrenal cortex were suggested as a 
cause of essential hypertension (Genest et al 1956) and adrenal cortex hyperplasia 
has  been  found  to  be  a  feature  of many  hypertensive  patients  at  post-mortem 
(Komiya  et  al  1991 ).  Although  no  single  causative  defect  in  corticosteroid 
biosynthesis has been identified, evidence from animal models and monogenic forms 
88 of hypertension demonstrate that modification of the CYP 11 B I and CYP 11 B2 genes 
can  affect blood pressure  and  cardiovascular  function  and  may therefore  help  to 
identify possible mechanisms contributing to essential hypertension. 
1.15.1  Animal Models of  Hypertension 
Animal models have proved extremely useful in studying the heritable component of 
essential hypertension.  The complexity of interpreting data from human subjects is 
greatly reduced by using inbred strains, which decreases the genetic heterogeneity, 
and also environmental influences can be completely controlled.  Several rat models 
of genetic hypertension have been developed (Rapp 2000).  Genetic crosses between 
hypertensive  and control  strains  enable  the  identificaton of the  individual  genetic 
causes of  hypertension. 
1.15 .1.1  Dahl salt sensitive rat 
In 1962, Dahl selectively bred rats according to the level of blood pressure achieved 
on a high salt (NaCl) diet.  Two strains of rat were selected.  In one strain, blood 
pressure  is  salt  sensitive  (ss)  and  rats  become  severely  hypertensive  upon  salt 
loading.  In the  other,  blood  pressure  is  salt  resistant  (sr).  Biochemical  analysis 
revealed  differences  in  corticosteroid  metabolism.  In  the  rat,  the  principal 
glucocorticoid  is  corticosterone,  which  is  synthesised  from  DOC  by  11 ~­
hydroxylase.  11 ~-hydroxylase is  also  able  to  catalyze  IS-hydroxylation  and  an 
alternative end product is 18-hydroxydeoxycorticosterone (18-0H DOC), which may 
have  weak mineralocorticoid activity.  The  ratio  of corticosterone to  18-0H-DOC 
varies and may be due to variations in  11 ~-hydroxylase structure and function.  In 
the ss strain adrenal cortex, there is a proportionally greater synthesis of 18-0H DOC 
89 relative  to  corticosterone  (Rapp  &  Dahl  1972).  Investigating  the  CYP 11 BI  gene, 
which  encodes  for  11 ~-hydroxylase  as  a  possible  candidate  gene,  revealed 
polymorphisms  which  associate  with  18-0H DOC  levels  as  well  as  with  blood 
pressure. The 11 ~-hydroxylase in the sr strain has 5 mutations in exons 2, 6, 7 and 8 
(Cicila et a/1993).  A combination of  two ofthese, V381L and I384L, causes a loss 
of 11  ~-hydroxylase function in vitro and is thought to be the explanation of why the 
sr animals synthesise less 18-0H-DOC (Matsukawa et al 1993; Nonaka et al 1998). 
A chromosome 7 congenic strain of Dahl rats  confirms that this region contains a 
QTL for blood pressure, with the CYP II  B I gene being the likely candidate (Cicila et 
a/1997).  Mutations have also been identified in CYPJJB2 ofthe Dahl rat (Cover et 
al 1995).  However, these appear to cause a decrease in aldosterone synthase activity 
in the  ss  animal and so  their contribution to the hypertensive phenotype is  unclear. 
The Dahl rat is an excellent example of  how genetic differences, in this case resulting 
in altered corticosteroid production, can lead to hypertension.  It is also a good model 
of how environmental  factors  (salt)  and  genetic  factors  can interact to  produce  a 
hypertensive phenotype. 
1.15.2  Mendelian Hypertensive Conditions 
Several genes have been identified that cause Mendelian forms  of hypertension in 
man.  These disorders are caused by single gene defects that result in severe, early 
onset hypertension. Although rare, these mutations, which all result in altered renal 
salt  reabsorption,  give  insight  into  possible  molecular  pathways  involved  in  the 
pathogenesis of  hypertension (Lifton et a/2001).  Of  particular interest to this review 
are those involving variation at the CYP II  B locus. 
90 1.15.2.1  Glucocorticoid suppressible hyperaldosteronism CGSH) 
Glucocorticoid  suppressible  hyperaldosteronism  (GSH)  is  an autosomal  dominant 
condition  characterized  by  elevated  aldosterone  levels  despite  suppressed  plasma 
renin together with hypertension and hypokalaemia (Rich et al1992; Sutherland et al 
1966).  The aldosterone levels follow a circadian rhythm identical to that of ACTH 
and can be treated successfully with a synthetic glucocorticoid (dexamethasone) that 
inhibits ACTH  production from the pituitary gland.  GSH is  caused by a chimeric 
gene that forms when the 11 P-hydroxylase (  CYP 11 B I) and the aldosterone synthase 
(CYP JJB2)  genes  become  misaligned  during  meiosis  and  crossing  over  occurs 
(Lifton et al 1992).  The chimera has a 5' end containing the promoter region of the 
CYPJJBI gene and exons 1-3 joined to exons 5-9 of CYPJJB2.  This results in the 
gene expression and enzymatic activity of aldosterone synthase being controlled by 
ACTH instead of  Ang II and which therefore does not respond to Na  + status.  Ectopic 
secretion  of aldosterone  from  the  adrenal  fasciculata  increases  salt  and  water 
reabsorption and raises blood pressure. Substitution of more than the first 3 exons of 
CYP II  B I  results in an inactive chimeric gene suggesting residues after ex  on 3 are 
crucial to aldosterone synthase activity. 
1.15 .2.2 Apparent Mineralocorticoid Excess CAME) 
Apparent  mineralocorticoid  excess  (AME)  is  an  autosomal  recessive  trait 
characterized by early onset hypertension with hypokalemia and metabolic alkalosis, 
suppressed renin and very low circulation levels of aldosterone.  Despite the  low 
levels  of aldosterone, hypertension in these  subjects responds to  mineralocorticoid 
receptor  blockade.  Genetic  analysis  of affected  families  revealed  an  association 
between  the  disease  and  loss  of  function  mutations  in  the  gene  for  11 P-
91 hydroxysteroid  dehydrogenase type  II  (ll~HSD2) (Murre  et al  1995).  In  normal 
subjects,  circulating  cortisol  levels  are  up  to  1000  fold  greater  than  circulating 
aldosterone levels.  Cortisol has a similar affinity for the MR as  aldosterone but is 
prevented from binding under normal circumstances by the enzyme 11 ~HSD2  which 
converts it to the inactive steroid, cortisone (Funder et al 1988; Stewart et al 1987) 
(see  section 1.9.3).  When  ll~HSD2 is  inactivated, cortisol is  free  to  activate MR 
resulting in hypertension. 
1.15 .2.3  11 ()-hydroxylase deficiency 
Congenital  adrenal hyperplasia is  the  generic  name  given to  a  group  of inherited 
disorders resulting from mutations in the enzymes involved in corticosteroidogenesis 
(see section 1.8).  11 ~-hydroxylase deficiency is  the second most common cause of 
congenital  adrenal  hyperplasia,  accounting  for  5-8%  of  cases  in  the  general 
population (White et al 1992) with a higher frequency  in  an Israeli population of 
Moroccan Jewish origin (Rosier et al 1992). It is an autosomal recessive condition 
resulting from  inactivating mutations  in the  CYP II  B I  gene,  which causes  adrenal 
hyperplasia  due  to  the  increased  drive  of ACTH  attempting  to  maintain  normal 
circulating cortisol levels. The result is low-renin hypertension and hypokalemia due 
to the accumulation of the precursor DOC, which has mineralocorticoid properties. 
The  circulating levels of DOC are  normally too  low to activate the MR but in this 
condition result in mineralocorticoid excess. The accumulating precursor steroids are 
shunted  into  pathways  of androgen  biosynthesis,  causing  female  virilization.  and 
postnatal hyperandrogenism in both sexes (White &  Speiser 1994). 
92 Mutations causing II  j3-hydroxylase deficiency 
The  disruptive  mutations  are  distributed across  the  entire  gene  but with a slightly 
higher frequency in exons 2, 6, and 8. There also appear to be mutational 'hot spots' 
in codons 318, 384 and 448  (see  table 1.3).  Several mutations disrupt the reading 
frame  of the  coding  sequence,  resulting  in  the  biosynthesis  of a  truncated  non-
functional  protein.  These  include  nonsense  mutations;  W116X,  K174X,  W247X, 
Q338X,  Q356X or frameshift mutations, delC32,  2bp insertion at codon 394, 28bp 
deletion or a 5bp insertion in exon 2 (see table 1.3).  The complete loss of enzymatic 
activity  is  usually  explained  by  mutations,  which  result  in  the  haem-binding  or 
substrate-binding  domains  being  incomplete  or  absent.  Many  of the  missense 
mutations in exons 2, 5, 6, 7 and 8 have also been shown to abolish 11 ~-hydroxylase 
activity  completely  after  transfection  in  cell  culture;  V129M,  T318M,  A331 V, 
E371G, R374Q, R384Q, V441G and R448C (Curnow et al1993; Geley et al1996). 
In  vitro analysis of mutations Pro42S, Asn133His and Thr319Met showed that they 
partially  reduced  11~-hydroxylase  activity  to  15-37%  of the  wildtype  activity 
(Joehrer et al 1997). These mutations were identified in subjects with a non-classic 
or mild form of 11 ~-hydroxylase deficiency.  It is characterized by milder androgen 
excess  with  slightly  elevated  blood  pressure  in  some  cases.  The  symptoms  of 
advanced bone age, accelerated growth, acne and menstrual cycle abnormalities may 
develop  during  childhood  or  at  puberty.  A  similar  non-classic  form  of 21-
hydroxylase  deficiency  also  exists,  and  in  fact  occurs  more  frequently  than  the 
classic form (Merke & Bornstein 2005).  Therefore it is likely there are more cases of 
non-classic  11 ~-hydroxylase deficiency  that  have  not  been  identified  due  to  the 
relatively mild signs and symptoms of  androgen excess. 
93 Merke et al  identified three novel mutations causing 11 ~-hydroxylase deficiency, a 
nonsense  mutation  at  codon  19,  a  novel  missense  mutation  in  codon  318 
(Thr318Arg) and a G to A substitution at the first base pair of intron 5 (318+ 1  A-G) 
within the splice site  (Merke et al  1998).  These mutations suggest that splice site 
variants may be important causative mechanisms of 11 ~-hydroxylase deficiency and 
also  identify codon 318  as  an additional mutational 'hot spot'.  Merke et  al  (1998) 
also  identified two  apparent polymorphisms  within the  CYP II  B I  gene  of healthy 
control subjects.  These turned out to be gene conversions events in exon 1 (R43Q) 
and  exon  7  (A386V)  whereby  the  11 ~-hydroxylase-specific  residue  had  been 
replaced  with  the  corresponding  aldosterone  synthase-specific  residue.  The 
frequency of  these or similar gene conversion events within the general population is 
unknown. 
94 Mutation  Ex on  Putative  3D  Effect in vitro  Reference 
location 
Gln19STOP  1  N terminus  Truncated protein  Merke et al (1998) 
delC32  1  A-helix  Complete loss of  activity  Curnow et al (1993) 
Pro42Ser  1  A-helix  15% t activity  Joehrer et al (1997) 
del28bp  2  B'-B3 loop  Truncated protein  Skinner et al (1996) 
(S105-Ll13) 
Trp116Cys  2  B-C loop  97% t activity  Krone et al (2005) 
Trp116STOP  2  B-C loop  Complete loss of  activity  Naiki et al (1993) 
Ins 5bp 121  2  C-helix  Truncated protein  Skinner et al (1994) 
Val129Met  2  C-helix  Complete loss of  activity  Geley et al (1996) 
Asn133His  3  C-helix  17% t activity  Joehrer et al (1997) 
Lys174STOP  3  D-helix  Truncated protein  Curnow et al (I 993) 
Trp247STOP  4  G-helix  Truncated protein  Geley et al (1996) 
Gly267Arg  5  G-helix  May alter splicing  Skinner et al (1996) 
Leu299Pro  5  Start of I helix  99% t activity  Krone et al (2005) 
Thr318Met  5  !-helix  Complete loss of  activity  Curnow et al (1993) 
Thr318Arg  5  !-helix  Undetermined  Merke et al (1998) 
318+1G-A  5+1  - Altered splicing  Merke et al (1998) 
Thr319Met  6  !-helix  37% t activity  J  oehrer et al (1997) 
Ala331Val  6  !-helix  Complete loss of  activity  Geley et al (1996) 
Gln338STOP  6  J-helix  Truncated Protein  Curnow et al (1993) 
Val348Ala  6  J-helix  Undetermined  Skinner et al (1994) 
Gln356STOP  6  BetweenJ-K  Truncated Protein  Curnow et al (1993) 
helix 
Glu371Gly  6  K-helix  Complete loss of  activity  Geley et al (1996) 
Arg374Gln  6  K-helix  Complete loss of  activity  Curnow et al (1993) 
Arg384Gln  7  Haem side chain  Complete loss of  activity  Curnow et al (1993) 
Arg384Gly  7  Haem side chain  Undetermined  Nakagawa et al 
(1995) 
Ins2bp394  7  ~1-4  Truncated Protein  Helmberg et al 
(1992) 
Arg427His  8  Meander  May affect haem binding  Skinner et al (1994) 
delF438  8  Meander  Complete loss of  activity  Krone et al (2005) 
Val441Glu  8  Meander  Complete loss of  activity  Curnow et al (1993) 
Arg448Cys  8  Haem side chain  Complete loss of  activity  Geley et al (1996) 
Arg448His  8  Haem side chain  Complete loss of  activity  White et al (1991) 
Ins3bp464  8  L-helix  Complete loss of  activity  Geley et al (  1996) 
Table 1.3.  Mutations in CYPJJBJ causing 11~-hydroxylase deficiency 
95 The  reason for the disruptive  effects of many of these  missense mutations  can be 
hypothesised from their putative 3D locations. As  mentioned previously, in P450 11 ~ 
the haem interacts with Arg448 and Arg384 and mutations at these sites completely 
abolish enzyme activity (Curnow et a/1993; Geley et a/1996; Nakagawa et a/1995; 
White et a/1991  ).  The residue T318 lies within the I  -helix or putative active site and 
is completely conserved in all CYP450s.  It is thought to be essential for binding of 
molecular oxygen and/or proton transfer,  which  are  essential  for  enzyme  activity 
(Curnow et a/1993; Merke et a/1998).  Amino acid residues E371  and R374 within 
the  K helix form  part of the  ERR-triad and  so  mutations  at  these  sites  would be 
expected  to  cause  enzyme  destabilization  (Hasemann  et al  1995).  Residue  P42 
within  the  A  helix  is  conserved  in  all  CYP II  B  isoenzymes  and  thought  to  be 
essential  for  proper  orientation  of the  enzyme  in  the  mitochondrial  membrane 
(Joehrer et al 1997).  Amino acid N133, also conserved in the CYP  liB family, lies 
within a region that may form  part of the  substrate  access  channel (Joehrer et al 
1997).  Within this region, there is  also  a cluster of glycines (G123,  G128,  G134), 
which are conserved between P459ll~ and P450aldo, and are involved in the flexibility 
of  the B-C loop.  The B-C loop is thought to be important for substrate recognition as 
it contains the proposed SRS-1  (Gotoh 1992) (see section 1.14).  Mutations within 
this region, such as W116, would be expected to affect substrate binding (Krone et al 
2005).  Residue L229 is located very close to the !-helix/active site.  The introduction 
of a proline, which is a large cyclic residue, at this site may alter the position of the 
helix relative to  the haem,  disrupting enzyme function (Krone  et al 2005).  Other 
residues  such as  V129  and  A331,  although their exact role  is  unknown,  they  are 
conserved between the CYP II  B isoenzymes and so  can be indirectly assumed to be 
functionally important. 
96 Although the frequency of lip-hydroxylase deficiency within the general population 
is very rare, it draws attention to the CYP llBllocus as a possible candidate that may 
contribute to hypertension.  Also, the more recent identification of  mutations causing 
a  milder  non-classic  lip-hydroxylase  deficiency  highlights  the  possibility  of the 
existence of  mutations that cause very subtle differences in enzyme activity that may 
be more difficult to recognise by phenotypic analysis. 
1.15.3  Mendelian Hypotensive Conditions 
As  well  as  the hypertensive conditions, there  are  also  several Mendelian forms  of 
hypotension  resulting  from  loss-of-function  mutations  in  9  different  genes  that 
impair renal sodium reabsorption (Lifton 2001).  These include the genes encoding 
aldosterone  synthase  (Pascoe  at  al  1992),  21-hydroxylase  (Amor et al  1988),  the 
mineralocorticoid receptor (Geller et al  1998) and the subunits of the ENaC (Chang 
et al1996). 
1.15.3.1 Aldosterone synthase deficiency 
Aldosterone  synthase  deficiency  usually  presents  m  newborn  infants  as  a  life 
threatening  electrolyte  imbalance.  It  is  characterised  by  salt  wasting  and 
hyperkalemia with elevated plasma renin activity and decreased aldosterone levels, 
resulting  in  dehydration,  vomiting  and  failure  to  thrive.  There  are  two  types  of 
aldosterone  synthase  deficiency,  previously  thought  to  be  two  separate  enzyme 
deficiencies and referred to as corticosterone methyl oxidase type I (CMOI) and type 
II  (CMOII)  (Ulick  1976).  However,  the  realization  that  aldosterone  synthase  is 
responsible for all 3 of the final stages of aldosterone synthesis (lip-hydroxylation, 
IS-hydroxylation and 18-oxidation) (see section 1.8.7) indicates that both types must 
97 be  caused  by  mutations  m  the  CYP II  B2  (aldosterone  synthase)  gene.  Type  I 
deficiency  appears  to  disrupt  IS-hydroxylation  as  indicated  by  low  to  normal 
secretion of IS-hydroxycorticosterone and little or no aldosterone production.  Type 
II affects IS-oxidation resulting in low or normal aldosterone levels at the expense of 
increased secretion of its immediate precursor, IS-hydroxycorticosterone (Ulick et al 
I992b). The largest numbers of  Type II cases identified have been Iranian Jews, born 
from  consanguineous parents, but the disease has also been documented throughout 
Europe and North America. 
Mutations causing aldosterone synthase deficiency 
Aldosterone synthase deficiency is a rare autosomal recessive condition arising from 
mutations within the CYP II  B2 gene.  Like II  P-hydroxylase deficiency the causative 
mutations are  spread throughout the  entire gene,  in this case CYP II  B2,  but with a 
tendency to  cluster in exon 3 (see  tables  1.4a  and  b).  However,  the  number of 
mutations  reported  to  cause  aldosterone  synthase  deficiency  is  less  than  those 
reported to cause II  P-hydroxylase deficiency. 
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Mutation  Ex on  Putative  3D  Effect in vitro  Reference 
Location 
Val35del5bp  1  A-helix  Truncated protein  Mitsuuchi  et  a! 
(1993) 
6bp  duplication  3  Between  C'- Complete loss of  activity  Kayes-W  andover  et 
153  D helix  a! (2001) 
Glu255STOP  3  G-helix  Truncated protein  Peter et a! (1997) 
Tyr265STOP  3  G-helix  Truncated protein  Lopez-Siguero et a! 
(1999) 
Leu324Gln  6  I-helix  Undetermined  Lopez-Siguero et a! 
(1999) 
Arg384Pro  7  P1-4  Complete loss of  activity  Geley et a! (1995) 
Val3 86Ala/Glu  7/3  p  1-4/E'-helix  Complete loss of  activity  Lopez-Siguero  et  a! 
188Asp 
(1999) 
Leu461Pro  8  L-helix  Complete loss of  activity  Nomoto  et  a! 
(1997) 
Arg173Lys/  7/3/3  P1-4/D-and  t  11 P and 18-hydrox,  Portrat-Doyen  et  a! 
Glu198AspN  al  E-helix  no 18-oxidase activity  (1998) 
386Ala 
Table 1.4a.  Individual and  combined mutations  in  CYPJJB2 causing Type 1 
aldosterone synthase deficiency (CM0-1) 
TYPE II 
Mutation  Ex on  Putative  3D  Effect in vitro  Reference 
Location 
V al3 86AlaJ  Arg  7/3  p  1-4/between  0.2% activity ofWt  Pascoe eta! (1992) 
181Trp  D-andE-helix 
Thr185Ile  3  E-helix  t 180H No 180x  Peter  et  a!  (1998) 
Lisurek eta! (2004) 
Arg181 Trp/del  3/  BetweenD-E  Complete loss of  activity  Zhang eta! (1995) 
C372  and K-helix 
Val386Ala/Thr3  7/5  I-helix  Complete loss of  activity  Zhang eta! (1995) 
18Met 
Ex  on  3+4  3/4  - Normal aldosterone  Fardella  et  a! 
conversiOn  (1996) 
T498A  9  C-terminus  llP and 18-hydrox,  Dunlop eta! (2003) 
no 18-oxidase activity 
Table 1.4b.  Individual and  combined  mutations  in  CYPJJB2 causing Type 2 
aldosterone synthase deficiency (CM0-11) 
99 Most of  the mutations causing Type I aldosterone deficiency result in a complete loss 
of aldosterone  synthase  activity  in  vitro  (see  table  1.4a).  They  include  the  5bp 
deletion in exon 1 that results in a premature stop codon (Mitsuuchi et al 1993), the 
nonsense mutation in exon 4 (E255X) which produces an enzyme lacking the haem 
binding domain (Peter et al1997), and a missense mutation in exon 8 (L461P) also 
thought to  be  important for  haem-binding  (Nomoto  et al 1997).  The  substitution 
R384P also causes Type I deficiency (Geley et al1995).  This arginine is conserved 
in all mitochondrial P450 enzymes and is  thought to  interact with the haem group 
(see previous section 1.14.2).  A similar mutation has been identified in CYP llBI 
that also completely abolishes activity (Curnow et al1993). 
Many of the mutations causing type II  deficiency, result in mildly impaired activity 
or  only  affect  certain  functions  of aldosterone  synthase  (see  table  1.4b ).  For 
example, Thr185Ile increases  11 ~-hydroxylase activity while severely reducing 18-
hydroxylation  and  abolishing  aldosterone  synthase  activity  (Lisurek  &  Bernhardt 
2004).  Interestingly,  CYP  11B2 and  CYP llBI are  identical  at this  position.  The 
substitution T498A  retains  11 ~-hydroxylase and  18-hydroxylase  activities  but not 
18-oxidase  activity,  coinciding  with  the  clinical  diagnosis  of type  II  deficiency 
(Dunlop et al2003).  These mutations give insights into which residues are important 
for the different functions of  aldosterone synthase. 
However, there is  some inconsistency between the CYP II  B2 activity as  assessed in 
vitro and the clinical phenotype observed (Portrat-Doyen et al 1998).  For example, 
the mutations reported by Zhang et al were present in a compound heterozygote with 
Arg181Trp/delC372  on  one  allele  and  Val386Ala/Thr318Met  on  the  other.  The 
clinical symptoms were suggestive of  Type II aldosterone deficiency, with detectable 
100 serum aldosterone  and elevated  IS-hydroxycorticosterone,  but the  mutants  had no 
measurable aldosterone synthase activity in  vitro (Zhang et al 1995).  This may be 
explained  by  other  in  vitro  studies  demonstrating  higher  aldosterone  production 
using  a  CYP 11 B1-containing  vector  compared  to  empty-vector,  implying  that 
CYP 11 B 1 may be capable of very low levels of aldosterone synthesis (Dunlop et al 
2003).  However,  the  opposite  situation  occurs.  The  presence  of  mutations 
R173K/E198D/A386V  produces  a  phenotype  consistent  with  Type  I  aldosterone 
synthase deficiency but in vitro studies showed residual activity comparable to Type 
II deficiency (Portrat-Doyen et al 1998).  Hence, the complications and dispute over 
the characterization of  the two subtypes of  aldosterone synthase deficiency. 
In several cases, the simultaneous presence of more than one homozygous mutation 
is  required  to  produce  the  phenotype  of  aldosterone  synthase  deficiency. 
Individually, several mutants such as  R173K, V386A, E198D or R181W have only 
modest effects on enzyme activity in  vitro but produce much greater effects when 
present in combination, suggesting there is significant interaction between the mutant 
loci  (Pascoe  et al  1992b;  Portrat-Doyen et al  1998;  Zhang  et al  1995).  Indeed, 
R173K and V386M occur frequently  in most populations  studied,  which supports 
their minor effects on enzyme activity.  However, when present, together they must 
interact  to  induce  a  conformational  change  in  the  enzyme,  resulting  in  altered 
activity.  In some subjects with apparent clinical symptoms of aldosterone synthase 
deficiency, no mutation affecting P450aldo activity could be identified (White 2004). 
The causative gene(s) in these cases remains to be determined. 
The putative 3D locations of several of  these mutants are within the conserved P450 
structural  core,  such as  residues  173  (helix  D),  318  (helix  I),  324  (helix  I),  386 
101 (strand 4 of ~-sheet 1)  and 461  (helix L),  confirming an essential functional role of 
these regions of the enzyme.  However, although these mutations give key insights 
into  what  residues  are  essential  for  enzyme  function,  they  do  not  give  enough 
information  to  explain  fully  the  relationship  between  gene/protein  structure  and 
enzyme activity. 
All these Mendelian disorders  are  very rare  and  do  not explain the  overall  blood 
pressure variation in the  general population.  However, they do  provide an  insight 
into the various pathways through which genetic variation can alter blood pressure. 
In the  light of these  rare  syndromes  it is  of interest that a slightly impaired  11 ~­
hydroxylase  function  has  been  previously  found  in  subjects  with  essential 
hypertension  compared  to  controls.  A  study  20  years  ago  by  de  Simone  and 
colleagues reported an increase in the levels of the precursor DOC following ACTH 
stimulation in hypertensive patients  compared to  controls  (de  Simone  et al  1985). 
More recently, a similar observation was made in hypertensives from Italy who had 
an  elevated  ratio  of  11-deoxycortisol  to  cortisol,  which  is  a  marker  of  11 ~­
hydroxylase  activity  (Connell  et  al  1996).  Section  1.10.2.1  described  how 
dysregulated aldosterone synthesis, as determined by an elevated ratio of aldosterone 
to  its  principle  trophin  renin,  appears  to  be  a  common  feature  of  essential 
hypertension.  Subsequent to  the  preceding  discussion of widespread variation in 
CYP JJBJ  and  CYP JJB2,  what  is  the  possibility  that  similar  genetic  variant(s) 
contribute to the predisposition to  essential hypertension?  This is the subject of the 
final section. 
102 1.16  Possible  Genetic  Basis  for  Hypertension  with  an 
Elevated ARR 
As  mentioned previously there is  now evidence that altered aldosterone production 
resulting in an elevated ARR may be  a common feature  of essential hypertension 
(Lim et al2002a).  Hypertension with a raised ARR may be a subset of  hypertension 
that  develops  gradually  as  a  result  of the  interaction  between  environmental  and 
genetic influences (Connell et al 2003).  The potential role for corticosteroids in the 
development  of  hypertension  has  previously  been  discussed.  The  enzymes 
aldosterone  synthase  (encoded  by  CYP II  B2)  and  11 ~-hydroxylase (encoded  by 
CYP JJBI)  are  responsible  for  the  last  stages  in the  synthesis  of aldosterone  and 
cortisol respectively.  The  monogenic  forms  of hypertension (section  1.15.2)  and 
animal models such as the Dahl rat (section 1.15.1), mentioned previously, highlight 
both these genes as key candidates for hypertension. 
1.16.1  CYP11B2 Polymorphisms and Hypertension 
Two common variants have been described in the CYP II  B2 gene (White &  Slutsker 
1995).  The  first  is  a  single  nucleotide  (cytosine/thymidine)  substitution in the  5' 
promoter region  at  position  -344C/T  that  disrupts  a  putative  binding  site  for  the 
steroidogenic factor SF -1.  The other involves the second intron of CYP II  B2, part of 
which is converted to the intron 2 sequence found in the adjacent gene CYP II  BI. 
These variants are in tight linkage disequilibrium so that the common haplotypes are 
T/Conv (38%), C/Wt (45%) and T/Wt (16%) (Davies et al 1999).  It has previously 
been reported that the  SF -1  T  allele  and the  intron conversion allele  occur more 
frequently in hypertensive subjects than in normotensives (Brand et al 1998; Davies 
103 et al  1999),  especially those  with a  high  ARR  (Lim  et al 2002b  ),  although  this 
finding is not supported in all studies (Kupari et al 1998; Mulatero et al 2000).  The 
association between the SF -1  T allele and blood pressure is supported by evidence of 
an epistatic  interaction of this  locus  with the  Y chromosome on the  likelihood of 
developing higher blood pressure (Charchar et al 2002).  These polymorphisms also 
appear  to  be  associated  with  higher  average  aldosterone  levels,  as  measured  by 
excretion rates of its principle metabolite tetrahydroaldosterone (Davies et al 1999), 
as well as higher average plasma aldosterone levels (Paillard et al 1999).  Again, this 
finding  has  not  always  been  confirmed  (Pojoga  et  al  1998).  As  mentioned 
previously,  recent studies  demonstrate  that up  to  15%  of unselected patients  with 
hypertension  have  a  raised  aldosterone  to  renin  ratio  suggesting  that  altered 
regulation  of  aldosterone  production  may  be  a  common  factor  in  essential 
hypertension (Lim et al 1999b  ).  However, in vitro studies suggest that, although the 
T allele at -344 has a 4 fold decreased affinity for SF-1, this has no  effect on gene 
transcription (Bassett et al 2002).  This strongly suggests that it is not the functional 
variant  and  that it may  be  in  linkage  disequilibrium  with the  as  yet unidentified 
functional  variant(s).  The reduced binding of SF-1  may enable more to  bind to  a 
functional site elsewhere. 
1.16.2  CYP11B2 and altered llfl-Hydroxylation 
Other studies have focused on the relationships of  these CYP II  B2 polymorphisms to 
basal and ACTH-stimulated corticosteroid levels (Davies et al2001).  No correlation 
was found between the genotypes of either polymorphism and basal corticosteroid 
levels.  Similarly, no  relationship of genotype was  seen to the response of the  end 
products cortisol and corticosterone to ACTH stimulation.  However, their respective 
104 precursors, 11-deoxycortisol and deoxycorticosterone, showed a significantly greater 
response to  ACTH stimulation in those  subjects with the  SF-1  T allele and the  IC 
conversion alleles.  This suggests that these genotypes are associated with impaired 
11~-hydroxylase activity.  A similar association was found between these alleles and 
plasma  11-deoxycortisol  levels  following  ACTH  stimulation  in  Finnish  males 
(Hautanena et al 1998).  The SF-1  polymorphism has also been shown to associate 
with markers  of 11 ~-hydroxylase function  in  a  normotensive  population.  In  this 
case,  the  TT  group  showed  increased  excretion  levels  of tetrahydrodeoxycortisol 
(THS) and tetrahydrodeoxycorticosterone (THDOC), the principle metabolites of S 
and DOC  respectively,  compared to  the  CC  group  (Connell  et al  1996).  Several 
aspects  of corticosteroid  metabolism,  including  aldosterone  excretion  rate  and 
markers of 11 ~-hydroxylase efficiency have been shown to be heritable (Inglis et al 
1999).  Recent studies have also demonstrated that the excretion of THS is heritable 
(19.4%) and that the -344 T allele is more strongly associated with higherTHS levels 
than  the  C  allele.  (Connell  et  al  2004).  Importantly,  a  slightly  impaired  11 ~­
hydroxylase function is  a consistent finding in subjects with essential hypertension 
compared to controls (Connell et al1996; de Simone et al1985; Honda et al1977). 
How could variations  in CYP  II  B2 affect  11 ~-hydroxylase activity?  One  obvious 
explanation is  that  CYP  II  B2 polymorphisms  are  without  effect but are  in strong 
linkage  disequilibrium  (LD)  with  functional  polymorphisms  in  CYP liB  I.  The 
CYP II  B I gene encoding the enzyme 11 ~ hydroxylase is adjacent and homologous to 
CYP  11B2.  It is  possible,  even  likely,  that  the  -344  and  the  intron  conversion 
polymorphisms in CYP  11B2 are in linkage with variants in CYP liB  I  and that these 
are  responsible  for  the  observed phenotype  of altered  11 ~-hydroxylase efficiency. 
105 This is  supported by experimental evidence of an association between the CYP II  B2 
polymorphisms and urinary levels of tetrahydro-deoxycortisol (THS), the principle 
metabolite of S (Kennon et al 2004).  Keavney et al have shown that the -344C/T 
and  IC  polymorphisms  in  CYP II  B2  are  in  linkage  disequilibrium  with  two 
polymorphisms in CYP 11 B  I;  a CTG to CTA substitution in codon 7  5 of ex on 1 and 
a G to A substitution in intron 3 (Keavney et al 2005).  The association with urinary 
THS  levels was  found to be  strongest with the  exon 1 polymorphism, but this  is  a 
synonomous  base  change  and  so  is  unlikely  to  account  for  the  biochemical 
phenotype of impaired  11 ~-hydroxylase deficiency.  Another study recently found 
strong  linkage  disequilibrium  between  polymorphisms  in  CYP II  B2  and 
polymorphisms in CYPIJBI; a nonsynonymous  substitution (T to  C)  in codon 75 
and a G to A substitution in intron 6 (Ganapathipillai et al2005).  Using the ratio of 
urinary THS to total cortisol metabolites (tetrahydroxycortisone (THE) + tetrahydro-
11-deoxycortisol (THF) + 5aTHF)  as  a marker of 11 ~-hydroxylase function,  they 
reported a decreased  11 ~-hydroxylase activity in subjects with an  increased ARR. 
The  main  CYP II  B  haplotypes  identified  also  associated  with  11 ~-hydroxylase 
efficiency,  supporting  the  hypothesis  that  markers  in  CYP 11 B I  account  for  11 ~ 
hydroxylase activity in vivo. 
These findings provide strong evidence that the -344 CIT and IC  polymorphisms in 
CYP IIB2 are in LD with genetic variants in CYP IIBI that account for the observed 
phenotype of impaired 11 ~-hydroxylation.  However further fine mapping across the 
entire CYP II  B locus is required to identify potential causative variants. 
106 1.16.3  Altered 11{3-Hydroxylase  Efficiency  and Hypertension  with  a 
raisedARR 
If the -344 CIT and intron conversion polymorphisms identified in CYP JJB2 are  in 
LD  with  functional  variants  in  CYP II  BI  causing  reduced  11 ~-hydroxylase 
efficiency, then how does this account for the association with increased aldosterone 
levels, hypertension and an elevated ARR?  It seems plausible that mild long-term 
deficiency of 11 ~-hydroxylase activity may result in a resetting of  the hypothalamic-
pituitary axis  by causing a sustained mild increase  in ACTH drive to  the  adrenal 
cortex  to  maintain  normal  plasma  cortisol  levels  (Connell  et  al  2003).  If as 
suggested this mildly impaired 11 ~-hydroxylase efficiency is  genetically determined 
then it is  effectively a minor variant of classical  11 ~-hydroxylase deficiency  (see 
section  1.15.2.3).  Lifelong  exposure  to  a  slightly  enhanced  ACTH  drive  to  the 
adrenal cortex may eventually promote the development of hyperplasia of the zona 
glomerulosa and zona fasciculata, resulting in increased synthetic capacity for both 
cortisol  and  aldosterone.  As  mentioned previously adrenal  gland hyperplasia  is  a 
common histologic  finding  in hypertensive patients  at post mortem  (Komiya et al 
1991).  ACTH  stimulates  the  expression  of  a  number  of  genes  required  for 
aldosterone synthesis inlcuding StAR, P450scc (CYP JJA) and P450-21  hydroxylase 
(CYP2I)  producing  a  potential  increase  in  aldosterone  synthetic  capacity  (Miller 
1988).  In  support of a role  for  ACTH in regulating aldosterone  is  recent research 
demonstrating that POMC-derived peptides are  necessary to  develop and maintain 
normal  aldosterone  production  (Coll  et  al  2004).  Although  chronic  ACTH 
stimulation has  been shown to  repress  aldosterone synthesis  (Oelkers 2000), these 
studies have used supraphysiological concentrations of ACTH, not equivalent to the 
107 mild and chronic increase suggested here.  In ACTH-dependent Cushing's disease, in 
which  there  is  chronic  sustained  exposure  of  the  adrenal  cortex  to  ACTH, 
aldosterone levels are in fact neither suppressed or elevated (Whitworth et al 2000). 
In  fact,  ACTH  increases  the  expression  of a  number  of genes  necessary  for 
aldosterone production emphasizing the potential for enhanced aldosterone synthetic 
capacity and response to stimuli such as angiotensin II or potassium (Miller 1988). In 
hypopituitary patients the  angiotensin IIIaldosterone response  is  blunted indicating 
that ACTH may be involved in setting the sensitivity of this relationship (Seifert & 
Oelkers  1981 ).  Therefore the genetic change in 11 ~-hydroxylase efficiency may in 
the  long  term  and  in  combination  with  other  genetic  and  environmental  factors, 
promote ACTH dependent adrenal zonal hyperplasia with an increased sensitivity of 
aldosterone to  its main agonist Ang II resulting in hypertension with a raised ARR 
(Connell  et al 2003;  Freel  &  Connell 2004).  In support of this  are  early  studies 
demonstrating  a  good blood pressure  response  to  dexamethasone  in patients  with 
essential  hypertension,  suggesting  that  ACTH  was  sustaining  production  of a 
hypertensinogenic adrenal steroid (Hamilton et al 1979).  Also endogenous levels of 
the  adrenal androgen dehydroepiandrosterone sulfate (DHEAS), which is regulated 
by ACTH, are increased in subjects with hypertension (Schunkert et al1999b  ). 
1.17  Aims 
Genetic variation in CYPJJB2 (-344 CIT and intron conversion polymorphisms) has 
been linked to  two  key  corticosteroid phenotypes  in essential hypertension; raised 
ARR and decreased 11 ~-hydroxylase efficiency.  It is unclear exactly how variation 
in  CYP II  B2  can alter the  biochemical  function  encoded by a  neighbouring  gene 
(CYP JJBI) but the hypothesis that shall be  investigated is  that the  -344  CIT and 
108 Intron conversion variants in CYPJJB2 are in linkage with variants in CYPJJBJ that 
account for the reduced 11 ~-hydroxylase efficiency. 
The aim of this study was to  investigate the way in which genetic variation at the 
CYP JJBJIB2  locus  leads  to  altered  11~-hydroxylase  function  through  detailed 
analysis  of the  pattern  of genetic  variation  across  the  whole  locus.  This  will 
hopefully enable the identification of variants across the CYP 11 B  1  I  B2 locus that are 
in  LD  with the  -344  CIT  and  IC  polymorphisms.  The  functional  effects  of any 
variants identified will be tested in  vitro in order to  determine the genetic variation 
responsible for the observed phenotype of  impaired 11 ~-hydroxylation. 
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Materials and Methods 
110 2.1  Functional Effects of Mutations in CYPJJBJ 
2.1.1  Single Stranded Conformational Polymorphism method 
The  method of single  stranded conformational polymorphism (SSCP) was  used in 
our laboratories to screen for mutations in the coding region of  the CYP II  B I gene by 
Mrs Christine Holloway and Dr Angela Fisher.  Each exon was amplified by PCR 
from genomic DNA using radiolabelled primers (Oswel DNA Service, Southampton, 
UK) (table 1,  appendix 2).  Each 25-!lL PCR contained 1.5  mM MgCh, 0.25  mM 
dNTPs,  12.5 pmol each primer and  1 Unit of thermostable  Taq DNA polymerase 
(Promega Corp., Southampton, UK) and was  denatured at 94C for 3 min, followed 
by 30 cycles of 94°C for  1 min, 55°C annealing for  1 min and 72°C  extension for  1 
min,  and  a final  incubation of 72°C  for  7 min.  The  annealing temperature  varied 
depending on the melting temperature of the primers being used.  In most cases the 
PCR amplicon was greater than 250bp so an appropriate restriction enzyme was used 
for  digestion to  produce  smaller  fragments  to  ensure  increased  sensitivity  of the 
SSCP  analysis  (table  1,  appendix  2).  The  PCR  products  were  denatured  and 
separated by electrophoresis (30W, 6h, room temperature) on a non-denaturing 7.5% 
polyacrylamide  gel.  Autoradiographs  of the  gels  were  produced and  the  banding 
pattern of the  individual patients  compared to  determine  sequence  variants.  The 
presence of any identified mutations were then confirmed by automated sequencing 
using  the  ABI  Big  Dye  Terminator  v3.1  Cycle  Sequencing  Kit  (PE  Applied 
Biosystems, Foster City,  CA, USA) (see section 2.2.6).  For exons 2,  3,  4 and 7 it 
was  not possible to  selectively amplify CYP 11 B I  without CYP 11 B2  so  if variants 
were  identified in these  areas  by  SSCP  the  products  were  subcloned into  pGEM 
easy/T-vector (Promega) prior to sequencing. 
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amino  acid in exons  1,  2 and 3 at the  following  locations:  R43Q,  L83S,  H125R, 
P135S, F139L, L158P, L186V and T196A.  Mutant R43Q results in the replacement 
of  the  11 ~-hydroxylase-specific  residue  with  the  corresponding  aldosterone 
synthase-specific residue.  To  examine  the  functional  effect of these  mutations  in 
vitro they were  recreated by site-directed mutagenesis  and  transfected into  human 
placental JEG-3 cells (see section 2.1.4). 
2.1.2  Site-Directed Mutagenesis 
The eDNA encoding human 11~-hydroxylase (CYP IIBI), in the vector pCMV4 was 
kindly provided by Professor Perrin White.  The eDNA insert was  1.5kb  and  the 
vector was 4.8kb.  CYP 1J BI missense mutations previously detected by SSCP were 
constructed in vitro by site-directed mutagenesis (SDM) of the cloned eDNA.  This 
was performed using the Quick-Change SDM kit (Stratagene Ltd, Cambridge, UK). 
Mutation of nucleotides encoding amino acids arginine 43, leucine 83, histidine 125, 
phenylalanine  139,  leucine  186,  proline  135,  leucine  158  and  tyrosine  196  was 
performed  using  specific  sense  and  antisense  mutagenic  oligonucleotide  primers 
which  were  designed  individually  according  to  the  desired  mutations  (MWG-
Biotech, Ebersberg, Germany) (table 2, appendix 2). 
2.1.2.1  SDM PCR protocol 
SDM was performed according to the kit's standard protocol. Briefly, the component 
reagents were assembled in a reaction tube and then incubated on a thermal cycler 
according to the amplification protocol. 
112 Component  Volume 
Reaction Buffer ( 1  OX)  5  ~-tl 
DsDNA template (1 Ong/1-tl)  4~-tl 
Sense Primer (12 5  ng/  ~-tl)  1  ~-tl 
Antisense Primer (125ng/~-tl)  1  ~-tl 
dNTP mix (  4mM)  1  ~-tl 
Nuclease free water (nfH20)  37~-tl 
Pfu Turbo DNA Polymerase  (2.5U/~-tl)  1  ~-tl 
Total volume 
Amplification protocol 
2. 95°C 
3. 55°C 
4. 68°C 
30 seconds 
30 seconds 
1 minute 
14 minutes 
50  ~-tl 
Initial Denaturation 
Denaturation 
Annealing 
Extension 
Steps 2, 3 and 4 were repeated for 12 cycles. 
2.1.2.2  Digestion of  parental DNA template 
Following temperature cycling, the product was  treated with  1  ~-tl  (1 0  U/~-tl) of the 
endonuclease Dpnl for  1 hour at 37°C.  Dpnl specifically digests methylated DNA 
such as  that which originates from  bacteria. It therefore  digests the parental DNA 
template but leaves the newly synthesized mutation-containing DNA intact. 
2.1.2.3  Transformation of Supercompetent Cells 
Epicurian Coli XL1-Blue supercompetent cells  (50~-tl) (Stratagene Ltd,  Cambridge, 
UK) were transformed with 4~-tl ofDpnl-treated sample DNA by heat pulsing for 45 
seconds in a water bath at 42°C.  The cells were then grown in NZY+ broth at 37°C 
for  one  hour.  The  transformation  reaction  was  plated  onto  LB/ampicillin plates 
113 (50)-Lg/ml) and incubated overnight (>16 hours) at 37°C.  Single transformed colonies 
were used to inoculate overnight incubations, which were shaken at 37°C overnight 
at 225 rpm in 5ml ofLB/ampicillin (l).lg/ml) broth. 
2.1.2.4  DNA Purification 
Plasmid  DNA  was  purified  from  the  overnight  incubations  usmg  a  QIAprep 
Miniprep Kit (QIAGEN Ltd, West Sussex, UK). The cultured LB was transferred to 
a  1.5ml  Eppendorf tube  and  centrifuged  at  maximum  speed  for  2  minutes  in  a 
tabletop centrifuge to pellet the bacterial cells. The cell pellets were resuspended in 
250J.!l Buffer Pl.  To lyse the cells, 250J.!l Buffer P2 was added and mixed by gently 
inverting the tube.  350J.!l Buffer N3  was added and mixed immediately by inverting 
the  tubes.  The  samples were  centrifuged for  10  minutes  at maximum speed in a 
tabletop  microcentrifuge.  The  supernatants  were  transferred  into  a  QIAprep  Spin 
Column and centrifuged at top speed for 1 minute. The flow-through was discarded 
and the column washed by adding 0.5ml Buffer PB and centrifuging at top speed for 
1 minute.  The wash step was repeated with 0. 75ml Buffer PE, and the column was 
centrifuged for  an additional minute to  remove  residual  wash buffer before  being 
placed in a clean 1.5ml microcentrifuge tube. DNA was eluted by adding 50J.!l nfl-hO 
to  the  center  of the  QIAprep  column,  letting  it  stand  for  1  minute,  and  then 
centrifuging it for  1 minute at top speed. The plasmid DNA minipreparations were 
stored at 4°C until required for further analysis. 
2.1.2.5  Restriction Digestion 
Restriction  analysis  was  performed  on  the  plasmid  DNA,  usmg  the  restriction 
enzyme  BamHI,  to  assess  quality  and  identify vectors  containing the  appropriate 
114 insert.  This enzyme linearizes CYP JJBI eDNA by hydrolysing it at a single site to 
produce a fragment of 6.3kb. 2f..ll of  plasmid DNA minipreparation (  ~ 1  OOng/f..ll) was 
combined with 0.5f..ll ofBamHI, 2f..ll Buffer J, 0.2f..ll ofBSA and 15.3f..ll ofnfl-I20  in a 
sterile 0.2ml PCR tube.  The reaction mixture was incubated at 3rC for 2 hours. The 
size of digestion product was analysed by electrophoresis of the whole reaction on a 
1% agarose gel for 40 minutes at 1  00 V. 
2.1.2.6  Confirmation of  Mutations 
Colonies of plasmids containing the insert as identified by restriction digestion were 
sequenced using the automated sequencing method described in Section 2.2.6.  The 
entire insert was sequenced using the primers; V6776, V6777 that bind to the vector 
and  N4019  that  binds  to  the  eDNA  (see  table  3,  appendix  2),  to  confirm  the 
presence of the desired mutations and to  confirm that no additional mutations were 
introduced inadvertently. 
2.1.3  Large-scale Plasmid Preparations 
Large  scale  plasmid  preparations  were  performed  usmg  a  Plasmid  Midi  Kit 
(QIAGEN Ltd, West Sussex, UK). A single colony from a freshly-streaked selective 
plate  was  grown  in  a  starter  culture  of 5ml  LBroth  containing  the  appropriate 
selective antibiotic for  ~8 hours at 3  7°C  with vigorous shaking.  The starter culture 
was diluted Ill  00 in selective LBroth and grown at 3  7°C with vigorous shaking for 
~  16 hours. The bacterial cells were then harvested by centrifugation at 6000 x g for 
15  minutes at 4°C.  The bacterial pellet was resuspended in 4ml of Buffer Pl. The 
lysis reaction was initiated by addition of 4ml Buffer P2 and inverting the tube 4-6 
times.  The solution was then incubated at room temperature for  5 minutes.  Next 
115 4ml of chilled Buffer P3  was added, the solution mixed immediately by inversion of 
the  tube  4-6  times  and  then incubated  on  ice  for  20  minutes.  The  solution was 
centrifuged  at  16000  x  g  for  40  minutes  at  4°C.  A  QIAGEN-tip  column  was 
equilibriated by applying 4ml of Buffer QBT and allowing the column to empty by 
gravity flow.  The lysate supernatant was applied to the column and allowed to enter 
the resin.  The QIAGEN column was washed with 2 x 1  Oml Buffer QC.  The DNA 
was then eluted by addition of 5ml Buffer QF.  The DNA was precipitated by adding 
3.5ml isopropanol to the elute, this was mixed and centrifuged immediately at 16000 
x  g  for  20  minutes  at  4°C.  The  supernatant  was  discarded  and  the  DNA  pellet 
washed with 2ml of  70% ethanol and centrifuged at 16000 x g for 1  0 minutes.  Again 
the  supernatant  was  discarded,  the  pellet  air-dried  for  2-4  hours  and  the  DNA 
redissolved in 200).ll nfl-hO. 
2.1.4  DNA Quantification using PicoGreen method 
PicoGreen dsDNA Quantitation Reagent (Molecular Probes, Leiden, Netherlands) is 
an  ultra-sensitive  fluorescent  nucleic  acid  stain  for  quantitating  double-stranded 
DNA (  dsDNA).  It is more sensitive than the commonly used method of measuring 
absorbance at 260nm and avoids the interference caused by contaminants commonly 
found in nucleic acid preparations such as nucleotides, single-stranded nucleic acids 
or proteins. 
Sufficient 1xTE buffer was prepared for the experiment from a 20x stock (Molecular 
Probes kit).  Serial dilutions of samples were pipetted onto a black microassay plate 
(1 OO).ll/well).  A DNA standard solution (2).lgl).ll) was made by diluting 1  O).ll of stock 
116 (100 ).lg/ml)  lambda DNA in 490J..Ll  TE.  This was used to produce a DNA standard 
curve in duplicate by loading the following onto a plate: 
TE (J..Ll)  DNA Standard (J..Ll)  Final DNA cone 
0  100  1mg/ml 
50  50  500ng/ml 
90  10  100ng/ml 
98  2  20ng/ml 
100  0  Blank 
A  working  solution of the  PicoGreen  Reagent  was  prepared  by  making  a  1  :200 
dilution of the concentrated stock in TE buffer being careful to maintain the solution 
in the dark, as PicoGreen is light sensitive.  1  OO).ll of  this working solution was added 
to  each standard/sample.  The plate was then covered in foil  to  protect it from  the 
light,  incubated  at  room  temperature  for  5  minutes  and  then  the  fluorescence 
measured  using  a  Wallac  Victor  1420  Multilabel  Counter  (PerkinElmer  Life 
Sciences, Boston, MA, USA). 
2.1.5  Transient Transfection system 
2.1.5.1  JEG-3 Cells 
Human JEG-3  choriocarcinoma placenta cells  (American Type Culture Collection) 
do not normally produce corticosteroids so are suitable for transfection with either of 
the  11 ~-hydroxylase or  aldosterone  synthase  genes.  Their  inability  to  produce 
aldosterone or cortisol was confirmed by incubating them with culture medium that 
did  or  did  not  also  contain  the  steroidogenic  precursors  11-deoxycorticosterone 
(DOC)  and  11-deoxycortisol  (S)  respectively  and  testing  the  medium  for  steroid 
production  using  HPLC  (High-performance  liquid  chromatography).  One  mam 
117 advantage  of these  cells  is  that they have  endogenous  adrenodoxin,  the  cofactor 
essential for the activity of many steroidogenic enzymes. This removed the need to 
co-transfect with adrenodoxin. 
2.1.5.2  JEG-3 cell maintenance 
JEG-3 cells were cultured at 37°C in 5% C02 in Minimum Essential Medium Eagle's 
(Sigma-Aldrich)  supplemented with 10% fetal  bovine serum  (Sigma-Aldrich),  1% 
sodium  pyruvate  (1 OOmM)  (GIBCO)  and  1%  penicillin/streptomycin  (5000U/ml) 
(GIBCO). 
2.1.5.3  Subculturing procedure 
Cells were passaged upon reaching 80-90% confluence.  The culture medium was 
removed  and  the  cells  rinsed  with  phosphate  buffered  saline  solution  (PBS). 
Trypsin-EDT  A solution (Sigma-Aldrich) was added to cover the cells and they were 
incubated at 37°C  for  5  minutes to  facilitate  the  dispersal  of the  cells.  5  ml of 
complete  growth medium was  added to  inactivate  the trypsin and the  cells  were 
pelleted at 1500rpm for 5 minutes.  The cells were resuspended in complete growth 
medium and aliquoted into new flasks according to the desired subcultivation ratio. 
2.1.5.4  Handling procedure for frozen cells 
Cells grown to approximately 90% confluence were typsinized and pelleted as before 
and  resuspended  in  complete  growth  medium  supplemented  with  10%  dimethyl 
sulfoxide (DMSO).  Aliquots were transferred to cryovials, which were then frozen 
gradually over 24 hours in a Nalgene cryo 1  °C freezing container.  These were then 
transferred to a liquid nitrogen freezer for long-term storage.  When frozen cells were 
required, they were removed from the liquid nitrogen and the vials thawed by gentle 
118 agitation in a 37°C water bath for 2 minutes.  The vial was decontaminated with 70% 
ethanol.  The cells were transferred under sterile conditions to a 75cm
2 tissue culture 
flask  containing 5ml of prewarmed growth medium and incubated at  37°C  in 5% 
C02. 
2.1.5.5  Transfection protocol 
1.5x10
5  JEG-3  cells  were  plated in 2ml  of growth medium on 6-well  plates  and 
incubated at 37°C overnight to achieve approximately 80% confluence. 
Cell Count 
Cell counts were done using a Bright Line Haemocytometer (Sigma-Aldrich).  Cells 
were removed from the flasks using Trypsin-EDT  A solution as if being subcultured 
and spun as  before to pellet the cells.  The cells were then resuspended in  lml of 
complete  growth medium.  20).11  of resuspended  cells  were transferred to  a  sterile 
centrifuge tube and diluted with 230).11  of Hanks Buffer (Sigma-Aldrich).  250).11  of 
Trypan Blue solution (Sigma-Aldrich) was added to stain the cells, inverted to  mix 
and incubated at room temperature for 2-3  minutes.  With the coverslip in place, a 
small  amount  of Trypan  Blue-cell  suspension  mixture  was  transferred  to  both 
chambers of the haemocytometer.  For each chamber of the haemocytometer, the 
numbers of viable cells (i.e. unstained cells) in the  lmm centre square and the four 
lmm comer squares  were  counted and the  mean calculated.  Each square  of the 
haemocytometer,  with coverslip in place,  represents  a total volume of O.lmm
3  or 
10
4cm
3
. Since lcm
3 is equivalent to approximately lml, the subsequent concentration 
per ml (and the total number of  cells) is determined using the following calculation: 
Cells/ml =the average count per square x dilution factor x 10
4 x 1 (original val) 
119 After calculating the number of cells per ml the amount of cell stock needed per well 
to  achieve  the  correct  number  of cells  (1.5  x  10
5  cells/well/2ml  medium)  was 
determined and the cells plated onto 6-well plates. 
Transfection mix 
Transfection  was  carried  out  using  6fll  Fugene  (Roche  Diagnostics,  Mannheim, 
Germany) and 3flg of wildtype or mutant plasmid in MEM/Eagle's for 24 hours for 
each well of  a 6-well plate.  The pGL3 control vector (0.1 flg) was added as a reporter 
gene  to  measure  transfection  efficiency.  The  transfection  mix  for  each  well 
contained: 
Component 
MEM (no additives) 
Fugene 
plasmid DNA 
pGL3 control plasmid 
Total volume 
Amount/well 
up to 100fll 
6.0fll 
3.0flg 
0.1flg 
lOOfll 
A master-mix was prepared for the wildtype and mutant constructs. The components 
were  added  in  the  order  above,  the  tubes  tapped  to  mix  and  incubated  at  room 
temperature for 30 minutes.  1  OOfll of transfection mix was dropped into the growth 
medium  of each well  and  the  plates  swirled  to  mix.  Cells  not  exposed  to  any 
transfection mix were used as a negative controL 
2.1.5 .6  Steroid Incubation 
After 24  hours  the transfection medium was  removed and  replaced with 4 ml  of 
growth medium supplemented with either DOC or 11-deoxycortisol over a range of 
120 Cells  were  incubated  with medium  in the  absence  or presence  of substrate  for  a 
further 24 hours.  All transfections were performed 6 times.  The steroid-containing 
medium  was  removed  for  HPLC  analysis  and  the  cells  lysed  for  protein 
measurements  (PIERCE,  Perbio  Science,  Northumberland,  UK)  and  luciferase 
activity (Promega Corp.) (see section 2.1.6). 
2.1.6  Measurement of  Transfection Efficiency 
Luciferase  activity  (Promega  Corp.)  and  protein  concentration  (Pierce)  were 
measured  on  cell  lysates  following  the  manufacturers'  protocols.  The  luciferase 
acitivity measured in relative light units (RL U) ranged from 1  x 1  0
4 to 1  x 10
5 across all 
samples  and  the  range  of total  cell  protein levels  was  0.5  to  1.2  (arbitrary units). 
Transfection efficiency was  determined by converting protein levels and luciferase 
activity into RLU per unit of total cell protein.  These transfection values were then 
converted to a proportion of the highest transfection value. The generated correction 
factors  ranged from  0.2  to  2 and the  corresponding steroid results  were  corrected 
accordingly. 
2.1.6.1  Preparation of  celllysates 
Cell  lysates  were  prepared using  Reporter  Lysis  Buffer  (RLB)  (Promega  Corp.). 
After removal of steroid-containing medium, cells were washed with PBS  and any 
residual traces of PBS were then removed.  0.5ml of 1xRLB was added to each well 
of  the 6-well plates.  The plates were placed at -70°C for 10 minutes and then thawed 
at  room  temperature.  The  cells  were  removed  by pipetting the  RLB  over them 
several  times  and  transferred  to  a  prechilled  1.5ml  Eppendorf tube.  They  were 
centrifuged at full speed in a microcentrifuge for 2 minutes. Lysates were stored at-
121 70°C  until  required.  The  supernatant was  assayed  directly  for  luciferase  activity 
whereas the whole cell lysate was used for determination of  protein content. 
2.1.6.2  Measurement of  Luciferase Activity 
Luciferase activity was determined using the Steady-Glo® Luciferase Assay system 
(Promega Corp.). A 10ng/mlluciferase (Luc) standard stock was prepared using 1x 
Cell Culture Lysis Reagent (CCLR) (Promega Corp.) containing 1mg/ml BSA.  This 
was used to produce the following concentrations of standard in duplicate: 
Vol of stock (ul) 
0 
6.25 
12.5 
25 
50 
100 
1 x CCLR (ul) 
100 
93.75 
87.5 
75 
50 
0 
Final Cone (ng/ml) 
0 
0.625 
1.25 
2.5 
5 
10 
1  OO)ll  of each standard replicate  or sample was  pi  petted on to  a white  micro well 
plate.  1  OO)ll  of the  Steady-Glo  Luciferase  Assay  reagent  was  added  to  each 
standard/sample.  This  was  mixed well  and  incubated at room  temperature  for  5 
minutes.  The light emmitted was measured using a Wallac Victor 1420 Multilabel 
Counter (PerkinElmer Life Sciences, Boston, MA, USA). 
2.1.6.3  Measurement of  protein levels 
Protein levels  were  determined with the  Pierce  BCA  (bicinchoninic  acid)  Protein 
Assay  (PIERCE,  Perbio  Science,  Northumberland,  UK).  A  set  of bovine  serum 
albumin (BSA) protein standards were prepared in the range 20-2000)lg/ml using the 
same diluent as the samples (RLB) (Promega Corp.) as follows: 
122 Vial  Vol of Diluent (RLB)  Vol and Source of BSA  Final BSAConc 
A  0  300!-ll Stock  2000!-lg/ml 
B  125!-ll  375!-ll Stock  1500!-lg/ml 
c  325!-ll  325!-ll Stock  1000!-lg/ml 
D  175!-ll  175!-ll of  vial B dilution  750!-lg/ml 
E  325!-ll  325!-ll ofvial C dilution  500!-lglml 
F  325!-ll  325!-ll ofvial E dilution  250!-lg/ml 
G  325!-ll  325!-ll ofvial F dilution  125!-lg/ml 
H  400!-ll  1  OO!ll of  vial G dilution  25!-lg/ml 
I  4001-ll  0  Blank 
25!-ll of  each standard or unknown sample replicate was pipetted on to a clear 96-well 
plate.  A BCA Working Reagent (WR) was prepared by mixing 50  parts of BCA 
Reagent A with 1 part of BCA reagent B.  200!-ll of the WR was added to each well 
and mix thoroughly for 30 seconds. The plate was covered and incubated at 37°C for 
30 minutes.  It was then cooled to room temperature and the absorbance measured at 
562nm using a Wallac Victor 1420 Multilabel Counter (PerkinElmer Life Sciences, 
Boston, MA, USA).  The protein concentration was  determined from  the  standard 
curve. 
2.1. 7  RNA-Bee Isolation of  RNA 
2.1.7.1  Cell Lysis 
After the removal of  the culture medium, cells were lysed directly in the culture dish 
by the  addition of 1ml of RNA-Bee™ RNA isolation reagent (Biogenesis, Poole, 
UK) to  5 x  106  cells.  The lysates were passed through a pipette several times to 
ensure complete lysis and transferred to a 1.5ml Eppendorf tube. 
2.1. 7.2  Phase Separation 
To separate the lysate into aqueous and organic phases, chloroform was added (0.2ml 
per 1ml ofRNA-Bee) and the tube shaken vigorously for 15-30 seconds.  The sample 
123 was then stored on ice for 5 minutes before being centrifuged at  12,000 x g for  15 
minutes  at  4  °C.  The  upper  colorless  aqueous  layer  was  carefully  removed  and 
transferred to a clean tube without touching the lower blue phenol-chloroform phase 
containing DNA and protein. 
2.1.7.3  RNA Precipitation 
Isopropanol (0.5ml) was added and the sample stored at room temperature for 5-10 
minutes.  It was  then centrifuged at  13,000 x  g for  5 minutes  at 4°C.- The  RNA 
precipitate,  which is  often not visible  before  centrifugation,  forms  a white/yellow 
pellet at the bottom of  the tube. 
2.1.7.4  RNA Wash 
The  supernatant was  removed and the RNA pellet washed with 75%  ethanol in a 
volume equal to the starting amount of  RNA-Bee.  The tube was vortexed to dislodge 
the pellet from the side of  the tube and centrifuged for 5 minutes at 7,500 x gat 4°C. 
2.1.7.5  RNA Solubilization 
The RNA pellet was  briefly air-dried (5-10  minutes) to  remove residual  traces  of 
ethanol but not allowed to dry completely as this greatly reduces its solubility.  Each 
RNA sample was dissolved in 20fll nfl-hO by passing the solution through a pipette 
tip several times then stored at -70°C. 
2.1.7.6  DNase Treatment 
Each RNA solution was treated with DNA-free™  (Ambion, Huntingdon, UK)  to 
remove any DNA contamination. 0.1  vol of 10 x DNase I buffer and lfll (2 units) of 
DNase I was added to each sample.  The samples were mixed and incubated at 37°C 
124 for  20-30  minutes.  5j.ll  of DNase  Inactivation  reagent  was  then  added  and  the 
samples mixed well.  They were then incubated for 2 minutes at room temperature, 
flicking the tube once during the incubation to mix.  The samples were centrifuged at 
10,000  x  g  for  1 minute  to  pellet the  DNase  inactivation reagent  and  the  RNA 
transferred to a new tube.  The RNA was then stored at -70°C. 
2.1.8  RNA Quantification using RiboGreen® method 
The  RiboGreen®  RNA  quantitation  kit  (Molecular  Probes,  Leiden,  Netherlands) 
allows  reliable  detection  of RNA  in  solution,  with a  sensitivity  that  is  orders  of 
magnitude greater than UV absorbance readings. 
2.1.8.1  Sample Preparation 
A 1 x Tris-HCl ethylenediaminotetraacetic acid (EDTA) buffer working solution (1  x 
TE)  was  prepared  by  diluting  20  x  TE  buffer  with  nfl-hO.  The  RNA  sample 
solutions were diluted 2000-5000 fold in 1 x TE.  1001-11 of each diluted RNA sample 
was  loaded  into  a well  of a  96-well  black microplate  (Nalge  Nunc  International, 
Hereford, UK). 
2.1.8.2  RNA standard curve 
The  ribosomal  RNA  standard,  provided  at  1  OOj.lg/ml  in  the  RiboGreen  kit,  was 
diluted 50-fold in 1 x TE to make a 2j.lg/ml working solution.  This was diluted in the 
black microplate as shown: 
125 Vol ().!1) of  Vol ().!1) of  Final RNA 
V  ol().!l) of  TE  2 ).!g/ml RNA  Diluted RiboGreen  Concentration 
Stock Solution  Reagent 
5  100  100  1000ng/ml 
50  50  100  500ng/ml 
90  10  100  100ng/ml 
98  2  100  20ng/ml 
100  0  100  Blank 
2.1.8.3  Reagent Preparation 
An aqueous working solution of the RiboGreen reagent was prepared by diluting an 
aliquot  of the  concentrated  dye  solution  stored  in  anhydrous  dimethylsulfoxide 
(DMSO) into 1 x TE using sterilized polypropylene plasticware, 200-fold.  1  00).!1 of 
the  working solution was  loaded into  each well  and mixed with the  RNA sample 
solution.  The  plate  was  foil-wrapped  to  protect  it  from  light  and  incubated  for 
approximately 5 minutes at room temperature. 
2.1.8.4  Fluorometry counting 
The  plate  was  loaded  manually  on  to  a  Wallac  Victor  1420  Multilabel  Counter 
(PerkinElmer  Life  Sciences,  Boston,  MA).  The  template  layout  within  the 
Workstation software was configured to describe the group and type of each well on 
the  virtual  microplate.  The  machine  measured  the  fluorescent  emission  of the 
samples at wavelength 535nm after excitation at 485nm.  RNA concentrations were 
then calculated for each sample, compensating for the dilution factor of each diluted 
sample. 
126 2.1.9  Real-time  quantitative  reverse  transcriptase-polymerase  chain 
reaction (QRT-PCR) 
One-step real-time QRT-PCR was performed using the LightCycler System (Roche 
Diagnostics, Mannheim, Germany) and the LightCycler RNA Master Hybridization 
Probes  kit  (Roche  Diagnostics).  A  homologous  mRNA  standard  for  human 
CYP 11 B I  was prepared from  commercially available adrenal eDNA using specific 
primers, hBlsense (exon 8)  and hBlantisense (exon 9)  (MWG-Biotech, Ebersberg, 
Germany) (table 4, appendix 2), following the protocol previously published for rat 
standard (Ye  et al 2003).  The  same primers  were  used in the  RT-PCR reaction. 
CYP II  B I sequence-specific hybridization probes were designed and synthesized by 
TIB  Molbiol  (Berlin,  Germany).  These  consisted  of a  fluorescein  probe  and  a 
LightCycler Red probe (see table 4, appendix 2). 
A master mix solution was prepared in a 1.5ml Eppendorf tube on ice by adding the 
reaction  components  in the  order  given below.  The  standard reaction  required  to 
perform a single colour detection takes place in a 20j..tl volume.  The amount in the 
"volume" column was multiplied by the number of reactions to be cycled, plus one 
additional reaction. 
Component  Volume  Final cone. 
H20, PCR grade  6.2,  .. tl 
Mn(0Ac)2 stock solution, 50mM  l.3f.!l  3.25mM 
B1  Fluorescin (FL)  0.4f.!l  0.2f.!M 
B 1 LightCycler Red705 dye (LC)  0.4f.!l  0.2f.!M 
Primer HB 1 sense  l..Of.!l  0.5f.!M 
Primer HB 1 antisense  l..Of.!l  0.5f.!M 
LightCycler RNA Master Hybridization Probes, 2.7 x cone  7.5f.!l  1 X 
Total volume  19)..11 
127 This was mixed gently and 19!J,l of  master mix pipetted into a precooled LightCycler 
Capillary (Roche Diagnostics, Mannheim, Germany).  l!J,g (at l!J,g/!J,l concentration) 
of the  RNA  template  was  added  to  the  capillary.  A  control  reaction  was  also 
constructed  by  replacing  the  RNA  with  nfl-hO  (water  blank).  The  capillaries 
containing the samples were placed in a holder and centrifuged at 700g for 5 seconds 
in a standard bench  top  centrifuge  (Roche  Diagnostics) before  being placed in the 
rotor of the LightCycler Instrument (Roche Diagnostics). The cycle programs were 
performed in the order: 
1) Reverse Transcription (R  T) 
2) Denaturation 
3) Amplification 
4) Cooling 
The cycle parameters were as follows: 
Cycle Program Data  RT  Denaturation  Amplification  Cooling 
Cycles  1  1  45  1 
Analysis Mode  None  None  Quantification  None 
Temperature Targets  S1  S1  S1  S2  S3  S1 
Target Temperature (
0C)  61  95  95  58  72  40 
20 
Incubation time  30 s  1 s  15 s  13 s  30 s 
mm 
Temperature Transition Rate ("C/s)  20  20  20  20  2  20 
Secondary Target Temperature (
0C)  0  0  0  0  0  0 
Step Size (
0C)  0  0  0  0  0  0 
Step Delay (Cycles)  0  0  0  0  0  0 
Acquisition Mode  None  None  None  Single  None  None 
The annealing temperature of the CYP II  BI probes was 58°C.  Fluorescent data are 
collected  during the  single  acquisition  phase.  lml aliquots  of sequential  tenfold 
mRNA standard dilutions were used to construct a standard curve.  The sample copy 
128 number was extrapolated from the standard curve at the base of  the sample's crossing 
point.  Each sample was measured three times  and a water blank was  included in 
each run. 
2.2  Screening  of  CYPJJBJ  and  CYPJJB2  genes  for 
Polymorphisms in a Normotensive Population 
2.2.1  Study Subjects 
Normotensive  subjects  were  selected  from  a  WHO  survey  of cardiovascular  risk 
factors  (MONICA IV),  which was  a random  sample of the north Glasgow patient 
lists of 30 general practitioners (Fraser et al1999). Study subjects completed a health 
questionnaire  and  attended  for  a structured medical  examination to  assess  overall 
cardiovascular risk.  Approval was obtained from  the appropriate ethics committee. 
The study group consisted of 238 male and 201  female subjects aged 36 to 57. They 
were  all normotensive with a fairly narrow blood pressure range within the group. 
These subjects had already been genotyped for,  and were selected according to, the 
CYP 11B2  -344  CIT  and  intron  Conversion  (IC)  variants.  The  IC  alleles  are 
designated wildtype  (Wt)  for the  CYP 11B2  intron 2 sequence or conversion (Con) 
when the intron 2 sequence of CYP II  B I has been introduced. 
2.2.2  Polymerase Chain Reaction amplification of  CYPJJBJ 
Subjects  were  selected who  were  homozygous  at both the  -344  CIT  and  IC  loci. 
Twenty-six subjects were selected for genetic analysis; TTIConCon (10), CCIWtWt 
(10) and TTIWtWt (6).  The aim was to have ten subjects in each genotype group but 
129 only  six  of the  439  subjects  were  TT/WtWt  and  none  were  CC/ConCon,  which 
reflects the population frequencies of  these haplotypes. 
Miss  Donna  M  Wilkinson  and  Dr.  E.  Marie  Freel  were  responsible  for  the 
amplification  and  sequencing  of the  CYP  11B2  gene  within  these  subjects.  The 
amplification of CYP IIB2 was  split into 3 separate PCRs: (i)  from the 5' region to 
intron  4  (~5Kb); (ii)  exon  5  to  exon  9  (~3Kb); (iii)  the  3'UTR  (~1.5Kb). The 
sequences  of the  primers  (MWG-Biotech,  Ebersberg,  Germany)  used  for  these 
reactions are listed in table 5, appendix 2. 
The CYP IIBI gene was amplified in two reactions encompassing: 
i) the 5' promoter region to ex  on 9 (  ~  7kb) 
ii) the 3'UTR  (~750bp). 
HPLC-purified  synthetic  oligonucleotides  were  designed  usmg  the  published 
sequences  of CYPllBI  and  CYP11B2  (see  appendix  1)  and  obtained  from  a 
commercial source (MWG-Biotech, Ebersberg, Germany).  Primers were generally 
between  20-24  base  pairs  and  had  approximately  50%  GC  ratios  (see  table  5, 
appendix  2).  The  melting  temperature  (T  m)  of  each  of  the  pnmers  was 
approximately 60°C. 
2.2.3  PCR Protocols 
Both PCRs were performed using the  Expand High Fidelity PCR System  (Roche 
Diagnostics, Mannheim, Germany).  This  system is  composed of a unique enzyme 
mix  with  proof-reading  capability  to  avoid  the  unwanted  introduction  of PCR-
generated mutations. 
130 5 'UTR to Exon 9 PCR 
Two separate reaction master-mixes were prepared in sterile 1.5ml Eppendorf tubes 
on 1ce. 
MIX 1 
Component  Volume/Tube (J.!l)  Final Concentration 
Template DNA 
dATP (lOmM) 
dCTP (10mM) 
dGTP (lOmM) 
dTTP (10mM) 
Sense primer, 10).!M (B1  5'UTR) 
Antisense primer, 1  OJ.!M (B 1 Exon9 AS) 
nflhO 
Total 
MIX2 
1.0 
0.5 
0.5 
0.5 
0.5 
0.75 
0.75 
8.0 
12.5).!1 
Component  Volume/Tube (J.!l) 
1  OX Buffer (15mM MgCh)  2.5 
Expand High Fidelity Enzyme mix  0.75 
nfl-hO  9.25 
Total 
(20-1 OOng/).!1) 
200J.!M 
200J.!M 
200J.!M 
200J.!M 
300J.!M 
300nM 
Final Concentration 
1 x (1.5mM MgCh) 
2.6 U/reaction 
A 'blank' reagent control was prepared which contained all the necessary components 
for PCR but replaced template DNA with nflhO. The total reaction volume was 25).!1. 
The reaction mixes were subsequently combined on ice in single 0.2ml thin-walled 
amplification  tubes  (ABgene,  Surrey,  UK)  before  being  placed  in  a  96-well 
AlphaTM sample block powered by the PTC-225 DNA Engine Tetrad® Cycler with 
heated lid (MJ Research, Waltham, MA, USA).  Amplification cycles and reaction 
conditions were as follows: 
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1. 94°C  2 minutes  Denaturation 
2.94°C  15 seconds 
3.65°C  30 seconds  Amplification (1 0 cycles) 
4. 68°C  8 minutes 
5.94°C  15 seconds 
6.65°C  30 seconds  Amplification (20 cycles) 
7.68°C  8 minutes+ 5sec/cycle 
8. 72°C  7 minutes  Extension 
3'UTRPCR 
Two  separate  reaction  master-mixes  were  prepared  on  ice,  as  above,  the  only 
difference being the primers used (see table 5, appendix 2): 
-Sense primer (M6635) 
-Antisense primer (B13'UTR+500) 
Again the total reaction mix was 25!-ll.  The reaction mixes were combined and kept 
on ice  before being placed in an Alpha  ™ sample unit of a  DNA Engine Tetrad® 
Peltier thermal  cycler.  The  amplification cycles  and reaction conditions  for  this 
reaction were as follows: 
Amplification Protocol 
1. 94°C  2 minutes  Denaturation 
2.94°C  15 seconds 
3. 55°C  30 seconds  Amplification ( 1  0 cycles) 
4. 72°C  1 minutes 
5.94°C  15 seconds 
6.55°C  30 seconds  Amplification (20 cycles) 
7. 72°C  1 minutes+ 5sec/cycle 
8. 72°C  7 minutes  Extension 
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1g ofagarose (Invitrogen, Paisley, UK) was added to 1 x TAE buffer (lOOml), mixed 
and heated in a 650W microwave oven for 60 seconds.  After 3 minutes of cooling, 
1  J..Ll  of ethidium bromide (1 Omg/ml) was added and mixed in.  The agarose was then 
poured into gel moulds with Teflon combs and allowed to set for 20 minutes before 
combs  were  removed.  Gels  were  submerged  in  1  x  TAE  buffer  in  standard 
electrophoresis  tanks  (Wide  Minis  Sub  Cell  Agarose  gel  apparatus)  (Bio-Rad 
Laboratories, Hercules, CA, USA).  10J..Ll  of PCR product was loaded with  5J..Ll  of 
loading dye onto the agarose gel.  The DNA molecular weight marker Hyperladder I 
(Bioline, London, UK) was also loaded in a separate well.  The gel was then resolved 
at 95V for 40 minutes.  DNA bands were visualized under a UV light. 
2.2.5  PCR clean-up 
Prior  to  sequencing,  PCR  products  were  cleaned  to  remove  excess  dNTPs  and 
primers, using the enzymes Shrimp Alkaline Phosphatase (SAP) and Exonuclease I 
(Exoi).  SAP removes the phosphate groups from excess dNTPs remaining from the 
PCR reaction; Exoi digests the single stranded PCR primers into dNTPs and their 
phosphate groups are removed by the SAP.  15 J..Ll  of PCR product was transferred to 
sterile, thin walled PCR (0.2ml) tubes.  1J..Ll  SAP  (1 U/J..Ll)  and 0.5J..Ll  Exoi (20U/J..Ll) 
were  added  and the  samples  incubated  at  37°C  for  30  minutes  followed  by  10 
minutes at 80°C on the Tetrad® thermal cycler. 
2.2.6  Automated Cycle Sequencing 
Automated sequencing was performed using the ABI Big Dye Terminator v3.1 Cycle 
Sequencing Kit (PE Applied Biosystems).  The technique  is  an adaptation of the 
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entire CYP 11 B  1 gene are shown in table 6, appendix 2. 
Sequencing reaction set-up 
Sequencing reactions were set up in 96-well plates containing the following: 
Template (50-lOOng)  x  ~-tl 
Sequencing Primer (3.2pmo11~-tl)  1.0~-tl 
Ready Reaction mix  0.5~-tl 
Sequencing Buffer  3.8~-tl 
Distilled Water (up to final vol20~-tl)  x  ~-tl 
After setting up gradients of template volumes it was found that for the 5' to  exon 9 
(7kb)  PCR,  the  optimal  volume  of template  for  sequencing  was  2~-tl  (  ~ 1  OOng) 
whereas  only  1~-tl  (~ SOng)  was required for the  3' UTR (750bp).  The  sequencing 
reactions were then incubated on an Alpha  ™ sample unit of a DNA Engine Tetrad® 
Peltier thermal cycler as follows: 
Reaction conditions 
1. 96°C 
2. 50°C 
3. 60°C 
45 seconds 
25 seconds 
4 minutes 
Sequencing reaction clean-up 
(These 3 steps are repeated 25 times.) 
Keeping  the  sequencing  reactions  m  the  96-well  PCR  plates,  a  sodium 
acetate/ethanol precipitation was performed as follows. 
A solution of sodium acetate (NaOAc) in 95% ethanol (EtOH) in the ratio  2~-tl 3M 
NaOAc:  50~-tl  95%  EtOH was  prepared  and  50~-tl  of this  solution  added  to  each 
sequencing reaction.  The plate was then sealed and inverted a few times to mix.  The 
sample  were  incubated  at  room  temperature  for  15  minutes  to  precipitate  the 
134 extension products.  The plate was  centrifuged for  30 minutes at 6000 x g and the 
supernatant immediately discarded. The plate was centrifuged again whilst inverted 
on  a  paper  towel  for  30  seconds  at  500  x  g  to  remove  all  residual  traces  of 
supernatant.  150~-tl of 70% ethanol was added to each well and the plated sealed and 
inverted  again  before  being  centrifuged  at  6000  x  g  for  10  minutes.  Again  the 
supernatant was removed by centrifuging the inverted plate. 
2.3  Genotyping  of CYPJJBJ  S'UTR  Polymorphisms  in  a 
Hypertensive Population 
Two  novel polymorphisms within the  5'  UTR of CYPllBI (-1889  G/T and  -1859 
A/G) were identified during sequencing of CYP II  B locus within the normotensive 
cohort.  The  entire  MRC  BRitish  Genetics  of HyperTension  (BRIGHT)  study 
population  (n  =  4020)  were  genotyped  for  these  polymorphisms  to  assess  their 
frequency and phenotypic associations in a large hypertensive population. A random 
subgroup  of  512  unrelated  subjects  were  selected  for  further  analysis  of 
corticosteroid metabolites. 
2.3.1  Study Subjects 
The MRC BRitish Genetics of  HyperTension (BRIGHT) study is a large multi  centre 
investigation  into  the  genetic  basis  of hypertension  comprising  >  2500  affected 
sibling pairs and trios. Hypertensive subjects were recruited from primary care with 
entry  to  the  study  being  dependent  on  a  pre-treatment  blood  pressure  of 
> 145/95mmHg (mean of 3 readings) which lies within the top 5% of the population 
BP  distribution  in  the  UK.  Subjects  with  a  body  mass  index  (BMI)  >30  were 
excluded from the study.  Full details of  the recruitment strategy have been published 
135 elsewhere (Caulfield et a/2003). The local ethics committees of  the partner institutes 
granted ethical approval for the study and fully informed written consent from all of 
the participants was obtained. 
2.3.2  Nested PCR Protocol 
In  order  to  increase  specificity  of the  genotyping,  a  nested  PCR  (i.e.  PCR 
amplification of the PCR product using specific primers) was performed. The initial 
reaction amplified a 2kb region specific to  CYP 11 B I  and the second reaction used 
this product as  a template to specifically amplify the region of interest (~350bp). In 
both reactions, a heat-activated thermostart Taq polymerase (ABgene,  Surrey, UK) 
was  used.  The  sense and anti-sense primers  (MWG-Biotech, Ebersberg,  Germany) 
used in both reactions are outlined in table 7, appendix 2. 
PCR Amplification I 
Component  Volume (J..ll) 
Buffer(10x)  250 
MgCb (25mM)  150 
dNTPs  500 
B15'UTR (sense)  100 
B1prom-260 (antisense)  100 
Thermostart Taq polymerase  25 
nfiH20  875 
Total  2000 
Final Cone 
1x 
1.5mM 
200J.!M each 
400nM 
400nM 
1.25U 
This was  mixed and 20).!1  of master mix added to  5).!1  of BRIGHT template DNA 
(5ng/)..ll),  which had been pre-plated  onto  96-well  PCR plates.  The  amplification 
reaction was performed on a 96-well Alpha  TM  sample block powered by the PTC-
225  DNA  Engine  Tetrad®  Cycler with heated  lid  (MJ  Research,  Waltham,  MA, 
USA).  The cycling parameters were as follows: 
136 1.  95 oc  15 minutes 
2.  95 oc  30 seconds 
3.  60 oc  30 seconds  X 35 
4.  72 oc  3 minutes 
5.  72 oc  7 minutes 
Steps 2, 3 and 4 were repeated 35 times.  The PCR products were then diluted 1:10 in 
nfl-hO and 1  )ll used as  a template for a second PCR reaction.  Again a mastermix 
was prepared on ice, this time in a 5ml universal tube: 
PCR Amplification 2 
Component 
Buffer (1 OX) 
MgC12 (25mM) 
dNTPs 
B15'7-32 (sense) 
Bl393-369 (antisense) 
Thermostart Taq polymerase 
nfH20 
Total 
Volume (Ill) 
250 
150 
500 
100 
100 
12.5 
1287.5 
2400 
Final Cone 
1x 
1.5mM 
200)-LM each 
400nM 
400nM 
0.625U 
This was mixed and 24).!1  of master mix pipetted into the wells of a fresh 96-well 
PCR plate.  1  )ll  of a  1: 10  dilution of PCR amplification mix 1 was then added to 
serve  as  the template.  The amplification conditions were  as  the  same  as  before, 
except that the number of  cycles was reduced to 20. 
PCR clean-up 
The PCR products were then cleaned using a NucleoFast® 96 PCR clean-up system. 
The NucleoFast® 96 PCR clean-up system is designed to retain PCR products on an 
ultrafiltration membrane  under vacuum whilst contaminants  (  dNTPs,  primers  and 
137 salts) are filtered to waste. The PCR samples (25f.tl)  were centrifuged briefly before 
being transferred to a NucleoFast® 96 PCR plate.  The plate was placed on a vacuum 
manifold and a vacuum was applied until the samples had passed into the plate.  To 
wash the  samples,  1  OOf.tl  of nfl-hO  was  dispensed into  each well  and the  vacuum 
applied  until  the  water  had  passed  through  the  membrane.  50f.tl  of nfH20  was 
pipetted  directly  on to  the  membrane  of the  NucleoFast®  plate.  The  water  was 
pipetted up  and down several times before being transferred to a clean 96-well PCR 
plate and stored at 4°C until required. 
Determination of  genotypes 
Each of  the samples were sequenced by the automated sequencing method mentioned 
in  section  1.2.6,  using  6f.tl  of NucleoFast PCR product  and  the  primer B 1  prom-
1750(as) (table 6, appendix 2). 
2.3.3  Urinary Corticosteroid Metabolite Measurements 
Miss Mary C.  Ingram performed the urinary corticosteroid measurements.  24-Hour 
urine  samples  were  collected  in  plain  plastic  containers  without  preservative. 
Aliquots of urine were stored at -20°C. Excretion rates of steroid metabolites were 
measured by gas chromatography/mass spectrometry using the method of Shackleton 
(Shackleton 1993) with minor modifications. 
2.4  Analysis of  CYPJJBJ 5'UTR  polymorphisms in vitro 
2.4.1  Luciferase Reporter Gene System 
The  effects  of the  2 polymorphisms identified in the  5' region of CYP JJBJ  were 
investigated using a reporter gene  system.  The  CYPJJBJ  5' region (1937bp) was 
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vector lacks a eukaryotic promoter sequence and so expression of luciferase activity 
in cells transfected with this plasmid depends on insertion and proper orientation of  a 
functional promoter upstream of  the luciferase gene.  This construct (pB 1-193  7) was 
used as a template for production of  each of  the variants to be studied. 
2.4.1.1  SDM 
The -1889 G/T and -1859 A/G polymorphisms were recreated by SDM following the 
method  described  in  section  2.1.1.  Specific  sense  and  antisense  mutagenic 
oligonucleotide  primers  were  designed  individually  according  to  the  desired 
mutations (MWG-Biotech, Ebersberg, Germany) (table 8, appendix 2).  These were 
designed  against  the  template  sequence  (appendix  1)  to  produce  the  alternative 
alleles for each polymorphism.  Once these had been created, one construct was used 
as  a template  for  the  alternative pair of primers  so  that all  4 combinations of the 
alleles were  created.  The  entire  insert in each case  was  sequenced to  confirm the 
presence  of the  desired  mutations  and  that  no  unwanted  base  changes  had  been 
incorporated. 
2.4.1.2  Y-1  cell maintenance 
To  analyze the CYP II  BI 5' UTR reporter gene  expression, cells were required that 
possess  all  the  necessary  transcription  factors  to  bind  the  CYP II  B I  5'UTR  or 
regulatory region and transcribe the  luciferase gene.  Therefore an adrenal cell line 
was used. 
Y-1  mouse adrenal cells (American Type Culture Collection) were cultured at 37°C 
in  5%  C02  in  F-12K  Nutrient  Mixture,  Kaighn's  Modification  (GIBCO) 
139 supplemented with  15%  horse  serum  (GIBCO),  2.5%  fetal  bovine  serum  (Sigma-
Aldrich) and 1% penicillin/streptomycin (5000U/ml) (GIBCO). The subculturing and 
handling procedures were  as  reported for  the  JEG-3  cells  in sections 2.1.4.2  and 
2.1.4.3. 
2.4.1.3  Transfection Protocol 
Cells were plated at 3.5x10
5  cells/well in 6-well plates and incubated for  24  hours 
prior  to  transfection.  Transfection  was  carried  out  using  6f.ll  Fugene  (Roche 
Diagnostics,  Mannheim,  Germany)  and  1  f.!g  of wildtype  or  mutant  plasmid  in 
MEM/Eagle's (2ml)  for  42  hours.  The  pSV-~-Galactosidase (pSV-~-Gal) control 
vector (0.04f.lg)  (Promega Corp.) was  added as  a marker of transfection efficiency. 
Cells transfected with the pGL3 basic vector not containing any insert and cells not 
exposed to any transfection mix were used as negative controls. 
2.4.1.4  Agonist stimulation 
Following  transfection  for  42  hours,  the  transfection  medium  was  removed  and 
replaced  with 2ml of growth medium  containing  agonist:  either ACTH  (1 f.!M)  or 
Forskolin (lOf.!M) (Sigma-Aldrich).  Cells were treated with agonist for 6 hours. 
The  cells  were  then lysed  and  luciferase  activity  measured  as  in  section  1.1.5.2 
(Promega Corp.).  Protein (PIERCE) and  ~-galactosidase activity (Promega Corp.) 
measurements were used to  determine transfection efficiency and cell number and 
the luciferase results were corrected accordingly. 
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Preparation of  cell lysates 
Cells lysates were prepared as in section 2.1.5.1 using 250 ).d ofRLB. 
Measurement of  protein levels 
Protein levels were determined using the BCA Protein Assay (PIERCE) following 
the protocol described in section 2.1.5.3. 
2.4.2.1  Measurement of B-Galactosidase Activity 
~-Galactosidase  activity  was  measured  using  the  Tropix®  Galacto-Light  Plus™ 
chemiluminescent  reporter  gene  assay  system  (PE  Applied  Biosystems).  ~­
Galactosidase activity was determined in cell extracts transfected with the pSV  -~­
Gal  reporter  gene.  A  lyophilized  ~-galactosidase  standard  (Sigma-Aldrich)  was 
reconstituted to 1mg/ml in 0.1M sodium phosphate (pH 7.0) containing 0.1% BSA 
(Sigma-Aldrich).  This  was  diluted  to  a  1ng/f.ll  stock  solution  in  lysis  solution 
(1 OOmM potassium phosphate, 0.2% Triton X-1 00) containing 0.1% BSA with a pH 
of 7.8.  Standards (20!J.l) in the range 4 to 20ng as well as a 'blank' consisting of only 
lysis  solution, were plated in duplicate alongside each of the  samples (20!J.l)  on a 
white  96-well  plate.  The  chemiluminescent  Galacton-Plus®  substrate  (100  x 
concentrate)  was  diluted  1:100  with  Reaction  Buffer  Diluent  and  70!J.l  of the 
resulting  reaction  buffer  added  to  each  well.  Samples  were  then  mixed  and 
incubated at room temperature for 1 hour.  During this time the substrate Galactan-
Plus  (a  1,2-Dioxetane)  becomes  cleaved  by  the  enzymatic  activity  of the  ~­
galactosidase  contained in the  sample,  as  the  conditions  (pH  7 .8)  are  optimal for 
141 bacterial  p-galactosidase.  The  reactions were terminated by the  addition of 1  OOJ..Ll 
Accelerator  II,  which  increases  the  pH  to  > 12,  triggering  light  emission.  Light 
emission  was  measured  immediately  at  475nm  using  a  Wallac  Victor  1420 
Multilabel Counter (PerkinElmer Life Sciences, Boston, MA, USA). 
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Functional Effects of  Mutations within the 
llB-Hydroxylase (CYPJJBJ) gene 
143 3.1  Introduction 
Recent studies showing that up to 15% of unselected patients with hypertension have 
a  raised  aldosterone  to  renin  ratio  suggest  that  altered  regulation  of aldosterone 
production may be a common factor in essential hypertension (Fardella et al 2000; 
Gordon et al 1994b; Lim et al  1999b;  Loh et al 2000; Rayner et al 2000).  Two 
common  variants  (-344  CIT  and  intron  conversion)  in  the  aldosterone  synthase 
(  CYP II  B2)  gene  have  previously been associated not only with aldosterone levels 
and  hypertension  but  also  with  markers  indicating  an  impaired  11 P-hydroxylase 
efficiency, the enzyme product of the CYP JJBI gene (see section 1.16).  However, 
in  vitro  studies  suggest  that  the  -344  CIT  has  no  effect  on  gene  transcription, 
suggesting  that  it  is  not  the  functional  variant  and  may  therefore  be  in  linkage 
disequilibrium with an as  yet unidentified functional  variant, possibly in CYP II  BI 
(Bassett et al 2002). 
3.2  Aims 
The  aims  of this study were to  identify polymorphisms in CYP II  B I  that associate 
with hypertension and a raised ARR and therefore might contribute to  the  genetic 
component  of these  phenotypes.  The  functional  significance  of any  variants 
identified was then investigated in vitro. 
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3.3.1  Subjects 
Four  groups  of subjects,  normotensive  controls,  unselected  essential  hypertensive 
subjects or hypertensive subjects with either a high (2: 750) or low ARR (:S 200) were 
screened  for  mutations.  Each  group  comprised  40  subjects.  The  normotensive 
controls were  selected randomly from  the  Scottish Adult Twin Study (Inglis  et al 
1999).  This study contained data from  146 pairs of adult twins, aged 31-83  years. 
Only  one  twin  from  each  pair  was  selected  for  mutation  detection.  The  selected 
controls had no previous history of hypertension; in each subject in this group, blood 
pressure  was  <  140/90  mmHg  at  a  screening  visit.  The  unselected  essential 
hypertensive subjects were chosen at random from  a total of 138  patients recruited 
from  the  Blood Pressure  Clinic  at the  Western Infirmary,  Glasgow (Davies  et al 
1999).  All  were  aged  <64  years  and  had  high  blood pressure  confirmed  by  3 
independent measurements of >  160/90 before initiation of treatment.  The low and 
high ARR subjects were randomly selected from  a total of 375  patients referred to 
the Tayside Hypertension Clinic at Ninewells Hospital, Dundee (Lim et al 2002b  ). 
They were aged 18-80 years and all had blood pressures > 160/90 mmHg, confirmed 
over a period of at least 3 months before referral.  Both high and low ARR groups 
had mean aldosterone levels within the normal range with no  significant difference 
between the  groups.  Therefore,  renin levels  largely  determined the  differences  in 
ARR (see table 3.1). 
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The coding regions of CYP llBI were  initially screened by SSCP  (single-stranded 
conformation polymorphism), and the presence of any mutations confirmed by direct 
sequencing by Mrs Christine Holloway and Dr Angela Fisher.  The effect of each of 
these on enzyme activity was determined in vitro. 
3.3.3  Investigation of  enzyme activity in vitro 
Each of the  mutants  was  prepared by  site-directed mutagenesis  using the  Quick-
Change  site-directed  mutagenesis  kit  (Stratagene  Ltd,  Cambridge,  UK)  and  the 
pCMV4-Bl plasmid as a template (section 2.1.1).  Large scale purified preparations 
of the pCMV  4-B 1 wildtype, each of the mutants and the pGL3 control plasmid were 
made, analysed by restriction digestion and sequenced (sections 2.1.1, 2.1.2, 2.2.6). 
Transient  transfection  was  carried  in  JEG-3  cells  (section  1.1.4).  Cells  were 
incubated with or without substrate (S  or DOC) at a range of concentrations for 24 
hours.  The  incubation medium was  then removed for  steroid analysis  by  HPLC. 
Cells lysates were prepared for protein and luciferase measurements to determine cell 
number and transfection efficiency and steroid results were corrected appropriately 
(section 2.1.5).  RNA was extracted from cells transfected with the wildtype gene or 
each of the mutant constructs for  quantitative RT-PCR to  compare CYP  11 Bl RNA 
transcript levels (sections 2.1.6 to 2.1.8). 
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The subjects were already genotyped for the SF1  (-344 CIT) polymorphism by PCR 
and  Haeiii  restriction  digestion  following  the  conditions  previously  described 
(Davies et all999). 
3.3.5  Statistical Analysis 
Although the sample sizes for the transfection experiments were relatively small (n = 
6)  they  all  passed the  Kolmogrov-Smimov  normality  test  indicating  a  Gaussian 
distribution and that parametric testing was suitable. Statistical comparison of mean 
steroid levels over the range of substrate concentrations was accomplished by 2-way 
analysis  of variance  (ANOV  A).  Comparison  of fold  differences  compared  to 
wildtype  for  each  of  the  mutants  at  a  single  substrate  concentration  was 
accomplished  usmg  a  2-sample  t  test.  The  mRNA  expression  rates  were  not 
normally distributed even when log-transformed and so were analyzed by the Mann-
Whitney nonparametric test.  For all  analyses, p < 0.05  was required for  statistical 
significance. 
3.3. 6  Ethics 
The local ethics review commitees approved the patients' recruitment and subsequent 
genetic studies. 
3.3. 7  Modelling 
The protein structure of 11 ~-hydroxylase (P45011p)  has yet to be determined and so, 
to  give  some  idea of where  the  mutant  amino  acids  lie  in relation to  important 
147 functional regions of  the protein, the best 3D model possible was produced using the 
information currently available. 
The  P450  superfamily  proteins  all  have  a  similar  folded  structure  (Nelson  and 
Strobel 1989).  This enables tentative modelling of unknown proteins on the basis of 
those  crystal  structures  that  have  been  determined.  Krone  et al  confirmed  that 
P450u13  follows  the  general  topography  of the  P450  superfamily,  and  out  of the 
known crystal structures, mammalian CYP2C5 had the highest structural similarity 
(Krone et al2005).  Therefore, the structure of CYP2C5 (PDB accession code 1DT6) 
was used as a template for the 3D model ofP450lll3· 
The  amino  acid  sequences  of P450u13  (CYP JJBJ) and  21-hydroxylase  (CYP2C5) 
were  aligned  using  the  MultiAlin  multiple  sequence  alignment  (Corpet  1988). 
Human  11~-hydroxylase contains  503  amino  acids  and  mammalian  (rabbit)  21-
hydroxylase contains 473 amino acids.  P450 1113 has 24 residues at its N-terminus that 
constitute  the  mitochondrial  targeting  sequence.  These  are  not  present  in  21-
hydroxylase  as  it is  a microsomal P450;  the  alignment begins  after this  targeting 
sequence. 
The structure of CYP2C5 was imported into QUANTA (Accelyrs, San Diego, CA, 
USA) and according to the sequence alignment, amino acid residues were exchanged 
in  the  template.  Refinement  and  energy  minimization  were  carried  out  by 
REFMAC5  (Murshudov  et  al  1997)  and  the  model  validated  by  PROCHECK 
(Laskowski et al1993). 
148 3.4  Results 
3.4.1  Subjects 
Both the low and high ARR groups had mean aldosterone levels within the normal 
range.  The mean aldosterone level was 406 ± 54.29pmol/l for the low ARR (~ 200) 
group  and  503  ±  40.26pmol/l  for  the  high  ARR  (2:  750)  group  (see  table  3.1). 
Therefore, differences in their plasma renin levels accounted for the differences in 
ARR.  The renin level for the low ARR group was 4.81  ± 0.7 compared to  0.23  ± 
0.03 for the high ARR group. 
Aldo (pmol/1)  PRA (ngAl/ml/hr)  ARR 
Mean± SEM  Mean± SEM  Mean± SEM 
ARR~200  406 ± 54.29  4.81 ± 0.7  124 ± 8.14 
ARR2: 750  503 ± 40.26  0.23 ± 0.03  4089 ± 831.54 
Table 3.1. Mean plasma aldosterone (Aldo) levels and renin activity (PRA) for 
the hypertensive groups stratified by ARR 
3.4.2  Mutation Detection 
No mutations were identified that differed in frequency between the four groups of 
subjects.  However,  eight missense mutations  were  identified in CYP 11 B I, which 
alter the encoded amino acid.  These were located in exons 1, 2 and 3: R43Q, L83S, 
H125R,  P135S,  Fl39L, L158P,  L186V  and T196A.  Mutant R43Q  results  in the 
replacement  of  the  11 ~-hydroxylase-specific  residue  with  the  corresponding 
aldosterone  synthase-specific  residue.  Each  of the  mutations  were  identified  in 
individual subjects apart from L158P, which was identified in two subjects.  Mutants 
P135S, F139L and T196A were identified in the same subject (see table 3.2). 
149 Ex  on  Mutant  Base change  Amino acid change  Group 
1 
2 
3 
3 
3 
3 
3 
3 
R43Q  CGG-CAG  Arginine - Glutamine  ARR> 750 
L83S  TTG-TCG  Leucine - Serine  Unselected Hypertensive 
H125R  CAC-CGC  Histidine - Arginine  Unselected Hypertensive 
P135S*  CCT-TCT  Proline- Serine  Control 
F139L*  TTC- CTC  Phenylalanine - Leucine  Control 
L158P  CTC- CCC  Leucine - Proline  ARR < 200/ Control 
L186V  CTG-GTG  Leucine - Valine  Unselected Hypertensive 
T196A*  ACC- GCC  Threonine - Alanine  Control 
Table 3.2 CYPJJBJ Missense Mutations 
All mutations were identified in individual subjects, apart from  L158P, which was 
identified in 2 subjects. 
* All of  these mutants were identified within the same subject 
3.4.3  Restriction Digestion of  Plasmids 
Plasmid DNA was digested using the restriction enzyme BamHI to assess quality and 
the  presence  of an  insert  of appropriate  size.  This  enzyme  linearizes  CYP llBI 
eDNA by hydrolysing it at a single  site to  produce  a fragment of 6.3kb.  BamHI 
digests are shown in figure 3.1. 
150 6,000 bp ----. 
4,000 bp ----. 
1,000 bp ----. 
L  Wt  R43Q  L83S  Hl25R Pl35S  F139L  L158P L186V Tl96A 
Figure 3.1 BamHI digests ofpCMV4-Bl wild-type and mutant plasmids 
Analysed on a  1%  agarose  gel  stained with ethidium bromide.  BamBI linearises 
CYP liB  I  eDNA  to  generate  a  6.3kb  band.  A  single  band  of the  correct  size 
confirms  the  presence  of  the  CYP 11 B I  eDNA  insert.  Lane  L  contains  5  f!l 
HyperLadder I (Bioline, London, UK). 
3.4.4  Confirmation of  Mutations 
The presence of each of  the mutants (see table 3.2) was verified by sequencing using 
the automated sequencing method described in section 2.2.6.  The entire insert was 
sequenced to rule out the incorporation of any unwanted mutations.  Sequence data 
are  shown in figures 3.2a to h.  Sequencing revealed that the construct containing 
the L83S  mutant had an extra unwanted mutation (see figure 3.2b) but, as  this did 
not change the encoded amino acid, the construct was deemed suitable for use. 
151 l.A) 
R43Q 
Wt 
l.C) 
H125R 
Wt 
ATGC C  CAGCGTCCA 
AT  CCCC A  C  T CC A 
AT  ecce  C  T CC A 
GTGGGC GCAAATG1 
T  C  CAAA T  1 
GTGGGCACAAATG1 
\ 
T  CA CAAA T  1 
., 
I. 
l.B) 
'ACGA T T CGGGAGGA! 
' AC  ATT C  A  A 
L83S 
'ACGACTTGGGAGGA! 
' AC  ACTT  A  A 
Wt 
;AATGGG T CTGAATC 
l.D)  AA T  T CT  AA T 
P135S 
;AATGGGCCTGAATC 
AA T  CC T  AA T 
Wt 
Figure 3.2 A to D.  Sequences confirming presence of mutations R43Q, L83S, 
H125R and P135S respectively compared to wildtype pCMV  4-Bl. 
152 l.E) 
F139L 
Wt 
l.G) 
L186V 
Wt 
"GGCGC CTCAACCG 
C  CC T C AA CC 
TGACC GTGGACG 
T  A CC  T  A C 
TGACCCTGGACG 
T  A CCC T  A C 
l.F) 
L158P 
Wt 
GTTCC C CCCGAT 
TT CCCCCC  A T 
'I  \ 
GTTCCTCCCGAT 
TT CC T CCC  A T 
l.H)  C A C T A C G C C A T A G A A 
CA CT A C  CC AT A  AA 
T196A 
CA CT A CA CC AT A  AA 
Wt 
Figure 3.2 E to H.  Sequences confirming presence of mutations Fl39L, L158P, 
L186V and T196A respectively compared to wildtype pCMV4-Bl. 
153 3.4.5  SFJ (-344 CIT) genotyping 
The frequency of the -344 alleles was determined for  each of the 4 populations, as 
shown in table 3.3.  There was an overall 6%  failure  rate in the  genotyping.  The 
distribution of  genotypes was as expected from previous studies (Davies et al1999). 
Group 
Normals 
Unselected Hypertensives 
ARR>750 
ARR<200 
cc 
6 (0.18) 
8 (0.21) 
6(0.15) 
8 (0.20) 
TC 
19 (0.57) 
23 (0.60) 
22 (0.55) 
17 (0.43) 
TT 
8 (0.24) 
7(0.18) 
12 (0.30) 
15 (0.38) 
Table 3.3 Genotype distribution for SFl (-344 CIT) site 
%C 
47% 
52% 
43% 
41% 
%T 
53% 
48% 
57% 
59% 
Chi-squared analysis revealed no  significant difference in gene frequencies between 
groups (X
2 = 4.59, degrees of  freedom= 6, P = 0.59). 
3.4. 6  Steroid Conversions 
Graphs of  the steroid products, cortisol (F) and corticosterone (B), against a range of 
substrate  concentrations,  11-deoxycortisol  (S)  and  11-deoxycorticosterone  (DOC) 
respectively,  for  the  wildtype  11 ~-hydroxylase and  with  each of the  mutants  are 
shown  in  figures  3.3  to  3.10.  All  steroid results  were  corrected  for  transfection 
efficiency values.  These were calculated by converting protein levels and luciferase 
activity of cell lysates to  relative  light units  (RLU)  luciferase per unit of protein. 
These values were then converted to  fold differences of the mean wildtype control 
transfection.  A comparison of the fold difference to wildtype was made for each of 
154 the mutants at the lowest substrate concentration to give a rough idea of the potency 
ofthe effects. 
3  .4.6.1  Effects of  Mutants over a range of  substrate concentrations 
The potency of  the effects of  the 8 mutations on 11 ~-hydroxylation of  both substrates 
over a range of concentrations fell roughly into 3 groups (see figures 3.3 to 3.10). 
Severe inactivation with regard to both substrates 
Mutants L158P and L83S both severely reduced  11~-hydroxylase conversion ofboth 
substrates  (S  and DOC)  at all  concentrations tested (figures  3.3a and  b and  3.4a 
and  b).  Their  activities  vary  between  absolutely  no  conversion  at  the  lowest 
substrate concentration to a very small level of product observed (approximately 1 to 
3% that ofthe wildtype) at the highest concentration ofS and DOC tested. 
Partial inactivation; similar response for both substrates 
Mutant Pl35S greatly reduced the conversion of substrate S with product formation 
between approximately 2 to  10%  that of the  wild  type  over the  range  of substrate 
concentrations (figure 3.5a).  The  effect on DOC conversion was less  severe with 
product levels that varied between  10 to 40% that of the wild  type with increasing 
substrate concentration (figure 3.5b).  The F139L (figure 3.6a and b), R43Q (figure 
3.7a and b) and T196A (figure 3.8a and b), mutants resulted in product levels that 
were  approximately  30%  to  50%  of the  appropriate  wildtype  product  with  little 
variation in the potency of  the effect over the range of  substrate concentrations. 
155 Markedly different effects for the two substrates 
The  H125R mutant had a substrate-specific  effect,  reducing  conversion of S to  F 
when  compared to  the  wildtype  (figure  3.9a)  but  not  conversion  of DOC  to  B 
(figure 3.9b).  The extent ofthe reduction in the conversion ofS to F was maintained 
over the  range  of concentrations tested.  The  mutant L186V  also  had a  substrate 
specific effect; it increased the conversion of S to F over the range of concentrations 
tested compared to  the  wildtype (figure 3.10a) but did not significantly affect the 
conversion of DOC to B (figure 3.10b  ).  The magnitude of the increase in product 
formation was maintained over the various concentrations of S.  There appeared to 
be an increased product formation compared to wildtype at the lowest concentrations 
of DOC  tested.  However,  over  the  range  of concentrations  tested  this  was  not 
significant. 
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B 
Figure 3.3 Effects of mutant L158P (Leucine-Proline) 
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Effects  of mutant  Ll58P  on  the  conversion  of S  to  F  (A)  and  DOC  to  B  (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference ofthe 
Wildtype product at 0.1~-tM substrate Values are the mean± SEM (n = 6). A two-way 
ANOV  A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
157 Figure 3.4  Effects of  mutant L83S (Leucine-Serine) 
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Effects ofmutant L83S on the conversion ofS to F (A) and DOC to B (B) compared 
to wild type pCMV  4-B 1. Results are expressed as a fold difference of the Wildtype 
product  at  0.1 )lM  substrate.  Values  are  the  mean ±  SEM  (n  = 6).  A  two-way 
ANOV  A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
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Figure 3.5 Effects of mutant P135S (Proline-Serine) 
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Effects  of mutant  Pl35S  on  the  conversion  of S  to  F  (A)  and  DOC  to  B  (B) 
compared to wild type pCMV  4-B 1. Results are expressed as a fold difference of the 
Wildtype product at O.lf.lM substrate.  Values are the mean± SEM (n =  6).  A two-
way  ANOV  A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
159 Figure 3.6 Effects of mutant F139L (Phenylalanine-Leucine) 
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Effects  of mutant  F139L  on the  conversion  of  S  to  F  (A)  and  DOC  to  B  (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference of the 
Wildtype product at 0.1  ~M  substrate.  Values are the mean ±  SEM (n =  6). A two-
way  ANOV  A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
160 Figure 3.7 Effects of mutant R43Q (Arginine-Glutamine) 
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Effects of  mutant R43Q on the conversion of  S to F (A) and DOC to B (B) compared 
to wild type pCMV  4-B 1. Results are expressed as a fold difference of the Wildtype 
product  at  O.lJ.LM  substrate.  Values  are  the  mean  ±  SEM  (n  =  6).  A  two-way 
ANOV A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
161 Figure 3.8 Effects of mutant T196A (Threonine-Alanine) 
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Effects  of mutant  Tl96A on  the  conversion  of S  to  F  (A)  and  DOC  to  B  (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference of the 
Wildtype product at O.lJ.!M substrate.  Values are the mean± SEM (n =  6).  A two-
way  ANOVA  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
162 Figure 3.9 Effects of mutant H125R (Histidine-Arginine) 
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Effects  of mutant  H125R on the  conversion  of S  to  F  (A)  and  DOC  to  B  (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference ofthe 
Wildtype product at 0.1 J.!M  substrate. Values are the mean ±  SEM (n = 6).  A two-
way  ANOV  A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
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Figure 3.10 Effects of mutant L186V (Leucine-Valine) 
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Effects  of mutant  H125R on the  conversion of S  to  F  (A)  and  DOC  to  B  (B) 
compared to wild type pCMV4-Bl. Results are expressed as a fold difference of the 
Wildtype product at O.l)lM substrate. Values are the mean± SEM (n  =  6).  A two-
way  ANOV  A  was  used  to  compare  the  wildtype  and  mutant  over  the  range  of 
concentrations studied; the resulting p values are shown. 
164 3.4.6.2  Comparison of  fold differences in product formation 
Comparing the fold  differences  of each of the mutants to the  wildtype  at  a single 
concentration allows a rough comparison of  the severity of each of  the mutants.  This 
was  done  at the lowest concentration of substrate (O.lf..LM)  which should maximise 
the distinction between differences in affinity (see table 3.4).  Using this method, the 
potency of the effects of the  8 mutations on  11 ~-hydroxylation fell  roughly into  4 
groups: 
Severe inactivation with regard to both substrates 
The  p  values  indicate  that the  mutants  L83S,  L158P  and  P135S  have  the  most 
detrimental effects, with very poor conversion from  S to F observed for L83S  and 
P135S and no conversion of DOC.  There was no conversion of either substrate for 
L158P. 
Partial inactivation; similar response for both substrates 
The  mutants  R43Q  and  F139L  and  T196A  have  less  severe  effects  on  enzyme 
function, resulting in partial reduction in conversion of  both S and DOC. 
Markedly different effects for the two substrates 
The mutant H125R has a substrate specific effect with a significant inhibition of the 
conversion of S to F but not of  DOC to B. 
Increased activity with regard to both substrates 
Mutant L 186V has a unique effect, resulting in an increase in the conversion of both 
substrates. 
165 Mean F Production  Mean B Production 
Mutant  Fold diff  p value  Fold diff  p value 
to Wt±SEM  to Wt± SEM 
L158P  no activity  0.000  no activity  0.000 
L83S  0.02 ± 0.01  0.000  no activity  0.000 
Pl35S  0.06 ± 0.01  0.001  no activity  0.000 
R43Q  0.53 ± 0.05  0.009  0.07 ± 0.01  0.002 
Fl39L  0.27 ± 0.03  0.002  0.47 ± 0.04  0.003 
T196A  0.35 ± 0.13  0.042  0.43 ± 0.06  0.018 
H125R  0.63 ± 0.04  0.022  0.6 ± 0.06  NS 
L186V  5.59 ± 2.09  0.002  3.07 ± 0.35  0.007 
Table 3.4.  Mean product levels as  a fold  difference of the wildtype product ± 
SEM for each of the mutants.  Results for both the conversion of S to F and DOC 
to B are shown at 0.1~-tM substrate.  The p values represent a comparison between the 
mutant and wildtype product levels using an unpaired 2-Sample t test. 
NS =  non-significant 
In most cases, these observations are in agreement with the effects observed over the 
range  of  substrate  concentrations.  However,  when  comparing  the  range  of 
concentrations using ANOVA, the mutant L186V only had a significant effect on the 
conversion of S to  F and not on the  conversion of DOC to  B.  In contrast,  when 
comparisons  are  made  at  only  the  0.1~-tM  substrate  concentration,  there  was  a 
significant increase in the conversion of  both substrates. 
166 3.4. 7  QRT-PCR 
Real  time  QRT-PCR  shows  that  the  levels  of CYP liB  I  transcript  do  not  differ 
significantly  between  the  wildtype  plasmid  and  the  mutant  constructs  studied 
(figures 3.11 and 3.12). Thus, the expression levels within the cells are likely to  be 
similar and any observed changes in  11~-hydroxylase activity can be  attributed to 
structural  changes  in the  enzyme  and not to  changes  in gene  expression rate  and 
subsequent protein production. 
3.4.8  Modelling 
A putative 3D Model of 11 ~-hydroxylase was generated using homology modelling 
techniques (see figure 3.13).  From the model the mutant residues can be assigned to 
particular regions of  the molecule: 
Residue 
43 
83 
Putative 3D location 
Rope/loop  flanking  helix 
(exterior of  molecule) 
Roop/loop flanking helix B 
Effect on  11~-hydroxylation 
A  Partial reduction 
Severe reduction 
125  Roop/loop between helices Band C  Substrate specific (t S to F) 
135  Helix C  Partial reduction 
139  Helix C  Partial reduction 
158  Start ofhelix D  Severe reduction 
186  Start of  E' helix  Substrate specific ( i S to F) 
196  Start of  helix E  Partial reduction 
Table 3.5 Putative 3D locations of each of the mutant residues 
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Figure 3.11 QRT  -PCR Amplification Curve 
Amplification curve displaying fluorescence values versus cycle number.  Serial 10-
fold  dilutions  of CYP llBI mRNA  standard  are  shown  in  black.  Sample  copy 
number for the wildtype and each of  the mutants was extrapolated from the standard 
curve on the base of the samples crossing point.  This is a representative curve that 
was repeated 3 times.  A negative control (water blank) and also RNA extracted from 
untransfected cells was included in each run. 
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Figure 3.12 CYPJJBJ mRNA levels 
Levels  of CYP 11 B I  mRNA  from  cells  transfected with wild  type  pCMV  4-B 1 and 
each  of the  mutant  constructs.  Values  are  expressed  as  mean  mRNA  copy 
number/mg total RNA ± SD from 3 independent experiments.  Each of the mutants' 
mRNA copy number was compared to the wildtype using the nonparametric Mann 
Whitney test. 
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Figure 3.13  Homology Model of 11J3-Hydroxylase 
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I R43Q I 
3-Dimensional  model  of the  structure  of human  11  J3-hydroxylase  showing  the 
positions of each of the mutant residues in relation to the active site containing the 
haem. 
170 3.5  Discussion 
These  experiments  investigated  the  presence  of genetic  polymorphisms  in  the 
CYP II  B I  gene. In particular they were concerned with whether such variation was 
associated  with  raised  blood  pressure  and  ARR  and  whether  it  affected  the 
CYP 11 BI-dependent  activity,  11 ~-hydroxylation.  Several  novel  mutations  were 
identified in the four groups of subjects, normotensive controls, unselected essential 
hypertensives  or hypertensive subjects with either a high  (2::  750)  or low ARR  (:S 
200) that markedly change enzyme efficiency. However, their frequency was similar 
in normotensive and hypertensive groups and did not markedly differ when the low 
and high ARR groups  were  compared.  It has  previously been reported that the  T 
variant of the -344 CIT  polymorphism of the  adjacent CYP II  B2  gene  is  found  in 
higher frequency in hypertensive subjects, particularly in those with a raised ARR 
(Brand et al 1998; Davies et all999; Lim et al 2002b  ). This study was not powered 
to  look  for  such  an  association;  the  study  subjects  were  chosen  on the  basis  of 
phenotype not genotype. The frequency of the T allele was very similar within the 
four groups (see table 3.3).  It is therefore more likely that patients selected on the 
basis  of genotype  associated with a raised ARR might identify specific  mutations 
that are  linked to  the  development of this type  of hypertension.  In  addition,  this 
study examined only the coding region of CYP II  B I  and so it is  possible that other 
mutations exist in the untranslated regions, either 5' or 3' of the gene, or located at 
exonlintron boundaries that may alter splicing, which associate with a raised ARR. 
These regions therefore require further investigation (see Chapter 4). 
Although the variants  identified did  not  appear  to  associate  with hypertension  or 
ARR, they had marked and varied effects on the activity of the resulting enzyme.  It 
171 could be argued that these changes in enzyme function are due to altered levels of 
expression of  the modified proteins.  However real time quantitative RT-PCR (QRT-
PCR)  was  used  to  measure  and  compare  CYP llBI transcript  levels  between the 
mutants and the wildtype.  No significant differences were detected (figures 3.11 and 
3.12).  It would have been preferable to  perform Western Blotting to  demonstrate 
that protein expression was similar but, at the time of this study, a suitable antibody 
for  11 ~-hydroxylase was not readily available.  An alternative approach would have 
been to  use a construct containing a tag (  eg.  histidine tag) which would generate a 
labelled gene product.  A commercially-available antibody raised against this label 
could then be used for Western Blotting.  However the construct used in the present 
study was in a form that would have entailed a lot of extra cloning work and it was 
felt  that  the  sensitivity  of the  RT-PCR  approach  made  it  the  preferred  method. 
Although  the  QRT-PCR  technique  does  not  give  any  indication  of changes  in 
expression  levels,  it  confirms  that  the  transcription  of the  mutant  and  wildtype 
cDNAs  are  similar,  supporting  the  proposal  that  the  observed  changes  in  11 ~­
hydroxylase substrate conversion are  due to  structural changes in the protein.  The 
effects  of all  the  mutations  will  therefore  be  determined by the  difference  in the 
physical properties of the amino acids exchanged as well as the locus of the mutant 
residue within the protein. 
The mutants L158P and L83S both severely reduced  11~-hydroxylase conversion of 
both substrates  S and DOC  over a range  of concentrations  (figures 3.3  and  3.4). 
Both mutations change the polarity of the encoded amino acid.  The L158P mutant 
would also change the structure of the protein chain; the large cyclic proline residue 
would introduce a bend not present in the wildtype L158 form.  A similar effect on 
the  protein  conformation  would  result  from  the  P135S  mutation,  which  agam 
172 decreased  conversion of both substrates,  although the  effect on  S conversiOn  was 
much more pronounced than the effect on DOC conversion (figure 3.5).  The mutant 
T196A also results in a change of polarity of  the encoded amino acid.  It has a more 
subtle effect than the previous mutants, resulting in product levels that are 30 to 40% 
compared to wildtype (figure 3.8). Fl39L and R43Q have a similar effect, reducing 
the level of product formation to between approximately 30 to 50% compared to the 
wildtype  enzyme  (figures 3.6 and 3.7).  F139L  is  a fairly  conservative change  in 
amino acid, but R43Q might result in an altered charge.  Arginine (R) often forms 
salt bridges through hydrogen bonding with negatively charged amino acids that are 
important  for  protein  stability  Disruption  of this  stability  may  account  for  the 
decreased  enzyme  function.  The  H125R  mutation  resulted  in  substrate-specific 
alterations  in  enzyme  function,  whereby  conversion  of S  to  F  was  decreased 
compared to  the  wildtype but DOC  to  B  conversion was  unaffected (figure 3.9). 
This suggests that a histidine at this position is  important for the interaction with S. 
The mutant L186V had a unique effect that was  also  substrate-specific,  increasing 
conversion  of S  to  F  but not that  of DOC  to  B  (figure  3.10).  This  is  a  fairly 
conservative amino acid change and how it alters the protein environment to favour 
increased S conversion is unclear. 
In addition to the different physical properties of  the amino acid at a given locus, the 
proximity  of the  locus  to  an  important  functional  site  will  also  alter  enzyme 
efficiency and substrate specificity.  More  detailed understanding of the  structure-
function  relationships  of P45011 f3  awaits  elucidation  of its  3-dimensional  (3D) 
structure but some preliminary deductions can be made from the known structures of 
other cytochrome P450 enzymes. Studies of bacterial homologues suggest that P450 
enzymes consist of  a number ofhelices (A-L) (Ravichandran et all993) (see section 
173 1.14). The haem in cytochrome P-450 enzymes is  located between helices I and L. 
The P450  superfamily proteins have a conserved structural core  (Presnell sr  1989) 
and so it is possible to use known crystalline P450 structures as templates for others. 
Homology modelling ofP450ll~ suggests that the I helix (residues 301-331) contains 
many hydrophobic amino acids and is  the putative active site (Be1kina et al 2001). 
None  of the  mutations  investigated  in this  study  are  located  within this  putative 
active site but they all clearly alter enzyme activity.  It is possible that they disrupt 
one  of the  six proposed substrate recognition sites  (SRS 1-6)  or that they  alter the 
flexibility of the protein, affecting substrate access to the  catalytic domain (Gotoh 
1992). 
Generating a 3D  model of 11 ~-hydroxylase using the  structure of the  mammalian 
microsomal protein 21-hydroxylase (CYP2C5) as  a template  (Williams et al 2000) 
enabled these mutant residues to  be assigned to  particular regions of the molecule 
(see figure 3.13 and table 3.5).  From these putative 3D locations and results from 
previous structure-function studies, it is possible to speculate on the reason for some 
of  these alterations in enzyme function. 
Mutant R43Q 
Residue Arg43 is located near theN terminus of the protein, which may be involved 
in protein-membrane interaction (Belkina et al 2001).  Interestingly, a homozygous 
mutation at the adjacent locus (Pro42Ser) results in the non-classical form  of 11 ~­
hydroxylase  deficiency with only partially reduced  activity  (see  section  1.15.2.3) 
(Joehrer et al 1997).  It seems likely that, if present as  a homozygote, the mutation 
R43Q could produce a similar phenotype. 
174 Mutant H125R 
Residue  125  is  located  among  a  cluster  of glycines  (  G 123,  G 128  and  G  134) 
conserved in both  11 ~-hydroxylase and  aldosterone  synthase.  These  glycines  are 
thought to  be  involved in the flexibility of the  loop between helices B and C that 
contains the  substrate recognition site  1 (SRS1)  (see  section 1.14.3) (Gotoh  1992; 
Krone et al 2005). Mutations within this region may alter substrate specificity and in 
fact mutant H125R appears to  decrease the affinity for substrate S with no  effect on 
DOC. 
Mutants P 135S and Fl39L 
Residue 135 may form a bond with the haem moiety (see figure 3.13).  Mutation at 
this  locus,  especially  such a  dramatic  change  as  removal of the  large  orientation-
changing  cyclic  proline  residue  (P135S),  may  alter  the  haem  orientation  and 
therefore the efficiency of electron transport in the oxidase reaction (see section 1.7). 
Residues 135 and 139 appear to be located within helix C, which is thought to form 
part of the substrate access channel.  Again, mutations within this region have been 
asssociated with  11~-hydroxylase deficiency,  both classical  (Val129Met)  and  non 
classical (Asn133His) types (Geley et al1996; Joehrer et al1997). 
Mutant LJ86V 
Mutant L186V has a substrate specific effect but does not appear to be located within 
one of  the proposed substrate recognition sites (see section 1.14.3) (Gotoh 1992).  In 
the bacterial P450cAM, residue 186 helps to maintain the substrate access channel in 
the  closed conformation by binding to  residue Asp251  in the I helix.  Mutation of 
these residues favors  substrate binding by allowing easier diffusion of the substrate 
175 into the active site (Deprez et al 1994).  Mutation at locus  186 (L186V) in human 
P4501lp  may  also  have  a  similar  effect  on the  binding  of S  as  it  increases  the 
conversion of S compared to  wildtype.  This  is  a  substrate  specific  effect  as  the 
conversion ofDOC is not affected (figure 3.10). 
Mutations L83S, Ll58P and TI96A 
Mutations L158P, which is  situated at the start of helix D, and L83S that lies in the 
loop  just before  helix  B,  severely  reduce  enzyme  activity  (figures  3.1  and  3.2). 
Residue  196 is  located in helix E and also reduces enzyme activity but to  a lesser 
extent  (figure  3.8).  From  their  putative  positions  and  the  information  in  the 
literature, the reasons for these effects are not entirely clear.  Mutations at these sites 
may  alter the  position of the  helix  and  change  protein  conformation.  This  may 
position the haem in an orientation less favourable for the 11 ~-hydroxylation of S or 
DOC.  As  mentioned  previously,  all  these  changes  would  result  in  a  change  in 
polarity and the L158P may also alter the geometry of the protein chain that might 
account for their detrimental effects on enzyme activity. 
In summary,  although these  speculations  are  useful in partially accounting for  the 
effects of sequence changes, a more complete explanation requires the determination 
of a high-resolution x-ray structure of P45011p.  None of  the residues investigated are 
located  within  the  putative  active  site  of P45011p but  do  markedly  alter  enzyme 
function. Their location provides further clues to the structure-function relationships 
of cytochrome P450 enzymes.  Fisher et al similarly showed that changes in residue 
147 of P450aldo or P45011p,  also distant from the active site, reduced activity (Fisher 
et a/2000). 
176 Cytochrome P450 enzymes are unlike most other enzymes.  They can bind more than 
one substrate, making them an exception to the classic 'lock and key' principle of the 
specificity  of enzyme  function.  P450 11 ~  is  particularly  varied  in  the  range  of 
substrates  on  which  it  may  perform  both  liP- and  18- (and  possibly  19-) 
hydroxylation.  The different effects of  the mutations investigated in this study on S 
and DOC hydroxylation may give important insights into enzyme mechanisms.  The 
substrates  S and DOC  differ by the  presence and absence  respectively  of a  17 a-
hydroxy group, giving them different polarity and therefore affecting their interaction 
with the (hydrophobic, hydrophilic) amino acids of the substrate-binding site.  The 
substrate-specific  effect  of the  mutants  H 125R  and  L 186V  suggests  that  these 
residues  play an important role  in the  interaction of the  17a-hydroxyl group  of S 
with the enzyme. 
Since  the  initial  work was  conducted for  this  study,  techniques  to  perform  high-
throughput  screening  by  direct  sequencing  have  become  available.  Our  own 
experience, and that of others examining the CYP II  B locus in normotensive subjects, 
suggests that variation across the entire region is high (Cargill et al 1999; Halushka 
et al1999).  Each ofthe mutations identified was in subjects who were heterozygous, 
so that a normal CYP IIBI allele was present.  No subject had clinical symptoms of 
11 P-hydroxylase  deficiency,  although more detailed biochemical phenotyping was 
not  performed.  As  yet  no  individual  with  this  disorder  has  been  identified  as 
homozygous  for  these  mutations.  The  mutations  causing  11 P-hydroxylase 
deficiency are distributed across the entire gene but with a slightly higher frequency 
in exons 2,  6,  7 and 8 (Curnow et al1993; Geley et al1996) (see section 1.15.2.3). 
The causative mutations can be insertions, deletions, nonsense or missense mutations 
177 that  usually  result  in  a  complete  loss  of enzymatic  activity.  A  residual  11 ~­
hydroxylase activity of 3% is insufficient to prevent the clinical symptoms of classic 
11 ~-hydroxylase deficiency (Krone et al2005). 
A total of 8 mutations were  identified in  160  subjects screened (and other studies 
have  also  identified  a  high  frequency  variation).  The  carrier  rate  for  mutations 
within  this  gene  that  would  be  predicted  to  cause  significant  alteration  of 11 ~­
hydroxylation efficiency within the population may be in the order of 3 to 5%.  This 
might be  expected to  give rise to  a compound heterozygote rate of 1 in 2500  live 
births.  However, the reported rate of severe hydroxylase efficiency in a Caucasian 
population is very much lower than this (White et al 1994).  One possibility is that 
that severe mutations, such as  L83S and L158P, are embryonically lethal so that the 
live birth rate would be substantially lower than this. However this seems unlikely as 
even complete loss of 11 ~-hydroxylase is not lethal in utero due to maternal cortisol 
crossing  the  placenta.  Alternatively,  it  is  possible  that  a  substantial  number  of 
compound  heterozygotes  carry  mutations  that  reduce  but  do  not  abolish  11 ~­
hydroxylase  activity,  resulting  in  a  form  of  non-classical  11 ~-hydroxylase 
deficiency.  As mentioned previously mutations causing a nonclassical form of 11 ~­
hydroxylase  deficiency  have  been  identified  more  recently,  that  cause  partially 
disrupted enzyme activity in  vitro to  15-37% of the wildtype (see section 1.15.2.3) 
(Joehrer et al 1997).  In this circumstance, the phenotype is less severe, so that the 
classic presentation of virilising congenital adrenal hyperplasia in early life  is  not 
present.  Less marked reduction in  11 ~-hydroxylase activity gives rise to  a milder 
phenotype,  possibly  associated  with  the  development  of  hirsutism  and/or 
hypertension in later life.  The mutations R43Q, P135S, F139L and T196A appear to 
178 reduce  11 ~-hydroxylase substrate  conversion to  approximately  30  to  50%  of the 
wildtype.  It seems likely that, if  these were present as homozygotes, they would also 
result  in  a  nonclassical  phenotype.  Interestingly,  the  mutants  Pl35S, Fl39L and 
T196A were all identified in a single subject. It is possible these and other mutations 
have not been identified due  to  the milder phenotype of this form  of the disorder. 
The mutant H125R causes a mild reduction in the conversion of S to F with no effect 
on the conversion of  DOC to B.  How this would manifest itself in vivo is unclear. 
The identification of as  many as  5 mutants in 160  subjects that appear to partially 
reduce the conversion of substrate to  product in  vitro suggests that subtle forms  of 
11 ~-hydroxylase  deficiency  may  be  more  common  than  has  been  generally 
perceived.  Other  studies  have,  indeed,  reported  that  altered  11-hydroxylation 
efficiency is a common feature of  patients with essential hypertension, although such 
studies have not carried out a systematic examination ofthe CYPJJBJ gene (Connell 
et al 1996; de  Simone et al 1985; Honda et al 1977).  Analysis of the polymorphic 
variation of a much larger hypertensive population, with more extensive phenotypic 
data will allow a better determination of  the true frequency of  the variance as well as 
in association between polymorphisms  and  phenotypes  such  as  hypertension with 
mineralocorticoid features. 
179 CHAPTER4 
Haplotype Analysis of  the CYPJJBJ/2 Locus 
180 4.1  Introduction 
As described in section 1.16.3, the -344 CIT and intron conversion (IC) variants in 
CYP II  B2  have  been  consistently  associated  with  an  impaired  11 ~-hydroxylase 
efficiency (Davies et al2001; Hautanena et al1998; Kennon et al2004).  It is likely 
that  this  seemingly  paradoxical  association  can  be  explained  by  linkage 
disequilibrium  (LD)  between these  CYP II  B2  variants  and  key polymorphisms  in 
CYP11BI that could account for this phenotype.  The -344 CIT and IC variants are 
indeed in linkage with polymorphisms in CYP II  BI, specifically in exon 1 (225 G/  A, 
Leu75Leu), intron 3 (2803 A/G) and intron 6 (4265 G/A) (Ganapathipillai et al2005; 
Keavney et al 2005).  The  CYP II  B haplotypes  identified in each study associated 
with 11 ~-hydroxylase efficiency.  However, the CYP 11 BI polymorphisms identified 
were  either synonymous exonic  or intronic  and  so  are  unlikely to  account for  the 
biochemical phenotype of impaired  11 ~-hydroxylase efficiency.  Therefore, further 
fine  mapping  across  the  CYP II  B  locus  is  required to  identify potential  causative 
variants. 
4.2  Aims 
The aims of this study were to investigate the way in which genetic variation at the 
CYP 11 B I  12  locus  may  lead  to  altered  11 ~-hydroxylase function  through  detailed 
analysis of the pattern of genetic variation across the whole locus.  Through this it 
was  also  possible  to  determine  the  haplotype  structure  and  extent  of linkage 
disequilibrium across the entire CYP II  B locus. 
181 4.3  Methods 
4.3.1  Samples 
Genomic DNA was taken from a group of normotensive subjects already genotyped 
for  the  -344C/T and  IC  polymorphisms.  Twenty  six  subjects  were  selected  for 
genetic analysis; TT/ConCon (10), CC/WtWt (10) and TT/WtWT (6) (sections 2.2.1 
and 2.2.2). 
4.3.2  PCR and Sequencing 
The CYP II  BI gene from -2kb of  the 5' untranslated region (UTR) to the end of exon 
9 was amplified as a single PCR amplicon of approximately 7kb. The 3'UTR (750bp) 
was amplified separately (section 2.2.3).  Genetic variants were identified by direct 
sequencing of the PCR products (section 2.2.6) in collaboration with other members 
of  the group who sequenced the CYP 11B2 gene of  the same subjects to determine the 
pattern of  linkage across the entire CYP II  B locus. 
4.3.3  Haplotype analysis 
A  Bayesian  statistical  method  implemented  m  PHASE  v  2.1 
(http://www.stat.washington.edu/stephens/software.html)  was  used  to  construct 
phased  haplotypes  from  phase-unknown  genotype  data.  Linkage  disequilibrium 
(LD)  statistics  (D'  and  r
2
)  were  generated  using  the  programme  EMLD 
(http://reguest.mdacc.  tmc.edul~ghuang/Software/pub.htm,  which  calculates  LD 
between all possible pairs of genetic variants from unrelated individuals. This was 
further  investigated  using  GOLD,  which  provides  a  graphical  overview  of LD 
(http://www.sph.umich.edu/csg/abecasis/GOLD/) 
182 4.4  Results 
4.4.1  PCR of5'UTR to Exon 9 ofCYPllBl 
The 5' UTR and coding region of CYP II  B  I was amplified using the oligonucleotides 
Bl 5'UTR (s) and Bl exon 9 (as) to produce a fragment of approximately 7kb (see 
figure 4.1 ). 
Samples 1-4  Blank 
10,000 bp _____. 
4,000 bp _____. 
1,000 bp _____. 
Figure 4.1. 7kb PCR fragments from 4 different MONICA samples resolved on 
a  1%  agarose  gel.  Lane  1 contains  5!-!1  HyperLadder I  (Bioline,  London,  UK). 
Indicidual  bands  of  the  correct  size  indicate  specificity.  No  band  for  the 
control/blank reaction indicates no contamination. 
183 4.4.2  PCR of3'UTR ofCYPIJBJ 
The  3'UTR  of CYP llBI  was  amplified  usmg  the  oligonucleotides  M6635  and 
B13'UTR+500 (as) to produce a fragment of  approximately 750bp (see figure 4.2). 
10,000 bp ___. 
4,000bp--. 
1,000bp-+ 
400bp-+ 
Samples 1-8  Blank 
Figure 4.2. 750bp PCR fragments from 8 different MONICA samples resolved 
on  a 1%  agarose gel. Lane  1 contains  5J.Ll  HyperLadder I (Bioline, London, UK). 
Individual  bands  of  the  correct  size  indicate  specificity.  No  band  for  the 
control/blank reaction indicates no contamination. 
184 4. 4. 3  Polymorphism identification 
Polymorphisms were identified by direct sequencing of the genes.  An example of 
electropherograms of the 5'UTR of CYP IJBI, from  subjects in each of the groups, 
are shown in figure 4.3.  The sequence variation across the CYP JIB locus was fairly 
high.  For the purposes of this study, only the polymorphisms that differed between 
the  three  -344/IC  genotype  groups,  in all  subjects  of the  group,  were  chosen for 
further  analysis  (see  figure  4.4).  A  total  of 83  biallelic  polymorphisms  were 
identified across the entire CYP II  B locus  (  44,631 bp) that showed association with 
the  -344  CIT  and  IC  variants  in  CYP 11 B2  (see  figure  4.5).  Out  of the  83 
polymorphisms,  64  were  located  within the  CYP II  B2  gene  and  19  were  located 
within the  CYP 1J B I  gene.  They were spread throughout the genes' exons, introns 
and  their  nearby  untranslated  regions  (UTR),  with  the  highest  frequency  in  the 
intronic regions. 
185 A 
TT/ConCon 
CC/WtWt 
TT/WtWt 
B 
TT/ConCon 
CC/WtWt 
TT/WtWt 
-1889 
GTCTGTTAAG 
-1859 
TGTATAAGAA' 
T  T AT AA  AA ' 
~TTTTTGTAC G ~TGATTTTGTA 
~ TTTTT  T AC  T  ATTTT  T A 
Figure 4.3.  Sequence analysis showing two single nucleotide variants within the 
S'UTR of CYPllBJ.  Results are shown from one subject from each of  the 3 groups. 
A) G toT substitution at position -1889.  B) A toG substitution at position -1859. 
186 ACCTTCCAGGAACT ~  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
TT/ConCon  AC CTTC CAGGAACT ~  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT ~  GGCCCATTTT 
ACCTTCCAGGAACT ~  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  .,.GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
CC/WtWt  ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
AC CTTC CAGGAACT ~  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
ACCTTCCAGGAACT  GGCCCATTTT 
!!.CCTTCCAGGAACT f  GGCCCATTTT 
!!.CCTTCCAGGAACTR .,.GGCCCATTTT 
TT/WtWt  !!.CCTTCCAGGAACT  GGCCCATTTT 
!!.CCTTCCAGGAACT  GGCCCATTTT 
!!.CCTTCCAGGAACT  GGCCCATTTT 
!!.CCTTCCAGGAACT  GGCCCATTTT 
Figure 4.4. Sequence alignment of the three groups showing the presence of a 
CTG to  CTA synonymous (Leu  to  Leu) polymorphism in  codon 75  of exon 1, 
CYPJJBJ. 
187 5'  SF1  IC  3' 
(8)  (18-41) 
llUUll ll  UUlUU~lUUU  Ul  UUUH  UU  U  ll UUUl  Ull  lU  l 
CYP1182  CYP11B1 
Figure 4.5.  The positions of the 83 variations identified across the CYPJJB locus.  The SF1/-344C/T (No.8) and the intron conversion 
(IC) (Nos. 18-41) variants are marl{ed. 4.4.3.1  CYP II  B2 Polymorphisms 
Sixty four polymorphisms were identified in CYP II  B2 that associate with the  -344 
CIT and IC polymorphisms (see figure 4.6a).  Most ofthe polymorphisms identified 
were in intronic regions, particularly intron 2.  The majority of  these were associated 
with the intron conversion variant previously described by White &  Slutsker,  1995, 
which is  marked on the  diagram  (see  figure  4.6a  and  table  4.1).  This  actually 
includes variants 18-42, spanning approximately 240bp, where the CYP II  B2 residue 
has  been  replaced by the  corresponding  CYP liB  I  residue.  This  includes  an  8bp 
deletion  (AGAGCTGC)  that  corresponds  to  the  conversion  allele  allowing  easy 
identification.  Of the remainder, three single base substitutions were found in exons 
3  and  6.  Two  of these  are  synonymous  changes  with  no  effect  on  amino  acid 
sequence;  Phe168Phe  and  Arg374Arg.  These  mutations  have  been  previously 
described by the National Center for Biotechnology Information (NCBI), accessible 
on  the  dbSNP  website  (http://ncbi.nlm.nih.gov/SNP),  with  the  identification 
numbers; rs  4546 and rs4538 respectively.  The third coding variant, at codon 173 
(rs4539), does cause an amino acid change from Lys to Arg but has  been shown to 
have no effect on aldosterone synthase activity in vitro (Fardella et al1996a; Portrat-
Doyen et al 1998).  Four variants were identified in the  3'UTR region.  Finally, 
seven single  base  substitutions were  identified in the  5'UTR region of CYP  11B2, 
which can be linked to the  -344/IC  genotype.  The  pattern of association of these 
polymorphisms with the -344 CIT and IC variants is shown in table 4.1. 
189 4.4.3.2  CYP 11 B I Polymorphisms 
Nineteen polymorphisms were  identified in CYP llBI that associate with the  -344 
CIT and IC polymorphisms in CYP11B2 (see figure 4.6b).  As with CYPJJB2, most 
were  within  intronic  regions  (introns  2,  3,  4,  5,  6  and  8).  Two  of the  single 
nucleotide substitutions in exons 1 and 2 have previously been described by NCBI. 
Both  of these  are  synonymous  changes;  Leu75Leu  and  Asp82Asp  (rs6410  and 
rs5283 respectively).  The exon 1 polymorphism and two  of the identified intronic 
variants (Int3  2776 A/G and Int 6 4224 TIC) (see table 4.2) are the polymorphisms 
previously found to associate with the -344 CIT and IC variants (Ganapathipillai et al 
2005;  Keavney et al 2005).  Two  novel polymorphisms were  identified within the 
5'UTR at positions -1889 (G/T) and -1859 (A/G) upstream of the transcription start 
site.  When the polymorphisms are  separated into  alleles to  look at the pattern of 
association with the -344/IC genotype, it can be seen that most of  the polymorphisms 
associate with the T/Conv haplotype (as shown in red on table 4.2). 
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Figure 4.6.  Diagram showing the positions of the identified polymorphisms and 
the nucleotide variants in a)  CYPJJB2  and b) CYPJJBJ.  Previously  reported 
polyrnorphisms are shown in red. 
191 CYPJJB2 alleles 
Location  5'  5'  5'  5'  5'  5'  5'  5'  Int2  Int2 
Position  -1667  -1651  -1513  -1472  -663  -645  -470  -344  830  1049 
TT/ConCon  c  c  c  G  A  T  c  T  A  T 
CC/WtWt  G  T  T  A  T  c  T  c  G  c 
TT/WtWt  G  CIT  c  G  A  c  c  T  G  c 
Location  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2 
Position  1097  1461  1746  1750  1751  1782  1839  2095  2096  2100 
TT/ConCon  G  A  G  c  - A  A  G  c  c 
CC/WtWt  c  G  A  G  CT  G  G  A  T  T 
TT/WtWt  G  G  G  c  - A  A  A  T  T 
Location  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2 
Position  2101  2108  2110  2112  2114  2115  2117  2120  2122  2124 
TT/ConCon  A  T  G  G  T  - L 8bp  - - -
CC/WtWt  G  A  A  A  A  G  - A  T  c 
TT/WtWt  G  A  A  A  A  G  - A  T  c 
Location  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2  Int2 
Position  2151  2240  2241  2252  2259  2264  2268  2269  2271  2287 
TT/ConCon  A  G  T  c  T  c  c  c  - c 
CC/WtWt  G  c  c  G  G  A  T  G  T  T 
TT/WtWt  G  c  c  G  G  A  T  G  T  T 
Location  Int2  Int2  Int2  Int2  Int2  Ex3  Ex3  Int3  Int3  Int4 
Position  2316  2328  2374  2375  2399  2698  2712  2886  2888  3192 
TT/ConCon  G  G  c  A  T  c  A  c  T  T 
CC/WtWt  T  A  A  G  c  T  G  T  c  c 
TT/WtWt  T  A  c  A/G  TIC  c  A  c  T  TIC 
Location  Int4  Int4  Ex6  Int6  Int6  Int6  Int6  Int6  Int6  Int6 
Position  3257  3270  6573  6603  6855  6876  6879  6885  6887  6954 
TT/ConCon  A  T  c  c  T  AT  T  c  c  A 
CC/WtWt  G  c  A  A  T  GC  A  G  G  G 
TT/WtWt  AIG  c  A  A  G  AT  T  c  c  G 
192 Location  3'  3'  3'  3' 
Position  7615  7829  8066  8269 
TT/ConCon  A  - G  G 
CC/WtWt  G  TCC  T  A 
TT/WtWt  G  TCC  T  G 
Table 4.1.  The identified  CYPJJB2  polymorphisms separated into  alleles  to 
show the pattern of linkage with the -344/IC genotypes.  The positions are relative 
to the transcription start site ofCYPllB2. The -344  CIT and the IC  (8bp deletion) 
variants  are  highlighted  in light  blue.  The  alleles  that associate  with the  T  /Con 
haplotype are shown in red and those that associate with the -344 C allele are shown 
in blue.  For some polymorphisms the association was not clear, as subjects in the 
TT/WtWt group were heterozygous. 
CYPJJBJ Alleles 
Location  5'  5'  Exl  Ex2  Int2  Int2  Int2  Int2  Int2  Int2 
Position  -1889  -1859  225  626  1052  1655  1800  1960  2265  2295 
TT/ConCon  T  G  A  c  c  c  c  A  T  T 
CC/WtWt  G  A  G  T  G  T  T  G  c  c 
TT!WtWt  G  A  G  c  c  T  T  G  T  c 
Location  Int3  Int4  Int4  Int4  lotS  Int6  Int6  Int6  Int8 
Position  2776  3223  3244  3342  3799  4224  4264  4381  4941 
TT/ConCon  G  T  c  c  T  T  A  T  c 
CC/WtWt  A  G  T  T  G  c  G  G  G 
TT!WtWt  A  G  T  T  G  c  G  G  G 
Table 4.2.  The identified  CYPJJBJ  polymorphisms separated into  alleles  to 
show the pattern of linkage with the -344/IC genotypes. The positions are relative 
to the transcription start site of CYP  11 B1.  The alleles that associate with the T  /Con 
haplotype are shown in red and those that associate with the -344 C allele are shown 
in blue. 
193 4.4.4  Linkage disequilibrium 
There  was  strong LD  across  the  entire  CYP liB locus  (see  figure  4.7).  The  LD 
decreased slightly with distance, with loci in CYP liB  I  being in stronger LD  with 
each other than with loci  in CYP II  B2 and vice versa.  The  D'  value  was  almost 
uniformly high across the entire locus, approaching the maximum of 1.0 across much 
of the region and decreasing to  approximately 0.75  between pairs of loci  spanning 
CYP liB  I and CYP  11B2.  The r
2 value was slightly lower as it is more stringent and 
takes into account allele frequency.  However, it was still within the top part of the 
range with a minimum value of approximately 0.5 and a maximum of approximately 
1.0. 
4.4.5  Haplotype analysis 
The theoretical number of haplotypes, assuming free  recombination between the  83 
variants, is 9.671 x 10
24
.  Haplotype analysis using PHASE identified 136 haplotypes 
that were  conserved across  the  entire  region;  most of which were  of a very  low 
frequency.  Nine haplotypes had fequencies > 1%, describing 75% of chromosomes 
in the  data set (see  figure 4.8).  Only four  common haplotypes had frequencies  of 
greater than 5% and accounted for  68% of chromosomes in the data set (see figure 
4.9). 
194 A 
l42963B1 
l42403B1 
~1266B1 
~39677B1 
t36164B1 
J43270B2 
J22316B2 
rR-344B2 
B 
l42963B1 
l42403B1 
~1266B1 
~39677B1 
t36164B1 
J43270B2 
J22316B2 
rR-344B2 
1.00 
0.00 
5 Kb  25 Kb 
1.00 
0.00 
5 Kb  25 Kb 
Figure 4.7.  Data plots extrapolating pairwise linkage disequilibrium across the 
CYPJJB region.  A.  Plot ofD'. B. Plot ofr
2
. 
195 No  Haplotype  Pattern  Freq  % 
1  1112121  2  122121111211122221  2  11112212211211221211122122211211111122211111122221122121  0.202  >5 
5  1112121  2  122121111211122221  2  11112212211211221211122122211211111122211111122222122121  0.014  >1 
9  1112121  2  122121111211122221  2  11112212211211221211122122211211121122211111122221122121  0.069  >5 
29  1112111 2  122121111211122221  2  11112212211211221211122122211211111122211111122221122121  0.112  >5 
87  2122111 2  212221111122211112  1  22221121122112221211122211111211222221121121221112211212  0.015  >1 
89  2122111 2  212221111122211112  1  22221121122112221211122211111211222221121122221112211212  0.011  >1 
132  2221212  1  211212222122211112  1  22221121122122112122211211222122222211211111122211211212  0.012  >1 
133  2221212  1  211212222122211112  1  22221121122122112122211211222122222211212111122211211212  0.022  >1 
136  2221212  1  211212222122211112  1  22221121122122112122211211222122222211122222211112211212  0.297  >5 
t  t 
[=344 C/T I  [Ycsbpdel  1 
Figure 4.8.  The 9 most common CYPllB haplotypes and their frequencies.  Alleles coded  1 or 2 in  alphabetical order.  In the  case of 
inse1iions/deletions, no  insertion/deletion is  1;  insertion/deletion is  2.  The positions of the  -344C/T and  Intron conversion (8bp deletion) are 
shown.  The  8bp  deletion  (2)  is  representative  of  the  conversion  allele  whereas  no  deletion  (1)  is  the  wild  type. CYP1182  CYP1181 
SF-1  IC(Sbp del) 
-645  -344  2117  7615  -1889 -1859 225 625  4941 
T  T  Conv  A  T  G  A  C  c 
Frequency 
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Figure 4.9.  Schematic diagram of the 4 common haplotypes with a frequency of 
> 5%. The association of the SF1/IC variants with the -1889 Gff and -1859 A/G 
polymorphisms is  highlighted. The  CYP  11B2 T!Wt  allele combination was  only 
present in the haplotypes with a frequency of> 1%. 
197 4.5  Discussion 
This study demonstrates that overall the sequence variation across the CYP 11 B locus 
is high, supporting previous reports (Cargill et al 1999; Halushk:a et al 1999).  Recent 
work has also suggested that the -344C/T and IC polymorphisms in CYP 11B2 are in 
linkage with specific polymorphisms in CYP 11 B  1,  in ex  on 1 (Leu7 5Leu  ),  intron 3 
(A/G)  and intron 6 (G/A)  (Ganapathipillai et al 2005;  Keavney et al 2005).  The 
present  study  also  confirms  this  and  further  shows  that  there  is  tight  linkage 
disequilibrium across the entire CYP 11 B locus.  Several candidate SNPs have been 
identified  that  could  account  for  the  observed  phenotypes  associated  with  the  -
344C/T and IC variants in CYP 11B2. 
Out of  the 64 identified polymorphisms in CYP 11B2 found to be in linkage with the-
344/IC  genotype,  the  only  substitutions  within  the  coding  regions  were  either 
synonymous (F168F and R374R) or have previously been shown to have no effect on 
aldosterone  synthesis  (R173K)  (Fardella  et al  1996b  ).  However,  there  are  many 
polymorphisms located within introns.  These could potentially alter the splicing of 
the gene's primary transcript leading to altered protein synthesis. Although none are 
located directly within the  splice junctions at the  exon/intron boundaries they may 
disrupt the branch site that is  also necessary for proper intronic splicing.  These are 
splicing-related sites located deeper within the intron with the  consensus sequence 
(CIU)N(CIU)U(A/G)A(CIU)  where  the  emboldened  A  (adenosine  residue)  is 
invariant  and  conserved  between all  genes  and  N  is  any  nucleotide  (Madhani  & 
Guthrie  1994).  To  determine  whether  any  of the  intronic  polymorphisms  have 
functional  effects on splicing could be  studied using a minigene  system where the 
entire exonic and intronic regions are cloned into a vector.  The wildtype and mutant 
198 constructs would then be  transfected into  JEG-3  cells, the total RNA  isolated and 
reverse transcriptase PCR performed.  Sequencing the PCR product would determine 
any  splice  variants  resulting  from  the  allele  variants.  There  is  also  increasing 
evidence that introns contain transcriptional control elements  such as  enhancers or 
repressors (Kleinjan &  van Heynigen 2005).  Therefore intronic polymorphisms can 
also affect gene regulation. Co-transfection of a reporter gene construct, containing 
the 5' regulatory region, with a vector containing alternate forms of an intron would 
determine  whether  there  is  any  alteration  in  the  transcriptional  response. 
Interestingly, it has been demonstrated that regulatory elements can be as far as  1Mb 
up- or downstream of  the transcription unit (Klein  jan et al 2001; Lettice et a! 2002), 
therefore polymorphisms within CYP II  B2 have the potential to affect the regulation 
of CYP 11 B I  and  vice  versa.  This  would  be  an  interesting theory to  investigate. 
Especially to look at the influence of  the IC variant in CYP II  B2 on the regulation of 
CYP IIBI as  many of the polymorphic alleles  contributing to the  IC  originated in 
CYPllBI. 
Four variants were identified in the 3  'UTR of CYP II  B2.  Three of these were single 
base changes and the third was a 3bp (TCC) deletion.  It is possible these variations 
affect RNA stability and therefore protein production.  This could be tested using an 
in vitro coupled transcription/translation system followed by methods to quantify the 
RNA (RT-PCR) and protein (SDS-PAGE) produced and comparing the levels ofthe 
wild  type to each of  the variants. 
Seven single nucleotide substitutions were identified in the 5'UTR of CYP II  B2.  It is 
possible these could alter the transcriptional regulation of  the gene, resulting in either 
increased  or  decreased  expression.  If this  was  the  case,  one  or  several  of these 
199 polymorphisms  may  account  for  the  increased  aldosterone  levels  that  have 
previously  been  associated with the  T/Conv haplotype.  This  hypothesis  is  to  be 
tested in a separate study. 
Of particular interest to this study is that the  -344C/T and IC  variants in CYP 11 B2 
are  in strong  LD  with genetic  variants  in CYP II  B I.  Of the  19  polymorphisms 
identified in CYP II  B I, only two were located within the coding sequence and both 
of these  were the  synonymous  changes,  Leu75Leu and  Asp82Asp.  As  mentioned 
previously, the Leu75Leu polymorphism in exon 1 has been found to be in LD with 
the -344 CIT and IC  polymorphisms in CYP 11B2 and to  strongly associate with an 
impaired  11 ~-hydroylase  efficiency  (Keavney  et  al  2005).  However,  this 
conservative polymorphism cannot, itself, account for the biochemical change.  As in 
CYP 11B2,  the  majority  of the  polymorphisms  were  in  intronic  regions.  The 
polymorphisms  identified  in  intron  3  (2775  A/G)  is  located  very  close  to  the 
exonlintron boundary,  only 12  residues  away from  the  end of exon 3 and so  may 
disrupt the splice site.  The rest of  the polymorphisms were located deeper within the 
introns.  However,  as  mentioned previously,  these  could still potentially alter the 
splicing  of the  gene  resulting  m  altered  gene  products.  This  reqmres  further 
investigation. 
Two  of the  identified polymorphisms  were  located  in the  5'UTR of CYPllBI  at 
positions  -1889  G/T  and  -1859  A/G.  The  subsequent experimental  work of this 
thesis  focuses  specifically  on these  two  polymorphisms  (see  Chapters  5  and  6). 
They  do  not  change  the  amino  acid  sequence  but  may  change  the  gene's 
transcriptional properties, altering its basal expression or response to  stimuli.  They 
may  therefore  account  for  the  observed  biochemical  phenotype.  Most  of the 
200 CYP II  B I polymorphisms, including the -1889 G/T and -1859 A/G, show association 
with the T/Con haplotype, as  shown in red in table 4.2.  This is important, as it is 
these alleles that have previously been associated with an impaired 11 ~-hydroxylase 
efficiency. 
The tight LD across the CYP II  B locus is confirmed by the presence of  relatively few 
common haplotypes, with 4 haplotypes (frequency greater than 5%) accounting for 
68% of chromosomes in the data set (see figure 4.9).  The T/Wt allele combination 
was not identified in haplotypes greater than 1%, probably due to the lower number 
of subjects  in  this  group.  The  construction  of haplotypes  should  enable  the 
identification of 'tagging  SNPs',  to  account for  the  observed haplotypes,  allowing 
high throughput,  efficient genotyping of the  entire  CYP II  B  locus.  Although the 
sample size was small (26 subjects), previous work revealed that sample sizes of 23 
and  24  individuals  provide  a  better  than  99%  chance  of detecting  SNPs  of 5% 
frequency, and better than 87% chance for SNPs of 1% frequency  (Crawford et al 
2004).  If this is correct, our sample size is  sufficient for accurate determination of 
haplotypes.  However, the sample group in this study was selected according to their 
-344 CIT and IC genotypes and so  confirmation of these haplotypes is required in a 
larger unselected group, more representative of the general population.  The purpose 
of  the haplotype analysis in the present study was to determine wherther or not and to 
what extent haplotypes existed across B 1/B2. Further studies are currently underway 
to  define  these  haplotypes  in  unselected  populations  of  normotensive  and 
hypertensive  subjects.  This  will  allow  a  comparison  of the  frequencies  of the 
common haplotypes to see if  any are associated with the hypertensive phenotype. 
201 This study strongly suggests that the impaired 11 ~-hydroxylase efficiency associated 
with the  T/Con haplotype  in CYP 11B2  is  due  to  linkage with genetic  variants  in 
CYPllBJ.  In particular, two novel single nucleotide substitutions (-1889 G/T and-
1859 A/G) in the 5'UTR of CYP JJBJ  have been identified as key candidates due to 
their potential effects on gene expression. These polymorphisms will be investigated 
further to assess their frequency and phenotypic associations in a large hypertensive 
population as well as their functional effects in vitro. 
202 CHAPTERS 
Investigation of the Frequency and Phenotypic 
Associations of the CYPJJBJ 5'UTR Polymorphisms 
in a Hypertensive Population 
203 5.1  Introduction 
The SF1  -344 CIT polymorphism in CYP 11B2 has been previously associated with 
various  cardiovascular  phenotypes  including  hypertension  with  a  raised  ARR, 
increased  plasma  aldosterone  levels  as  well  as  increased  levels  of its  principle 
urinary metabolite tetrahydroaldosterone (THAldo) and left ventricular hypertrophy 
(L VH) (Brand et al 1998; Davies et al 1999; Delles et al 2001; Paillard et al 1999). 
However,  these  findings  have not been consistently reported in all  studies  so  that 
other  investigators  have  reported  no  association  or  even  an  association  with the 
contrasting  allele  (Kupari  et al  1998;  Pojoga et al  1998;  Schunkert  et al  1999a; 
Tsujita et al2001).  In contrast, one ofthe most consistent observations appears to be 
an  association  with  reduced  11 ~-hydroxylase  efficiency  (Davies  et  al  2001; 
Hautanena et al 1998; Kennon et al 2004).  However, the molecular basis for this is 
unclear, given that the biochemical phenotype is due to altered activity of the protein 
encoded by the adjacent CYP liB  I  gene.  As the -344 CIT polymorphism has been 
shown to  have  no  effect  in  vitro  it  seems  likely  that it is  in  linkage  with  other 
polymorphisms  that  directly  account  for  the  observed  phenotypes  (Bassett  et  al 
2002).  The  study  outlined in  Chapter  4  established  that there  is  strong  linkage 
disequilibrium across the entire locus encompassing the 11 ~-hydroxylase (  CYP II  B I) 
and  aldosterone  synthase  (  CYP 11 B2)  genes.  Two  novel  polymorphisms  were 
identified  in  the  5'UTR  of CYPllBI  (-1889  G/T  and  -1859  A/G)  as  potential 
candidates for the  impaired  11 ~-hydroxylase efficiency previously associated with 
the  -344  T  allele.  These  were  selected as  key  functional  candidates  due  to  their 
location in the 5' regulatory region of CYP II  BI and their potential effects on enzyme 
transcription.  It was  therefore  of interest  to  determine  whether  or  not  these 
polymorphisms do indeed associate with 11 ~-hydroxylase efficiency. 
204 5.2  Aims 
The aim of  this study was to investigate the frequency and phenotypic associations of 
the  -1889  G/T  and  -1859  A/G  CYP IIBI polymorphisms  in a  large  hypertensive 
population.  In particular, to focus on markers indicating impaired 11 ~-hydroxylase 
efficiency and their association with genotype. 
5.3  Methods 
5.3.1  Study subjects 
A large hypertensive study population was derived from the MRC BRitish Genetics 
of HyperTension  (BRIGHT)  study.  The  Bright  Study  is  a  large  multicentre 
investigation  into  the  genetic  basis  of hypertension,  comprising  >  2000  affected 
sibling pairs and trios. The primary aim of  the study was to collect a large collection 
of affected sibling pairs to permit a genome wide scan to identify loci that might be 
involved in the development of hypertension.  In this study, a range of phenotypes, 
including  body mass  index  (BMI),  blood chemistry and  corticosteroid metabolite 
excretion were also measured.  Hypertensive subjects were recruited from primary 
care with entry to  the study being dependent on a pre-treatment blood pressure of 
> 145/95mmHg (mean of 3 readings).  All had the onset of hypertension before 60 
years of age.  Subjects with a BMI > 30 were excluded from the study.  Full details 
of  the recruitment strategy have been published elsewhere (Caulfield et al2003). 
For the  present  investigation,  a  random  subgroup  of 512  unrelated  hypertensive 
subjects was selected for the analysis of urinary corticosteroid metabolite excretion 
rates.  Full demographic information (as  medians and inter-quartile ranges)  on the 
205 subjects included is  shown in table 5.1. Ethical approval for the study was  granted 
by the  local ethics  committees of the  partner institutes  and fully  informed written 
consent from all of  the participants was obtained. 
5.3.2  Genotyping of  the CYPJJBJ 5'UTR Polymorphisms 
The entire BRIGHT study population (n =  3599) was genotyped for the -1889 G/T 
and -1859 A/G polymorphisms using a nested PCR method to increase specificity. 
Nested PCR protocol 
The  initial  reaction  amplified  a  2kb  region  specific  to  CYP liB  I  and  the  second 
reaction used this product as  a template to  amplify the region of interest (  ~400bp) 
specifically (see  section 2.3.2).  In both reactions, a heat-activated thermostart Taq 
polymerase  (Abgene,  UK)  was  used.  The  sense  and  anti-sense  primers  (MWG-
Biotech,  Ebersberg,  Germany)  used in both reactions  are  outlined in appendix 2, 
table 7. 
5.3.3  Urinary Corticosteroid Metabolite Measurements 
Miss Mary C Ingram performed all the  urinary corticosteroid measurements on the 
subset of  the BRIGHT population (n =  512). Urine samples (24 hour) were collected 
in plain plastic containers without preservative.  Aliquots of urine  were  stored at -
20°C.  Excretion  rates  of  steroid  metabolites  were  measured  by  gas 
chromatography/mass  spectrometry  using  the  method  of Shackleton  (Shackleton 
1993)  with minor modifications.  The  ratio  of tetrahydrodeoxycortisol/total cortisol 
(THS/F) was used as an index of  11~-hydroxylase activity. 
206 5.3.4  Statistics 
Whether the  allele  frequencies  of -1889  G/T  and -1859  A/G within the  BRIGHT 
subgroup were in Hardy Weinberg equilibrium was determined using a Chi-squared 
test.  The  demographic  and  steroid  excretion  data  did  not  follow  a  normal 
distribution and so were compared by non-parametric methods (Mann-Whitney test). 
5.4  Results 
5.4.1  Genotyping of  -1889 G/Tand -1859 AIG 
Following optimisation of the  nested PCR conditions  each of the  BRIGHT study 
samples,  which  had  been  pre-plated  onto  96-well  PCR  plates  (25ng/well),  were 
amplified.  This produced a PCR amplicon of 393bp as  determined by agarose gel 
electrophoresis of a random selection of samples  (12  to  16)  from  each plate  (see 
figure 5.1).  The PCR products were then sequenced (see  section 2.2.6) using the 
primer B1prom-1750(as) (see table 6, appendix 2) to determine the -1889 and -1859 
genotypes. 
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Figure  5.1.  Nested  PCR fragments  (--- 400  bp)  from  14  random  BRIGHT 
samples,  resolved  on  a  1%  agarose  gel.  Lane  1  contains  5f..Ll  HyperLadder  I 
(Bioline, London, UK).  Individual bands ofthe correct size indicate specificity. The 
lack of a band in lane 7 indicates a failure.  In general the failure rate for each plate 
was approximately 10%. 
5.4.2  Demographic datafor BRIGHT  sub-group 
Blood pressure  and  other relevant  demographic  data  are  shown  in  table 5.1;  the 
population was significantly hypertensive but not significantly overweight.  The only 
difference  in characteristics of subject groups  separated according to  the  -1889 or 
-1859 SNPs was with waist/hip ratio (-1889 GG vs. TT p = 0.015; -1859 AA vs. GG 
p = 0.013). 
208 A) 
B) 
ALL  -1889 GG  -1889 GT  -1889 TT  p* 
SUBJECTS  SUBJECTS  SUBJECTS  SUBJECTS 
n=437  n=116  n=223  n=98 
Age (years)  64 (57-70)  63(56-68)  64(58-71)  63(56-70)  NS 
Mean SBP 
181(153-191)  157(153-190)  183(153-193)  157(152-190)  NS 
(mm/Hg) 
MeanDBP 
1  03(98-11 0)  1  04(1 00-11 0)  1  03(98-11 0)  103(99-110)  NS 
(mm/Hg) 
BMI  27(25-30)  27(24-30)  28(26-30)  27(25-30)  NS 
(kg/m2) 
WHR 
0.88  0.84  0.88  0.89  0.015  (0.81-0.93)  (0.80-0.91)  (0.81-0.94)  (0.83-0.94) 
LVmass  68  69  67  67 
index  (58-78)  (58-79)  (58-78)  (57-76)  NS 
ALL  -1859 AA  -1859 AG  -1859 GG  p** 
SUBJECTS  SUBJECTS  SUBJECTS  SUBJECTS 
n=437  n=106  n=225  n=106 
Age (years)  64 (57-70)  63(56-68)  64(59-71)  63(56-70)  NS 
Mean SBP 
181(153-191)  157(153-190)  183(153-193)  169(153-190)  NS 
(mm/Hg) 
MeanDBP  103(98-110)  104(100-110)  103(98-110)  103(99-110)  NS 
(mm/Hg) 
BMI 
27(25-30)  27(24-30)  28(26-30)  27(25-30)  NS 
(kg/m2) 
WHR 
0.88  0.84  0.88  0.89 
0.013  (0.81-0.93)  (0.80-0.91)  (0.81-0.94)  (0.83-0.94) 
LVmass  68  69  67  67  NS 
index  (58-78)  (58-79)  (58-78)  (57-76) 
Table 5.1.  Demographic information on  BRIGHT study sub-group separated 
by A) -1889 and B) -1859 genotypes.  In each case the data did not follow a normal 
distribution and so were compared by the non-parametric Mann-Whitney test. 
SBP- systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass index, 
WHR-waist-hip-ratio, L  Vmass-left ventricular mass. 
*comparison between -1889 GG and TT homozygotes 
**comparison between -1859 AA and GG homozygotes 
209 5.4.3  Genetic analysis ofCYPIIBI 
The  frequencies  of  the  -1889  (G-0.52,  T-0.48)  and  -1859  (A-0.50,  G-0.50) 
polymorphisms  within  the  BRIGHT  subgroup  are  illustrated  in  figure  5.2.  The 
alleles of both -1889 G/T and -1859 A/G were in Hardy-Weinberg equilibrium with 
Chi-square values of0.91 and 0.82 respectively. 
5.4.4  Association with THS/Total F Metabolites 
The major urinary corticosteroid metabolites examined are listed in table 5.2. There 
was  no  significant difference in the  excretion of the major aldosterone metabolite, 
THAldo  or  total  androgen  metabolite  excretion  for  subjects  homozygous  for  the 
-1889  G/T  or  -1859  A/G  alleles.  Importantly,  there  was  also  no  significant 
difference  in total cortisol metabolite  excretion rate  (nmol/24  hours)  between the 
-1889 GG vs.  TT (p = 0.4513) or -1859 AA vs  GG (p = 0.2789) genotypes.  The 
THS/ total F ratio  (index of 11 P-hydroxylase activity)  was  significantly higher in 
-1889 TT homozygotes than in GG homozygotes (p  =  0.025).  A similar pattern was 
seen with the -1859 SNP, with GG homozygotes tending to have a higher ratio than 
AA homozygotes  (p  =  0.056)  (table  5.2,  figure  5.3).  Figure 5.3  summarises  the 
means of  the THS/F ratios in all three genotype groups for both SNPs. There was no 
statistically  significant  difference  between the  -1889  TT  and  GT  groups  but  the 
THS/F  ratio remained significantly higher in the heterozygous  group than the  GG 
subjects (0.0 19).  A similar pattern is  seen for -1859, with no  statistical difference 
between the  GG and AG groups but a trend to  a higher ratio  in the heterozygous 
group than the AA homozygotes (p = 0.066). 
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Figure  5.2.  Frequencies  of  A)  the  -1889  G/T  and  B)  the  -1859  A/G 
polymorphisms in the BRIGHT population subgroup. 
211 A) 
B) 
Urinary Steroid  ALL  -1889 GG  -1889 GT  -1889 TT  p* 
Metabolites  SUBJECTS  SUBJECTS  SUBJECTS  SUBJECTS 
(nmoles/24hrs) 
ALDOSTERONE  3  3  3  3  NS  (THAldo)  (2-6)  (2-6)  (2-6)  (1-5) 
CORTISOL 
METABOLITES  1416  1305  1635  1385  NS  (TOTAL F;  (788-2670)  (652-2532)  (835-2824)  (793-2701) 
THF+aTHF+THE) 
ANDROGEN 
METABOLITES  606  663  580  550  NS  (TOTAL ANDRO;  (318-1208)  (276-1322)  (322-1209)  (340-1062) 
DHA+AETIO+ANDRO) 
11~-HYDROXYLASE  0.009  0.007  0.010  0.011 
EFFICIENCY  (0.005-0.014)  (0.005-0.0 12)  (0.006-0.015)  (0.006-0.015)  0.024 
(THS/TOT  AL F) 
Urinary Steroid  ALL  -1859 AA  -1859 AG  -1859 GG  p** 
Metabolites  SUBJECTS  SUBJECTS  SUBJECTS  SUBJECTS 
(nmoles/24hrs) 
ALDOSTERONE  3  3  3 
,., 
.) 
NS  (THAldo)  (2-6)  (1-6)  (2-7)  (1-5) 
CORTISOL 
METABOLITES  1416  1245  1647  1399  NS  (TOTAL F;  (788-2670)  (718-2314)  (798-2754)  (840-2705) 
THF+aTHF+  THE) 
ANDROGEN 
METABOLITES  606  636  580  630  NS  (TOTAL ANDRO;  (318-1208)  (257-1317)  (317-1213)  (358-1062) 
DHA+AETIO+ANDRO) 
11~-HYDROXYLASE  0.009  0.007  0.009  0.010 
EFFICIENCY  (0.005-0.014)  (0.005-0.012)  (0.006-0.015)  (0.005-0.0 16)  0.056 
(THS/TOT  AL F) 
Table 5.2.  Urinary corticosteroid excretion separated according to  A)  -1889 
and B) -1859 genotypes 
THF: tetrahydrocortisol, (a)THE (allo) tetrahydrocortisone, 
DHA:  dehydroepiandrosterone,  Aetio:  aetiocholanolone,  Andro:  androsterone 
THAldo:tetrahydroaldosterone, THS: tetrahydrodeoxycortisol, NS =non significant. 
Steroid results were compared by the non-parametric Mann-Whitney test. 
*  comparison between -1889 GG and TT homozygotes 
**Comparison between -1859 AA and GG homozygotes 
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Figure 5.3.  Box-whisker plots of 11~-hydro:xylase efficiency (THS/total F ratio) 
in all subjects stratified by the -1889 or -1859 genotypes. 
In each case comparisons of  the tetrahydrodeoxycortisol (THS)/total cortisol (F) ratio 
between  the  genotype  groups  was  analysed  by  non-parametric  testing  (Mann-
Whitney). 
213 5.5  Discussion 
A  consistent yet somewhat paradoxical  association  exists  between variants  in  the 
CYPJJB2 gene (-344 CIT and IC) and markers of 11~-hydroxylase activity, which is 
the enzyme encoded by the highly homologous CYP JJBI gene (Davies et al 2001; 
Hautanena et al1998; Kennon et al 2004).  It has been postulated that this is due to 
these CYP II  B2 variants being in linkage disequilibrium (LD) with polymorphisms in 
CYP JJBI.  Some previous studies (see section 1.16.1) identified polymorphisms in 
LD  between  CYP IIBI  and  CYP IIB2  but  none  could  explain  the  biochemical 
phenotype.  Therefore, in this study (see Chapter 4) the pattern of variation across 
the region was investigated in greater detail. 
The  study  in Chapter 4  confirmed that the  overall sequence  variation across  the 
CYP II  B locus  is  high and that there  is  strong LD  across the  entire region.  Two 
interesting  novel  polymorphisms  were  identified  in  the  5'UTR  of CYP II  B  I  at 
positions -1889 G/T and -1859 A/G that may alter transcriptional regulation of the 
CYP 11 B I  gene  and  therefore  affect  11 ~-hydroxylation efficiency,  the  phenotype 
closely associated with the T/Conversion haplotype in CYP IIB2. 
This  study  of  an  unselected  hypertensive  population  clearly  demonstrates  a 
significant association between these polymorphisms  and the  ratio  of THS/total F 
metabolites,  the  index  of impaired  11~-hydroxylase  efficiency.  Those  subjects 
homozygous  for  the  -1889  T  allele  showed  lower  11 ~-hydroxylation efficiency 
(increased urinary THS/total F ratio)  compared with those homozygous for  the  G 
allele.  Similarly,  subjects  homozygous  for  the  -1859  G  allele  had  reduced  11 ~­
hydroxylation  efficiency  compared  with  those  homozygous  for  the  A  allele.  As 
214 mentioned previously, it is  these alleles (-1889 T and -1859 G)  that are  in linkage 
disequilibrium with the  CYP JJB2  T/Con haplotype.  Therefore, these results  are  in 
agreement with previous studies that found an association between the -344 T and IC 
conversion alleles and an impaired  11 P-hydroxylase efficiency.  Importantly, there 
was no  difference in urinary excretion of total cortisol metabolites between the two 
genotype groups for each SNP (see table 5.2). These findings support the hypothesis 
that,  in  -344  TT  subjects,  normal  cortisol  production  is  maintained  by  a  subtle 
increase in ACTH drive to the adrenal cortex, which increases the availability of its 
deoxyprecursor 11-deoxycortisol (Connell et al2003). 
Reduced 11 P-hydroxylase efficiency is  a common feature of hypertensive subjects. 
In 1985, de  Simone and colleagues found a higher ratio of DOC/corticosterone and 
11-deoxycortisol/cortisol  in  hypertensive  subjects  compared  to  normotensive 
controls  after ACTH stimulation (de  Simone  et al 1985).  More  recently,  we  have 
made a similar observation in hypertensive subjects in whom the plasma ratio of 11-
deoxycortisol/cortisol was  elevated (Connell et al 1996).  However, until now,  the 
underlying genetic basis of this observation has not been explored.  The results from 
the BRIGHT study confirm this phenotype of altered  11 P-hydroxylation efficiency 
within a sub-group from a large, severely hypertensive cohort separated according to 
genotype at -1889 and -1859 of CYP 11 B I (11 P-hydroxylase  ).  However, there was 
no significant difference in mean blood pressure between the genotype groups when 
the cohort was separated according to the -1889 and -1859 polymorphisms.  This is 
perhaps  not  surprising  as  all  the  BRIGHT  study  subjects  are  significantly 
hypertensive  (within the  upper  5%  of the  blood  pressure  range)  and  so  it  seems 
unlikely that a predisposition to higher blood pressure would be detected. 
215 There was no  association found between the -1889 and -1859 polymorphisms and 
urinary  excretion  levels  of THAldo.  Our  group  has  previously  reported  an 
association between the  CYP 11B2  -344 T and IC  conversion alleles and increased 
urinary excretion of THAldo (Davies  et al  1999).  Therefore,  as  the  -1889 T and 
-1859  G  alleles  in  CYP 11 BI  are  in  LD  with  these  CYP 11 B2  alleles,  a  similar 
association with THAldo might be  observed.  However, this was not the  case (see 
table  5.2).  A  probable  explanation  for  this  is  that  many  of the  BRIGHT  study 
subjects  may  be  on antihypertensive  medication that could alter their  aldosterone 
levels including diuretics, ACE inhibitors and Ang II receptor blockers. Therefore, a 
more  detailed  analysis  of a  large  case-control  population,  ideally  of untreated 
hypertensives, is  required to  evaluate fully the  contribution of variation across the 
CYP II  B locus to aldosterone levels and hypertension and also the link between these 
phenotypes and the observed reduction in 11 ~-hydroxylase efficiency. 
Aldosterone is known to promote cardiac hypertrophy and fibrosis (Brilla et al 1990) 
(see section 1.9.1.4). Patients with primary aldosteronism are more likely to have left 
ventricular hypertrophy (LVH) than age- and sex- matched subjects with essential 
hypertension of similar severity (Rossi et al1997; Tanabe et al 1997).  There have 
been conflicting reports of an association between the -344 CIT polymorphism and 
LVH (Delles  et al 2001; Kupari  et al 1998;  Schunkert et al 1999a).  Because the 
-344  and  IC  polymorphisms  have  previously  been  asssociated  with  increased 
aldosterone levels, the relationship between -1889 and -1859 genotype and LV mass 
was also investigated.  No significant association with LV mass was found.  This is 
perhaps  not surprising  as  there  was  no  association with aldosterone  levels  either. 
Also there was an incomplete data set, as many subjects did not have ECG criteria to 
216 enable determination of their LV  mass, resulting in a small sample size (n =  233). 
Again,  analysis  of a  large  case-control population would allow assessment of the 
association  of genotype  with  hypertension  and  intermediate  phenotypes  such  as 
aldosterone levels and markers of  cardiovascular function such as LV mass. 
An  interesting  association  was  found  between  the  -1889  G/T  and  -1859  A/G 
polymorphisms and waist/hip ratio (see table 5.2).  Those subjects homozygous for 
the -1889 T allele showed higher waist/hip ratio than those homozygous for the  G 
allele (p =  0.015). Similarly, subjects homozygous for the -1859 G allele had higher 
waist/hip ratios than those homozygous for the A allele (p  =  0.013).  The reason for 
this  association  is  not  entirely  clear.  An  increased  waist/hip  ratio  indicates  an 
increased centralization of body fat stores.  The positive correlation between cortisol 
and waist/hip ratio is well established (Fraser et al 1999; Marin et al 1992). This is 
highlighted by the phenotype of extreme cortisol excess (Cushing's disease) where 
there is grossly increased central obesity (see section 1.10.1).  However there was no 
significant difference in cortisol levels between the -1889 or -1859 genotypes (see 
table 5.2).  It is these same alleles (  -1889 T and -1859 G)  that were also found to 
associate with an impaired 11 ~-hydroxylase efficiency and so cortisol levels may be 
maintained due  to  an mildly increased ACTH drive to the  adrenal.  Two possible 
explanations  may  therefore  be  considered.  Firstly,  a  slight  increase  in  ACTH 
production may  have  effects  on  the  levels  of other  steroids  such  as  the  adrenal 
androgens.  Obesity is known to  be associated with variations in adrenal androgen 
synthesis,  metabolism  and  action  that  differ  according  to  sex.  A  recent  study 
demonstrated  an increased  ACTH  level  in obese  subjects  and  that this  increased 
activity of the HP A axis correlates positively with androgen levels in obese women 
whereas the reverse association was observed for obese male subjects (Vicennati et 
217 a!  2006).  The  explanation for  these  observations  remains  unclear.  The  second 
possible explanation is that sites of origin for corticosteroids other than the adrenal 
cortex might be affected by genetic variation in CYP II  B I.  It is of interest that there 
is increasing evidence of extra-adrenal expression of steroidogenic enzymes such as 
lip-hydroxylase (Davies &  MacKenzie 2003) and the CYP IIBI gene was recently 
found to  be  transcribed in omental but not subcutaneous  adipose  tissue  of the  rat 
(MacKenzie  et  a!  2006).  However,  both  its  regulation  and  its  physiological 
significance remain to be determined, but it could be speculated that the -1889 T and 
-1859 G variants  are  associated with altered  expression of CYP 11BI  in fat  tissue 
resulting in an increased local production of  corticosteroids. 
In summary, this study confirms that the -1889 G/T and -1859 A/G polymorphisms 
located  in  the  5'  regulatory  region  of CYP II  BI  associate  with  liP-hydroxylase 
efficiency  in  a  hypertensive  population.  It seems  likely  that  the  reduced  liP-
hydroxylase  efficiency  previously  associated  with the  -344 T  and  IC  conversion 
alleles  in  CYP 11 B2  is  due  to  linkage  with the  -1889  T  and  -1859  G  alleles  in 
CYP II  B I.  However, in  vitro expression studies are required to  determine whether 
the  -1889  and  -1859  polymorphisms  have  functional  effects  on  CYP 11 B I 
transcriptional regulation. 
218 CHAPTER6 
Functional Effects of the CYPJJBJ S'UTR 
Polymorphisms and their Association with 
Hypertension 
219 6.1  Introduction 
As mentioned previously (see section 1.16.2), the -344 CIT and intron 2 conversion 
variants in the aldosterone synthase (CYP 11B2)  gene are  associated with increased 
levels of 11-deoxycorticosterone (DOC) and 11-deoxycortisol (S)  (and their urinary 
metabolites) (Davies et al 2001; Hautanena et al 1998; Kennon et al 2004).  This 
reflects  a  reduced  efficiency  of adrenal  11 ~-hydroxylase and  is  likely  to  be  a 
consequence  of variation in the  adjacent and  highly homologous  CYP 11 B  1 (11 ~­
hydroxylase)  gene.  The  studies  described  in  Chapter  4  confirmed  that  there  is 
strong linkage disequilibrium (LD) across the entire CYP11B locus and that the -344 
CIT and intron conversion variants in CYP 11 B2  are  in LD  with several variants in 
CYP 11 B1.  Two of these were novel polymorphisms identified within the 5'UTR at 
positions  -1889  (GIT)  and  -1859  (NG).  The  studies  described  in  chapter  5 
demonstrated a significant association between these polymorphisms and the ratio of 
THSitotal F (a marker of 11~-hydroxylase function) in a cohort of subjects from the 
BRIGHT study.  To test whether these polymorphisms can cause differences in 11 ~­
hydroxylase efficiency, their effects were studied in vitro. 
6.2  Aims 
The aims of  this study were to determine the effects of  the -1889 GIT and -1859 AIG 
polymorphisms  on  CYP 11 B  1 basal  transcription  and  response  to  stimuli  in  vitro 
using a luciferase reporter gene system. 
220 6.3  Methods 
6.3.1  Investigation of  Reporter Gene  activity in vitro 
All  4 combinations of the  -1889  and -1859  alleles were created in  vitro  using the 
Quick-Change  site-directed mutagenesis kit (Stratagene  Ltd,  Cambridge,  UK)  and 
the pB1-1937 plasmid as a template (section 2.1.4). The allele combinations of each 
construct and the  CYP lJ  B2 genotypes they associate with are  shown in table 6.1. 
Large scale purified preparations ofthe pB1-1937 wildtype, each of the mutants and 
the  psvpGal  control  vector  were  made,  analysed  by  restriction  digestion  and 
sequenced (sections 2.1.1, 2.1.2, 2.2.6).  Transient transfection was  carried in Y-1 
adrenal cells (section 2.4.1).  Cells were incubated with or without agonist; ACTH 
(lJ.lM),  dibutyryl  cAMP  ((Bu2)cAMP)  (lmM) or Forskolin  (lOJ.lM)  for  24  hours. 
Cell  lysates were  prepared and luciferase  activity  measured to  determine  reporter 
gene activity (section 2.1.5).  Protein levels and  p-galactosidase activity were also 
measured to  determine  cell number and  transfection efficiency  and  the  luciferase 
results were corrected appropriately (sections 2.1.5 and 2.4.2). 
Construct  -1889 residue  -1859 residue  CYPJJB2 Association 
1  G  A  CC/WtWt, TT/WtWt 
2  G  G  Rarely seen 
3  T  A  Rarely seen 
4  T  G  TT/ConCon 
Table 6.1 Constructs used for transfections showing their -1889 and -1859 allele 
combinations and the CYP  11B2 genotypes they would associate with. 
221 6.3.2  Statistics 
The in  vitro expression results for each construct were compared to the appropriate 
control using an unpaired 2-sample t test.  Whether the allele frequencies of -1889 
G/T and -1859 A/G within the BRIGHT case-control study were in Hardy Weinberg 
equilibrium  was  determined  using  a  Chi-squared  test.  The  demographic 
characteristics were not normally distributed and so a comparison of  the cases versus 
controls wasdetermined using a Mann-Whitney test.  In all circumstances, a p value 
of  less than 0.05 was accepted as significant. 
6.3.3  Investigation of  Transcription Factor Binding Sites 
To  investigate whether the -1889 G/T and -1859 A/G polymorphisms reside within 
putative transcription factor binding sites, the DNA sequence surrounding them was 
analysed  usmg  the  Transcription  Element  Search  Software  (TESS) 
(http://www.cbil.upenn.edu/tess) as well as the programme Matlnspector (Quandt et 
al1995). 
6.3.4  Study Subjects 
The  BRIGHT case-control association study comprises  800  unrelated hypertensive 
subjects (from the total of> 2000 affected sibling pairs and trios) with 800 age- and 
sex- matched  normotensive  control  subjects.  Full  demographic  information  (as 
medians and inter-quartile ranges) on the subjects included is shown in table 6.2. 
222 CASES  CONTROLS  p value 
AGE (years)  60 (52-66)  60 (52-66)  NS 
MEANSBP 
154 (141-249)  124 (116-132)  < 0.0001 
(mmHg) 
MEANDBP 
93 (86-101)  77 (73-82)  < 0.0001 
(mmHg) 
BMI (kg/m
2
)  27 (25-30)  25 (23-27)  < 0.0001 
Table 6.2. Demographic information on BRIGHT case-control study sub-groups 
SBP- systolic blood pressure, DBP-diastolic blood pressure, BMI-body mass index, 
NS-non-significant. 
6.4  Results 
6.4.1  Restriction Digestion of  Plasmids 
The  pB1-1937  construct  comprises  the  pGL3-Basic  vector  backbone  (4.8  kb) 
(Promega  Corp.,  Southampton,  UK)  and  an  insert  of approximately  1.9kb.  The 
plasmid DNA was digested using the restriction enzyme BamHI to assess quality and 
the presence of an insert of appropriate size.  This  enzyme does  not cut the B 1 5' 
UTR insert but linearizes the pGL3-Basic vector by hydrolysing it at a single site to 
produce a fragment of  approximately 6.7kb.  BamHI digests are shown in figure 6.1. 
223 1  2  3  4 
G+A  G+G  T+A  G+T 
6,000 bp  ..... 
4,000 bp  ..... 
1,000 bp  .... 
Figure 6.1. BamHI digests of pB1-1937 constructs 
Analysed on a 1% agarose gel stained with ethidium bromide.  BamBI linearises the 
pGL3 Basic vector backbone to generate a 6. 7kb band.  A single band of the correct 
size  confirms  the  presence  of the  CYP JJBI  eDNA  insert.  Lane  L  contains  5  !J.l 
HyperLadder I (Bioline, London, UK). 
6.4.2  Confirmation of  Mutations 
The presence of each of  the mutants was verified by sequencing using the automated 
sequencing method described in section 2.2.6.  The entire insert was  sequenced to 
rule out the incorporation of any unwanted mutations.  Sequence data are shown in 
figure 6.2. 
224 Construct 1 
G+A 
Construct 2 
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Figure  6.2.  Electropherograms  confirming  the  incorporation  of the  desired 
mutations in each of the pBl-1937 constructs. 
225 6.4.3  Transcriptional actvity in vitro 
Investigation of the -1889 G/T and -1859 A/G single base changes using luciferase 
reporter  gene  constructs  revealed  no  significant  effect  on basal  expression levels 
(figure 6.3).  The  construct containing the  -1889  T and the  -1859  G alleles  had a 
significantly reduced response  to  stimulation with  1J.-LM  ACTH  (p  = 0.001)  when 
compared to the wildtype allele combination -1889 G and -1859 A (figure 6.4).  The 
other 2 constructs (G + G and T +A) also appeared to have a reduced response to 
ACTH stimulation compared to the  wildtype  (G  + A)  but this did not quite  reach 
statistical significance (G + G p = 0.092, T + G p = 0.088).  Treatment with 1mM 
(Bu2)cAMP  failed to  stimulate reporter gene activity (figure 6.5).  Treatment with 
10J.-LM Forskolin produced a similar pattern to that of ACTH.  Construct 4 (T + G) 
had a significantly reduced response to forskolin compared to the wildtype construct 
1 (figure 6.6 p =  0.025).  Again, constructs 2 (G + G) and 3 (T +A) appeared to have 
a slightly reduced response  to  stimulation compared to  wildtype  but this  was  not 
statistically significant (G + G p = 0.514, T + G p = 0.311 ). 
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Figure  6.3.  Effects  of  the  -1889  G/T  and  -1859  A/G  variants  on  basal 
transcriptional activity 
Y  -1  adrenocortical  cells  were  transfected  with  luciferase  reporter  constructs 
containing pB 1-193 7 (1 J...Lg)  with various combinations of  the -1889 and -1859 alleles 
for 48 hours. Construct 1, referred to as the wildtype (-1889 G and -1859 A), is most 
commonly  associated  with  the  CC/WtWt  and  TT/WtWt  CYP11B2  genotypes. 
Construct 4  (  -1889 T  and -1859 G)  contains the alleles found in linkage with the 
CYP 11 B2 TT  /Con  Con genotype.  Results are expressed as a percent of the wild  type 
(construct  1)  activity.  The  results  represent  the mean ±  SEM of data  from  six 
independent experiments, each with an n of 3 to 9. Each construct was compared to 
the wild  type (construct 1) using an unpaired 2-sample t test. 
No  significant  difference  was  observed  between  the  constructs  under  basal 
conditions. 
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Figure 6.4. Effects of the -1889 G/T and -1859 A/G variants on transcriptional 
activity in response to ACTH. 
Y  -1  adrenocortical  cells  were  transfected  with  luciferase  reporter  constructs 
containing  pB1-1937  (lJ..!g)  with  various  combinations  of the  -1889  and  -1859 
alleles.  Construct  1,  referred to  as the  wildtype  (-1889  G  and  -1859  A),  is  most 
commonly  associated  with  the  CC/WtWt  and  TT/WtWt  CYP11B2  genotypes. 
Construct 4  (-1889 T  and -1859 G)  contains the alleles found in linkage with the 
CYP JJB2 TT/ConCon genotype.  Following transfection for 42 hours cells were then 
incubated with ACTH (1 J..!M)  for 6 hours.  Results are expressed as a percent of the 
basal reporter activity of  the wildtype (construct 1) and represent the mean± SEM of 
data from three independent experiments, each with an n of 3 to  9.  The results for 
each  construct  were  compared  to  the  appropriate  control  (basal  or  stimulated 
wildtype) using an unpaired 2-sample t test. 
* P <0.001 compared with G+A stimulated 
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Figure 6.5. Effects of the -1889 GIT  and -1859 AJG variants on transcriptional 
activity in response to dibutryl cAMP. 
Y  -1  adrenocortical  cells  were  transfected  with  luciferase  reporter  constructs 
containing  pB1-1937  (lf.!g)  with  various  combinations  of the  -1889  and  -1859 
alleles.  Construct  1,  referred  to  as  the wildtype  (-1889  G  and  -1859  A),  is  most 
commonly  associated  with  the  CC/WtWt  and  TT/WtWt  CYPJJB2  genotypes. 
Construct 4  (-1889 T  and -1859  G)  contains the alleles found  in linkage with the 
CYP  JJB2 TT/ConCon genotype.  Following transfection for 42 hours cells were then 
incubated with dbcAMP (lmM) for 6 hours.  Results are expressed as a percent of 
the basal reporter activity of the wildtype (construct  1)  and represent the mean ± 
SEM of  data from two independent experiments with ann= 3 and n = 6 respectively. 
The results for  each construct were compared to the appropriate control (basal or 
stimulated wild  type) using an unpaired 2-sample t test. 
No significant difference was observed between any of  the constructs stimulated with 
dbcAMP. 
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Figure 6.6. Effects of the -1889 G/T and -1859 A/G variants on transcriptional 
activity in response to Forskolin. 
Y  -1  adrenocortical  cells  were  transfected  with  luciferase  reporter  constructs 
containing  pBl-1937  (l~g) with  various  combinations  of the  -1889  and  -1859 
alleles.  Construct  1,  referred to  as  the  wildtype  (-1889  G  and  -1859  A),  is  most 
commonly  associated  with  the  CC/WtWt  and  TT/WtWt  CYP11B2  genotypes. 
Construct 4  (-1889 T and -1859 G)  contains the  alleles found  in linkage with the 
CYP  11 B2 TT/ConCon genotype.  Following transfection for 42 hours cells were then 
incubated with forskolin (10  ~M)  for 6 hours.  Results are expressed as a percent of 
the basal reporter activity of the wildtype (construct  1)  and represent the mean ± 
SEM of data from  three  independent experiments,  each with an n of 3 to  9. The 
results  for  each  construct  were  compared  to  the  appropriate  control  (basal  or 
stimulated wildtype) using an unpaired 2-sample t test. 
* P =  0.036 compared with G+A stimulated 
230 6.4.4  Transcription Factor Binding Sites 
Analysis of  the sequence surrounding the -1889 G/T and -1859 A/G polymorphisms 
revealed  that  they  disrupt  several  putative  transcription  factor  binding  sites. 
Comparison  of the  likelihood  scores  of the  identified  binding  elements  and 
investigation  of which  transcription  factors  were  most  likely  to  be  found  in 
steroidogenic tissues  suggested that the most likely binding sites were  an Sp 1 site 
encompassing residue -1889 and a half GRE  encompassing residue -1859 (figure 
6.7). 
6.4.5  Frequency  of -1889  GIT  and -1859  A/G  in  BRIGHT case-
controls 
The allele frequencies for both -1889 G/T (0.546/0.454 vs.  0.562/0.438) and -1859 
AIG (0.524/0.476  vs.  0.527/0.473)  were  almost  identical  in the  hypertensive  and 
normotensive  control  groups  (see  table 6.3).  The  alleles  of both -1889 G/T  and 
-1859 A/G were  in Hardy-Weinberg equilibrium  in both groups,  with  Chi-square 
values of 0.002 and 0.04 respectively in the hypertensive group and 3.79 and  1.04 
respectively in the control group. 
-1889 G  -1889 T  - 1859 A  -1859 G 
CASES  0.546  0.454  0.524  0.476 
CONTROLS  0.562  0.438  0.527  0.473 
Table 6.3. Allele frequencies of -1889 G/T and -1859 A/Gin the BRIGHT case-
control association study 
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Figure 6.7.  Map of the novel putative transcription factor binding sites in the 
hCYPllBl S'UTR.  The blue A and G represent the -1859 polymorphism and the 
red G and T represent the -1889 polymorphism. 
232 6.5  Discussion 
The two novel single nucleotide polymorphisms (SNPs) identified in the  5'UTR of 
CYP 11 B  1 at positions -1889 (G/T) and -1859 (A/G)  are  in linkage disequilibrium 
(LD) with the -344 CIT and intron conversion variants in CYP 11 B2.  These have the 
potential to  alter transcriptional regulation of the CYP 11 B  1 gene and therefore may 
account for the observed biochemical phenotype of  decreased 11 P-hydroxylation. 
This  study  investigated  the  effects  of the  -1889  G/T  and  -1859  A/G  SNPs  on 
CYP 11B1  gene transcription in  vitro  using  a luciferase reporter  gene  system.  The 
variants at each locus were tested individually and in combination.  Their effects on 
basal  expression as  well  as  the  response  to  various  agonists  were  examined.  No 
significant difference was observed between any of the constructs' basal expression 
levels.  This  is  perhaps  not  surprising  as  a  previous  study  examining  the 
transcriptional regulation of human CYP 11 B1  gene  indicated that the  DNA region 
between -214 and -65 was sufficient for basal gene expression (Wang et al 2000). 
Regions upstream of this (up to -11 02bp) had no  effect on basal expression levels. 
Treatment with (Bu)2cAMP had no effect on the reporter gene activity of any of the 
constructs.  However, previous  studies report a lack of cell responsiveness to  this 
cAMP  analogue  in  some  Y  -1  cell  strains  (Clyne  et al  1996).  ACTH  is  the  main 
regulator  of  CYP 11 B1  expression  in  vivo.  It  stimulates  expression  of  the 
steroidogenic  enzymes  and  steroid  hormone  production through  activation  of the 
cAMP  signalling  pathway.  Forskolin  is  a  small  molecule  agonist  of adenylate 
cyclase which bypasses the ACTH receptor by binding directly to adenylate cyclase 
and increasing cAMP synthesis.  Compared to  'wild type' (-1889 G and -1859 A), 
the  construct  containing  the  -1889  T  and  -1859  G  alleles  halved  reporter  gene 
233 activity  m  response  to  the  agonists  ACTH  and  forskolin,  indicating  reduced 
transcription (see  figures  6.3  to  6.6).  The  individual base changes represented by 
constructs 2 and 3 (G + G or T + A)  also had a slightly reduced response to  either 
ACTH or Forskolin stimulation when compared to  wildtype but this  did not reach 
statistical significance.  This suggests there is an interaction between the -1889 T and 
-1859 G variants resulting in a reduced transcriptional efficiency.  This might occur 
if they are located within the binding sites of co-operative transcription factors (see 
below).  These  results  support the  urinary  steroid results  from  Chapter  5,  which 
indicated that the -1889 T and -1859 G alleles were  associated with an impaired 
11 P-hydroxylase  efficiency.  They  strongly  suggest  that  the  reduced  11 P-
hydroxylation associated with the  T  /Con haplotype in CYP  11 B2 is  due  to  linkage 
with the -1889 T and -1859 G variants in CYP IIBI. 
To  investigate  why  these  variants  are  important  for  transcriptional  regulation  of 
CYP II  B I, the sequence surrounding them was analysed computationally for putative 
transcription factor binding sites.  Several possible candidates were generated.  The 
most promising of these were a putative Sp1  (selective promoter factor  1)  binding 
site (-1891/-1882) and a half GRE (-1864/-1859) encompassing the -1889 G/T and 
-1859 A/G polymorphisms respectively.  Sp1  belongs to  a large  family  of protein 
factors  that  all  recognize  similar  sequences  and  have  similar  transactivation 
properties  (Hagen  et  al  1992;  Kingsley  &  Winoto  1992).  Sp 1  regulates  the 
transcription  of many  genes;  it  stimulates  the  cAMP-dependent  transcription  of 
steroidogenic  genes  including  bovine  CYP llAI  (P450scc),  human  StAR  gene, 
CYP I7 (P450cl7) and ferrodoxin (Lin et al2001; Liu &  Simpson 1997; Sugawara et 
al2000; Yeh et al2000).  Sp1  usually binds to the DNA sequence GGGGCGG with 
high  affinity  (Letovsky  &  Dynan  1989).  However,  variant  G-rich  sequences  that 
234 deviate  by  at  least  one  nucleotide  and  bind  Sp 1 with  lower  affinity  seem  to  be 
sufficient for steroidogenic transcription (Y eh et al 2000). 
The close proximity of the Sp1  binding site and the half GRE is of great interest as 
glucocorticoid  binding  sites  can  act  synergistically  with  binding  sites  for  other 
transcription factors,  including  Sp 1 (Schule  et al  1988;  Strahle  et al  1988).  The 
significance  of the  half GRE  is  unclear.  However,  as  mentioned  in  Chapter  1, 
steroid/GR complexes have been shown to bind composite GREs comprised of GRE 
and a binding site for another transcription factor such as AP 1 (Diamond et al 1990; 
Pearce &  Yamamoto 1993; Zhang et al 1991 ).  In these instances, it is thought that 
both DNA binding by the steroid/GR complex and protein-protein interactions with 
other  factors  are  required  to  determine  transcription.  Whether  a  half  GRE  is 
sufficient for  steroid/GR binding and whether the half GRE and the  Sp 1 sites  are 
close  enough  to  establish  an  interaction  remain  to  be  determined.  It will  be  of 
interest to  determine whether these putative transcriptional factor  binding sites  are 
capable of altering function.  Electrophoretic mobility shift assay experiments would 
determine  whether Sp 1 and a steroid/GR complex are  capable of binding to  these 
putative binding sites  and whether this binding is  disrupted by the presence of the 
-1889 T and -1859 G variants respectively. 
To  investigate the  role  of the  half GRE,  it  would be  interesting to  determine  the 
effect  of  the  synthetic  glucocorticoid,  dexamethasone,  on  the  reporter  gene 
expression of each of the  constructs.  This  would test whether the  presence of the 
-1859  G  variant  that  appears  to  disrupt  the  half GRE  alters  the  transcriptional 
response.  However, as  there  seems to  be  an  interaction between the  -1889 T and 
-1859 G variants following stimulation, the effect of dexamethasone on the response 
235 to  ACTH  or  forskolin  stimulation  should  also  be  tested.  It is  possible  that,  in 
response to stimulation, there is an increased activation of Sp 1.  Therefore, it would 
also  be  interesting to  investigate  the  effect  on  reporter  gene  expression,  for  each 
construct, of cotransfecting with an expression vector containing Sp 1.  The combined 
effect of cotransfecting with Sp 1 and incubating with dexamethasone in the absence 
or presence of ACTH should indicate whether there is  any interaction between the 
two proposed binding sites. 
11~-Hydroxylase  efficiency  is  mildly  impaired  in  subjects  with  essential 
hypertension compared to controls (Connell et al 1996; de  Simone et al 1985).  The 
-344 T  and  IC  conversion alleles  have  been  shown  to  occur  more  frequently  in 
hypertensive subjects, particularly those with a raised ARR (Lim et al 2002b  ).  As 
mentioned in Chapter 4,  the -344 CIT and IC  polymorphisms are also in LD  with 
other variants in CYP 11 B2 that may also alter the relationship between aldosterone 
and Ang II. 
To  determine  if the  CYP11B1  -1889  G/T  and  -1859  A/G  polymorphisms  are 
associated with hypertension,  their frequencies  were  compared in a  subset of the 
BRIGHT study with age  and sex matched controls (see table 6.2).  There was  no 
apparent difference in allele frequencies between the hypertensive and normotensive 
control  groups  for  either  polymorphism  (see  table  6.3).  This  may  indicate  that, 
although  they  may  account  for  the  intermediate  phenotype  of  reduced  11 ~­
hydroxylase efficiency, they are not directly associated with hypertension.  However, 
a more detailed analysis of a large case-control population using haplotype tags  is 
required to  evaluate  fully  the  contribution of the  CYP 11 B  locus  to  hypertension. 
Additionally,  a  more  detailed  stratification  of  sub-phenotypes  within  essential 
236 hypertension  will  be  required  before  the  contribution  of single  gene  loci  can be 
determined.  For example, it is possible that one or more of  the novel SNPs identified 
in CYP II  B2  have effects  on enzyme activity or expression, resulting in increased 
aldosterone  levels that have previously been associated with the T/Con haplotype. 
Recent reports that 10 to  15% of patients with essential hypertension have a raised 
ARR suggest that altered aldosterone regulation may be a relatively common feature. 
This  study  demonstrates  that  the  -1889  G/T  and  -1859  A/G  polymorphisms  in 
CYP 11 B  I  that associate  with reduced  11 ~-hydroxylase efficiency are  in LD  with 
those variants in CYP II  B2  that associate with higher aldosterone levels.  How the 
two effects are related requires further investigation. 
In  conclusion,  the  -1889  G/T  and  -1859  A/G  polymorphisms  in  the  5'UTR  of 
CYP II  B I  have significant effects  on  gene transcription.  This is  the  first time that 
single  nucleotide polymorphisms  in the  regulatory  region of CYP II  B I  have  been 
shown to have a major effect on gene transcription.  This study strongly suggests that 
the impaired  11~-hydroxylase efficiency previously associated with the -344 T and 
IC  alleles in CYP II  B2 is due to linkage with these two novel polymorphisms in the 
5' regulatory region of CYP II  BI. 
237 CHAPTER 7 
General Discussion 
238 Hypertension  and  cardiovascular  disease  are  maJor  human  health  issues  with 
important yet undefined genetic components.  In Chapter 1, the case was made that 
corticosteroids,  and  in  particular  aldosterone,  are  central  influences  in  these 
processes.  Aldosterone  can cause both hypertension and cardiac remodelling and 
recent  studies using the  ARR as  a screening tool  suggest that altered aldosterone 
regulation  may  be  a  relatively  common  feature  of essential  hypertension  (see 
sections  1.9.1,  1.10.2  and  1.16).  Moreover,  genetic  variants  in  the  aldosterone 
synthase,  CYP  11 B2,  gene  (-344  CIT  and  I  C)  correlate  both  with  increased 
aldosterone  levels  and  raised  blood  pressure  in  many  studies.  However,  these 
probably do  not explain either biochemical or clinical differences for  two  reasons. 
Firstly,  when  tested  in  vitro,  the  -344  CIT  polymorphism  did  not  influence 
aldosterone  synthesis.  Secondly,  the  biochemical  phenotype  most  consistently 
associated with these variants was altered 11 ~-hydroxylation efficiency, which draws 
attention to the homologous gene CYP llBI (see section 1.16.2).  It was plausible to 
suggest  that  the  association  of increased  aldosterone  levels  and  reduced  11 ~­
hydroxylase efficiency with the  -344  CIT and IC  variants is  indirect through other 
linked genetic variations.  The  studies  described in this thesis have  addressed this 
question.  Are  the  two  phenomena,  altered  aldosterone  levels  and  altered  11 ~­
hydroxylation,  separate  or  linked?  Polymorphic  variation  across  the  entire 
CYP JJB2/BI  region  was  evaluated.  The  functional  significance  of some  newly 
identified variations was tested.  Finally, preliminary evaluation of possible clinical 
importance was made. 
An important and unequivocal observation that can be  made from  these  studies  is 
that there is a high degree of sequence variation within the CYP II  B I and CYP II  B2 
genes.  Despite the potential this gives for many haplotypes, the degree of linkage 
239 disequilibrium is so great that most alleles fall within four common haplotypes.  This 
identified many polymorphic differences  in both genes that are  linked to  the  -344 
CIT  and IC  variants  in CYP 11B2.  Therefore,  if any  of these  polymorphisms  are 
functional, it is possible that they could explain the biochemical and clinical changes 
associated with these variants. 
The mutations identified in Chapter 3, within the coding region of CYP 11 B I,  had 
effects  on  biochemical  activity,  causing  either  increased  or  decreased  enzyme 
activity that in some cases was substrate specific.  Although attempts were made to 
determine the locations of these mutants within the protein these  were necessarily 
speculative.  If  the precise 3D crystal structure of 11 ~-hydroxylase was available, the 
specific  effects  of  the  different  mutants  could  be  valuable  in  deciphering 
structure/function relationships. 
No  clinical associations  (with hypertension or ARR)  could be made in this  study. 
This could imply either that they are not relevant or that the study was not of  a design 
to  identify a relationship.  The  study could be  improved and developed in several 
ways. Firstly, only the coding regions of CYP II  BI were screened.  Further mutations 
could  exist in the  untranslated regions,  either 5' or  3' of the  gene,  or  located at 
exon!intron  boundaries  that  may  alter  splicing,  which  might  associate  with 
hypertension and a raised ARR. These studies are currently underway.  Secondly, the 
mutation detection was performed by SSCP.  Whilst a useful and sensitive technique, 
it has  certain disadvantages.  The  method can be prone to  both false  positive and 
false negative results.  In this instance, the false positives are less of a problem as the 
presence of  mutations was confirmed by sequencing.  However, false negative results 
mean  that  important  mutations  may  have  been  overlooked.  The  more  recent 
240 introduction of very stringent, high throughput sequencing methods would remove 
the risk of false positive or negative results and also reduce the labour intensity if  the 
study were to be repeated.  Finally, the T variant of the -344 CIT polymorphism of 
the  adjacent  CYP 11 B2  gene  has  previously  been  found  in  higher  frequency  in 
hypertensive  subjects  with a raised ARR but this  was  not the  case  in the  current 
study.  An important point is  that the investigation outlined in Chapter 3 was  not 
powered to look for such an association; the study subjects were chosen on the basis 
of phenotype not genotype.  It is therefore more likely that patients selected on the 
basis of genotype  associated with a raised ARR might identify specific  mutations 
that are linked to the development of  this type of  hypertension.  Therefore, the rest of 
the experimental work of this thesis focused on examining the linkage between the 
-344 CIT and IC variants and other polymorphisms in CYP 11 B2 and CYP 11 B  1 and 
their functional effects and clinical relevance. 
Many novel variants were identified in CYP 11 B2 that are linked to the -344 CIT and 
IC variants.  Most of  these were within the introns and 3'UTR of CYP 11B2 and their 
functional  effects  remain  to  be  determined.  Of  particular  interest  was  the 
identification of 7 SNPs within the  5'  regulatory region of CYP 11 B2.  Due to their 
potential to alter gene transcription, it is hypothesized that they may provide the link 
between  the  apparently  non-functional  -344  CIT  polymorphism,  increased 
aldosterone levels and hypertension with a raised ARR.  Analysis of their effects in 
vitro  using reporter gene constructs and investigation of their clinical  associations 
will determine if this is indeed the case.  However, these were not examined further 
in the present study. 
241 An important and new finding described in this thesis is  that the -344 CIT and IC 
variants in CYP II  B2 are in strong LD with many genetic variants in CYP II  B I.  Two 
novel and interesting polymorphisms were identified in the  5'  regulatory region of 
CYP IIBI at positions -1889 (G/T) and -1859 (A/G).  These were found to associate 
with an  impaired  11 ~-hydroxylase efficiency  in a hypertensive  population and  to 
significantly alter the transcriptional response of CYP IIBI to stimulation by ACTH 
or Forskolin in  vitro  (Chapters 5 and  6).  Therefore,  it seems plausible that it is 
these  polymorphisms  that account for  the  observed variations  in  11 ~-hydroxylase 
efficiency in vivo. These studies strongly suggest that the reduced 11 ~-hydroxylation 
previously associated with the  T/Con haplotype  in CYP IIB2 can be  explained by 
linkage  with  the  -1889  T  and  -1859  G  variants  in  the  5'  regulatory  region  of 
CYPIIBI. 
Evidence of a slightly reduced 11 ~-hydroxylase efficiency is a consistent finding in 
subjects with essential hypertension compared to normotensive controls.  However, 
preliminary investigation of the  -1889 G/T  and -1859 A/G polymorphisms in the 
BRIGHT case-control population failed to  show any association with hypertension 
(see  Chapter  5).  Therefore,  further  studies  are  required  to  determine  the  link 
between this biochemical phenotype and hypertension.  For example, a more detailed 
analysis of a much larger case control population with better phenotypic data would 
enable  determination of their  association with  specific  subgroups  of hypertension 
such  as  hypertensives  with  a  raised  ARR.  Also,  investigation  of an  association 
between the common CYP II  B haplotypes and hypertension would determine more 
fully the contribution of  this region to hypertension. 
242 These studies have provided an explanation, with good experimental evidence, for 
the  decreased  11 P-hydroxylation  efficiency  associated  with the  -344 CIT and  IC 
variants;  linkage  with  the  CYP IIBI  -1889  GIT  and  -1859  AIG  5'  UTR 
polymorphisms.  Can these variants also explain the link to raised aldosterone levels? 
One explanation for the increased aldosterone levels and blood pressure associated 
with the -344 CIT is a linkage with other CYP 11B2 5'  UTR polymorphisms.  Such 
polymorphisms  have  been  identified  here  but  whether  they  alter  aldosterone 
synthesis remains to  be  determined.  An alternative hypothesis that has  previously 
been  speculated,  is  that  altered  11-hydroxylation  efficiency,  that  is  genetically 
determined, might give rise to  a phenotype of mineralocorticoid hypertension as  a 
result of a long-term but very mild increase in ACTH drive to the adrenal cortex, to 
maintain normal plasma cortisol levels (see section 1.16.3). The results presented in 
this  thesis  support  this  theory;  analysis  of the  steroid  results  in  the  BRIGHT 
population according to  the -1889 GIT or -1859 AIG polymorphisms revealed no 
significant difference in urinary cortisol metabolite excretion between genotypes but 
an increase in THS excretion rate in the -1889 T and -1859 G groups (see Chapter 
5).  It has  been postulated that this  subtle  increase  in  ACTH drive  results  in  an 
enhanced aldosterone synthetic capacity of  the adrenal cortex and response to stimuli 
such as angiotensin II or potassium, leading to the phenotype of hypertension with a 
raised  ARR  (see  section  1.16.3).  To  investigate  this  hypothesis,  it  would  be 
interesting to compare the ACTH levels of untreated hypertensive patients separated 
according  to  either  CYP JJBJ  or  CYP JJB2  genotypes  or  the  main  CYP liB 
haplotypes.  The sensitivity of  their aldosterone response to an extremely low dose of 
exogenous  ACTH,  following  suppression of endogenous  levels  with the  synthetic 
243 steroid dexamethasone, would determine if there is  a link between ACTH drive and 
aldosterone synthesis.  However, the impact of a small decrease in 11 ~-hydroxylase 
efficiency could be  more fully  determined in an  animal model.  For example rats 
given a very low dose of the  11 ~-hydroxylase inhibitor, metyrapone, would enable 
determination of the full effects of this enzyme inefficiency on adrenal structure and 
function, corticosteroid levels and blood pressure. 
Therefore  although  an  explanation  for  the  paradoxical  link  between  CYP II  B2 
variants  and  11 ~-hydroxylase function  has  been provided,  the  causative  link with 
hypertension and a raised ARR remains to be determined. 
244 APPENDICES 
245 Appendix 1:  Nucleotide sequences of human CYPJJBJ and CYPJJB2 
Nucleotide Sequence 
The nucleotide sequences for human CYP llBJ and CYP  1JB2 were obtained from 
the Entrez Nucleotide database.  The accession numbers for these sequences are as 
follows: 
CYPlJBJ  CYP1JB2 
5' Flanking Region and exon 1  D10169  D10170 
Exon 1 and 2  M32863  D13752 
Intron 2  X85218  D13752 
Exons 3 to 8  M32878  D13752 
Ex  on 9 and 3  'UTR  M32879  M32881 
Exons are shown in bold and the untranslated regions and intron in lower case.  The 
oligonucleotides used for PCR and sequencing, listed in appendix 2, are indicated by 
their  name  above  the  relevant  highlighted  sequence.  Where  oligonucleotide 
sequences overlap the second sequence is underlined as  is the primer name.  Sense 
and antisense oligonucleotides are indicated by> and< respectively. 
CYPJJBJ 
BlS'UTR>  (B15'7-32 >) 
1  tcctt~QC:at cccttgtaag ttggattcct aagtatttta ttctctttga 
51  agcaattgtg aatgggagtt  cactcatgat ttggcctctc tgtttgtctg 
101  ttaagggtgt  ataagaatgc ttgtgatttt tgtacattga ttttgtatcc 
151  tagagcttgc  tgaagttgct tatcagctta aggagatttt  gggctgagac 
< B15'258-238 
201  aatggggttt tctagatata caatcatgtc  cgtctgccaa acagagacaa 
251  tttgacttcc tcttttccta attgaatacc ctttatttcc ttctcctgcc 
301  taattgccct ggccagaact  tccaacacta tgttgaatag gagtggtgag 
< B15'393-369  F81092 > 
351  agagggcatt cctgtcttgt  accagc~~t:c acagggaatg cttccagttt 
246 401  ttgaccattc agtatgatat tggctgtggg tttgccatag atagctctta 
451  ttattttgag atacgtccca tcaataccta atttattgag agtttttagc 
501  gtgaaggttg ttgaattttg tcaaaggcct tttctgcatc tattgagata 
551  atcatgtggt ttttgtcttt ggttctgttt atatgctgga ttacatttat 
F81093 > 
601  tgatttgcat atattgaacc agccttgcat  cccagggatg aagcccactt 
651  gat.catggtg gataagcttt ttgatgtgct gctggattcg gtttgccagt 
701  attttattga ggatttttgc atcaatgttc  atcaaggata ttggtctaaa 
751  attctctttt ttggttgtgt ctctgcccgg ctttggtatc aggatgatgc 
801  tggcctcata aaatgagtta gggaggattc cctctctttc tattgattgg 
F81094 > 
851  aatagtttca gaaggaatgg taccagttcc tccttgtacg tctggtataa 
901  ttcggctgtg aatccatctg gtcatggact ctttttggtt ggtaatctat 
951  tgattattgc cacaatttca gatcctgtta ttggtctatt cagagattca 
1001  acttcttact ggtttagtct tgggagagtg tatgtgtcga ggaatttatc 
1051  catttcttct agattttcta gtttatttgc gtagaggtgt  ttgtagtatt 
F81095 > 
1101  ctctgatggt agtttgtatt tctgtgggat  cggtggtgat  atccccttta 
1151  tcatttttta ttgcatctat ttgattcttc tctctttttt tctttattag 
1201  tcttgctagc ggtctatcaa ttttgttgat cctttcaaaa aaccagctcc 
1251  tggattcatt aattttttga agggtttttt gtgtctctat ttccttcagt 
1301  tctgcactga ttttagttat ttcttgcctt ctgctagttt tgaatgtgtt 
1351  tgctcttgct tttctagttc ttttaattgt gatgttaggg tgtcagtttt 
1401  ggatctttcc tgctttctct tgtgggcatt  tagtgctata aatttccctc 
1451  tacacactgc tttgaatgtg ttccagagat  tctggtatgc tgtgtctttg 
1501  ttctcgttgg tttcaagaac atctttattt ctgccttcat tttgttacgt 
1551  acccagtagt  cattcaggag caggttgctc agtttccatg taattgagcg 
F81097 > 
1601  gttttgagtg agtttcttaa tcctgagttc tagtttgatt gcactaaaat 
1651  ttttaaaaag taaaaaaaat acatgtggtt  taatacaatt  catgccaact 
1701  cattccctcg ttttttgcta taaaccttgc 
< Blprom-260(as) 
aaggagatga ataatccaag 
1751  gctcttggat aagataaggg ccccatccat cttgctcctc tcagccctgg 
1801  aggaggaggg  agagtccttt tcccctgtct acgctcatgc  acccccaatg 
F31463 > 
247 1851  agfCcctgcc  tccagccctg 
'~~~~-··  ...  -- "  acctctgccc  tcggtctctc  aggcagatcc 
1901  agggccagtt  ctcccatgac gtgatccctc  ccgaaggcaa  ggcaccaggc 
1951  aagataaaag gattgcagct gaacagggtg gagggagcat  tggaATGGCA  Exl 
<B9865 
2001  CTCAGGGCAA  AGGCAGAGGT  GTGCATGGCA  GTGCCCTGGC  TGTCCCTGCA 
2051  AAGGGCACAG  GCACTGGGCA  CGAGAGCCGC  CCGGGTCCCC  AGGACAGTGC 
2101  TGCCCTTTGA  AGCCATGCCC  CGGCGTCCAG  GCAACAGGTG  GCTGAGGCTG 
2151  CTGCAGATCT  GGAGGGAGCA  GGGTTATGAG  GACCTGCACC  TGGAAGTACA 
2201  CCAGACCTTC  CAGGAACTGG  GGCCCATTTT  CAGgtaaagc  cctccctggc 
2251  cctcgctgga acacccagtg ccctgccctt gctgcccagg  accctgccgg 
2301  gcactcagca ctgccattcc cagcaggtcc  cggcactctg catcctttgg 
2351  aagagggaag  atcgagcacg tgctgtctgt gcgctgcagg  gcagggcatg 
2401  tgcagagcaa atgggagctc  ggctgcagag  agggcaggac  tcagaggcac 
2451  tgaagttaag aggttccggg cagtcagcaa gagggcgttt  agctgtgaag 
2501  ccgctaatcc  aggagagggg  agggtggaca  ggagacactt tggattggga 
Y6265 > 
2551  ctgcagggtg gggccagcag ggactagacc  ccgtccagca gggcctcctg 
2601  cttggcccca  cagGTACGAT  TTGGGAGGAG  CAGGCATGGT  GTGTGTGATG  Ex2 
2651  CTGCCGGAGG  ACGTGGAGAA  GCTGCAACAG  GTGGACAGCC  TGCATCCCCA 
2701  CAGGATGAGC  CTGGAGCCCT  GGGTGGCCTA  CAGACAACAT  CGTGGGCACA 
< Y6266 
2751  AATGTGGCGT  GTTCTTGCTg  taagcggcga gctgagagct gggagcaggg 
2801  tggcagcctg gtgtaggggg gaggcgagag  aggcaggacc  caaaagcaca 
2851  tctgccctgg gcccctgtgg tgggcagtga  gggtgagcac  ccgacccaga 
2901  ggacggccat  tccgtggggt  cgtgtctgcc  ctgtggttgg ggaagcaggg 
2951  cgtggtggag aaatgggcac  gggcacctct  gcagagaaga  tgcagagcaa 
3001  tgagcccttc tgtgtagtga gaacccgctc  tgcaccaacc  ttggcggatg 
3051  ctttctcttg cggtctgggg actgtcttcc ataggtcaga  aaactgaggc 
3101  ctgagaaggt  actccactgg cccaggtcac  aggctgagta ctgagcctgt 
3151  ggttcgccgg ggccgcagcc  tccctcaggg  cgctcagggt  ccctgcagtc 
3201  ctggcaaacc  ttcctgatgg ggacagtccg gggcaggagg  caggtgggga 
Bl lnt2(3280) > 
3251  tgcaggtggc  tggtggctcc attgttctca gaagc:aaggc ac:gaggtg~g 
248 3301  gcggttgatg gcactgggga ggatgtttcc  tggccctgcg  agatgggcgg 
3351  ccgttggtca ggtgggcagg gagaggctga tgcttggagt  cagtcacctg 
3401  caggaatgtt gtcattagga cgggggaagg  actggacgag gatgtcacag 
3451  tggcgacagc  ccccactcca tggcaggagg  agaacgcttt  tgggaatagt 
3501  ggggtttagg taaaagggca  cccaagggtg ggggccttca  ctgaggctgg 
Bl Int2(3580) > 
3551  cctacagacg gacatctggg agggagtcag gacccaggaa ggcaagtcca  ..  ..  . ..  . 
3601  gaaggctggg  tgcacataac  ggaaggaagg  ggagcgcacc  tgtatgtgtg 
3651  tgtgtcttgc atctgtgcac atctgtgtgt ttctctgtac ctgcatttgc 
3701  acgtgttgtg tgtgcancgt gtgtgcacgt gtctgtgtgc atgtatgtgt 
3751  ggtgtgtgtg cacgagtgtc  tctgtgtgtg catgtgcagg  tgctggcatg 
3801  ggtgtagtgt  ctgtgcactt gtgtacatgt gtctcttcac acatggtgtt 
3851  gaggtcttgc  atgggcgcat  gtgagcatgt gcatcttctg cctgccatca 
'  ' 
Bl  Int2(3890)  > 
3901  ctgtcaacag ctcacagcca gctggacata aataaagctt  tgagttttgc 
3951  aggaatgtgg  ctgacagggg aaattcctcc  ccaccattcc  ctggggcatc 
4001  catggagccc  ccacgcactc  tggctgtagg  tgaggatggc  atgaagcaca 
4051  aagcttggtt tctgtcctgc  agaagatgca gacacttcag tcctgctgcc 
4101  ccagaggcac  tgtgcccagg gcagggaagg  gcggggagga  gagggcagcc 
4151  aggggctctc  ccctcaggac  actgtgtggg tgaggtgggc  aaagcttgac 
4201  aacaggggtc  agttcctttc ttgcagaaaa  tccctccccc  ctactacagg 
4251  gagggcccgc  atgggtgagg  tggtgccaga  cttggggcgc  caggtcccgg 
4301  gaatgacctc agttaccctg tcagcacctg  tgggcagaag  ctaccatctc 
4351  atccctgctt agacctgagt ggcctttgtc  cagcacctgg aggcsstctg 
4401  agaaaaggct  gcagctcgaa  cacaaacagg  cagcttctac  cagggccccc 
Y6263 > 
4451  agtcagctcc  ctgcaggccg attccccttg ggacaaggag  gatgggatac 
'  .  '  ······ 
4501  gggtcagggc  ctgtgtcttg ctggggcggc  ctcacaagct  ctgccctggc 
< N4020 
4551  ctctgtagGA  ATGGGCCTGA  ATGGCGCTTC  AACCGATTGC  GGCTGAATCC  Ex3 
4601  AGAAGTGCTG  TCGCCCAACG  CTGTGCAGAG  GTTCCTCCCG  ATGGTGGATG 
4651  CAGTGGCCAG  GGACTTCTCC  CAGGCCCTGA  AGAAGAAGGT  GCTGCAGAAC 
4701  GCCCGGGGGA  GCCTGACCCT  GGACGTCCAG  CCCAGCATCT  TCCACTACAC 
249 4751  CATAGAAGgt  gtgggccaca  tgggttgatc  cagcctcaga gaccctggag 
4801  tggccaggga  cggggatggg ggactgaagg  gagtgtgggg  aggcagccag 
B4250 > 
4851  gaggcccggt  tcccttgtgc tcagcagtgc atcctccccg  cagCCAGCAA  Ex4 
4901  CTTGGCTCTT  TTTGGAGAGC  GGCTGGGCCT  GGTTGGCCAC  AGCCCCAGTT 
4951  CTGCCAGCCT  GAACTTCCTC  CATGCCCTGG  AGGTCATGTT  CAAATCCACC 
5001  GTCCAGCTCA  TGTTCATGCC  CAGGAGCCTG  TCTCGCTGGA  CCAGCCCCAA 
5051  GGTGTGGAAG  GAGCACTTTG  AGGCCTGGGA  CTGCATCTTC  CAGTACGgtg 
5101  aggccaggga  cccgggcagt  gctatgggga  aggacaccat  cgggccccca 
<B4251 
5151  atttctccct ctccaccacc  cagtggggaa  tggaggccac  agggaggggt 
5201  cggggattcc  tcaccgtcct gccagggaga  ttggtgtgag gctggggctg 
5251  ggctgggctg  atccggagaa  tttgggatga gagcagggag acttggtgct 
M6642 > 
5301  gggctagctg gcaggaggag gacactgaag gatgtttccc  agcaccaaag 
5351  tctgagggct gcctcccgct  ccccggatag  GCGACAACTG  TATCCAGAAA  Ex5 
5401  ATCTATCAGG  AACTGGCCTT  CAGCCGCCCT  CAACAGTACA  CCAGCATCGT 
5451  GGCGGAGCTC  CTGTTGAATG  CGGAACTGTC  GCCAGATGCC  ATCAAGGCCA 
5501  ACTCTATGGA  ACTCACTGCA  GGGAGCGTGG  ACACGgtcag  gccggcaacc 
5551  agccccaccc  agagagggtg atgccaagcc  tgcctcccag gcactgcctg 
<M6643 
5601  ccaatgtcac acggcgccca cgtgtcccat  gcccaggcta  tgggccccac 
5651  atttcttact tgggattgtg atgtgataaa cacgtttgca ggttgccatg 
5701  gttggaatgg ggggttcctt tccttctgtg gaggactcag ggaaacgggg 
5751  tttggatggg cattaggatt tgaagtcttg ggctctgtcg tgctcagggt 
5801  atgcatgtct gcacccctca  cagggaggtt  gtcctgggag gggtgtcccg 
F42117 > 
5851  ggggctgagt  cctcctgtgc aaggtctgac cctgcagctg tgtctcctgc 
5901  agACGGTGTT  TCCCTTGCTG  ATGACGCTCT  TTGAGCTGGC  TCGGAACCCC  Ex6 
5951  AACGTGCAGC  AGGCCCTGCG  CCAGGAGAGC  CTGGCCGCCG  CAGCCAGCAT 
6001  CAGTGAACAT  CCCCAGAAGG  CAACCACCGA  GCTGCCCTTG  CTGCGTGCGG 
< F42299 
6051  CCCTCAAGGA  GACCTTGCGg  tgggtgctgg ctgaggcctc cctgtggccc 
6101  tggccctgct  ggagagtcag  cccccactgg gtggttgcag acagaatctg 
6151  ggctataaac  acctacccag cagccatcct gactgctctc  tcgcgtcaag 
250 6201  gacagggagc  tcttcttcct ctggaatccc  tcttcaacgc  cctggggatt 
6251  aacgtggggg catgtccttc tgcgctcggg gctgcttaag ttaggggagg 
6301  tttggccggg  ctcagcaggt  gcaaggaagc  acttcctaca cctgggcttc 
6351  ccatggatct gggacctctg cggggtcttc  ggtaggaagg  gtgcagagag 
Y6259 > 
6401  cacaggaacc  ccatcccagc  tgagaccctt  tctatggatg cccccacctc 
6451  cagGCTCTAC  CCTGTGGGTC  TGTTTCTGGA  GCGAGTGGCG  AGCTCAGACT  Ex7 
6501  TGGTGCTTCA  GAACTACCAC  ATCCCAGCTG  GGgtgagtga  gccccacacc 
<Y6260 
6551  ctcgagctga gaacctccct  ccccagtcat  tccctgatcc  ccgctctgct 
6601  ccgtccgcag  ACATTGGTGC  GCGTGTTCCT  CTACTCTCTG  GGTCGCAACC  Ex8 
6651  CCGCCTTGTT  CCCGAGGCCT  GAGCGCTATA  ACCCCCAGCG  CTGGCTAGAC 
6701  ATCAGGGGCT  CCGGCAGGAA  CTTCTACCAC  GTGCCCTTTG  GCTTTGGCAT 
6751  GCGCCAGTGC  CTTGGGCGGC  GCCTGGCAGA  GGCAGAGATG  CTGCTGCTGC 
6801  TGCACCATgt  gagcaggccc  gggctgggga  ggggcctggg  cggggtctgg 
6851  gcagcatggg cggggcttga gcaatgtggg actggcctcg gcagagtggg 
6901  agtggcctgc atgtttcctg gactgggcag  agcgggtact  gggagaacct 
6951  gggccaggtt  gaggctgtgt  aggtcctggg caggagttgg tatggtgagg 
7001  agcgtaccat  ctgggtgagg ttgctgctaa accgggtcag  gtgggaactg 
7051  ggggaagtcg ggtggagcct  gtacaggata gtggggcttg ggcaatacct 
7101  gggctggatg aattctgggc  ctgggctgta aggtggggct  ggtcaggaat 
M6635 > 
7151  gaaacaggtt  ggaggccagg  ctgctgttcc cccttcagca taatctctgc 
7201  aactttgagg gtctgagaag gctgcaccac  gtgcatgggc  tgcggaccaa 
7251  gccagatgga  aacccggctt  ctgtcctagG  TGCTGAAACA  CCTCCAGGTG  Ex9 
7301  GAGACACTAA  CCCAAGAGGA  CATAAAGATG  GTCTACAGCT  TCATATTGAG 
< B1Exon9(as) 
7351  GCCCAGCATG  TGCCCCCTC9  TCACCTTCAG .. AGCCATCAAC  TAAtcacgtc 
7401  tctgcaccca gggtcccagc  ctggcaccag cctccctttc tgcctgaccc 
7451  caggccaccc ctcttctctc ccacatgcac  agcttcctga gtcacccctc 
7501  tgtctaacca gccccagcac  aaatggaact  cccgagggcc  tctaggacca 
7551  gggtttgcca ggctaagcag caatgccagg gcacagctgg ggaagatctt 
7601  gctgaccttg tccccagccc  cacctggccc  tttctccagc  aagcactgtc 
251 7651  ctctggcagt  ttgcccccat ccctcccagt  gctggctcca ggctcctcgt 
7701  gtggccatgc  aagggtgctg tggttttgtc ccttgccttc ctgcctctag 
7751  tctcacatgt ccctgttcct cttcccctgc cagggcccct  gcgcagactg 
7801  tcagagtcat  taagcgggat  cccagcatct  agagtccagt  caagttccct 
7851  cctgcagcct gccccctagg cagctcgagc  atgccctgag  ctctctgaaa 
< Bl3'UTR+500 
7901  gttgfcgccc i:ggaataggg  tcctgcaggg tagaataaaa aggcccctgt 
'  ,- "  .,~  ''  " 
7951  ggtcacttgt  cctgacatcc ccattttcaa gtgatacaac  tgagtctcga 
8001  gggacgtgtg  ttccccagct gatcgtgtca gcctcatgcc  cctggcctca 
8051  tctttcatgg accaggcctt  gttccaggag  tgggcgttgg gtcctctgct 
8101  tcctgtgctg tcccctgggg aaggtcccaa ggatgctgtc  aggagatgga 
8151  agagtcatgt  ggggtgggaa  cctggggtgt ggttccagaa atgtttttgg 
8201  caacaggaga gacaggattg ggccaacaag gactcagacg agttttattg 
8251  actattctct gaca 
CYPJJB2 
T8303D > 
1  Gaai:tctgca tcctgtgaaa ttatccttca aaagtgaaca taaatatttt 
51  ctcaggtaaa  taaaaattga ggggattcgc  tgccaataga actgacttgc 
101  cagaaatgtt ttttaaaagt tctgcagaga gaaagaaaat  gatacaggtc 
151  agcaaccctg  agctacataa agaaaggaag  agcatttcag aaggaatcag 
201  taaagagaaa atgaagtctt ttattttttc ttaatcttaa ttgatctaag 
251  agtttgctaa aacaaaacaa  caacaataaa aataggccgg gcgcggtgac 
301  tcaccacacc  tgtaatccca gcactttggg aggccgaggt  gggcagatca 
351  cctgaggtca ggagttcgag actagcctgg ccaacacggt  gaaaccccgt 
401  ctctactaaa aatacaaaaa  ttagctgggc  gtggtggtgg cacatgcctg 
451  taatcccagc  tacttgggag gctgaggcgg gagaattgct  tgaacccggg 
501  agacagaggt  cgcagtgagc  cgagatcaca ccattgcact  ctagcctggg 
551  cgacagagtg agactctgtc  tcaaaaataa ataaataaat aaataaataa 
601  ataataaaaa taaataaata aaagccagaa agtgtatttg atgatcatag 
252 651  ttatgtatat gtgaaatgaa ggacagcaat  gatgcaaggg atgggtgagt 
701  ggaattaaaa atatcttatt atttatttat tttgagatgg agtcttgctt 
751  tgctgcccag gttggagtgc  agtgggatga tctcaactca ctgcaacctc 
801  cgcctccttg attcaagcat tcatcttgac tcagcctgct  gagaagccga 
851  gattacaggc  atgcgccacc  acacctggct aattttgtat ttttagtaga 
901  gacagggttt  tgccatgttg gccaggctgg tctcgaactc  ctgacctcag 
951  gtgatccacc  tgcatcagcc  tcccaaagtg  ctgggatgac  agacatgagc 
1001  cactatgccc  agcctaagaa tatctgatga ttataaagtg cttgcattac 
1051  ctctgaagct gtatagtgtt atatgaaggt  ggagttggag agatgagttt 
1101  taagcgtata  ttgcaaactc  tagggcaacc  actaaagaag  tgagacccag 
1151  cctctagaaa aaaaaaaaaa  aaaggaaatt  agctatcaag ccacgaaaag 
1201  aaatggagga  accttaaacg catattacta actgagatac gtcactttga 
1251  aaaggctaca  aacggtgtca ttccaactat acaacatttt ggaaaaggcc 
1301  aaagcatggt  gatgataaaa aagatcggag atgtcaggga ctggggcagg 
1351  agggatgagc  aggcagagca  caggttttct tttcctcttt ttaagacagt 
1401  gaaaatactc  ctaggatcct  gcaaggaggg atacaaatta catacatttg 
1451  tcaaaaccca cagcatgttg accaccagga  ggagacccca tgtgactcca 
1501  ggaccctggt  tgataacaac  gtatcgagat tcctcacatg gaaccagtgc 
1551  gctcctgtgg tggagggtgt  acctgtgtca gggcaggggg  tacgtggaca 
1601  ttttctgcag tttttgatca attttgcaat gaactaaatc  tgtggtataa 
1651  aaataaagtc  tattaaaaga atccaaggct ccctctcatc tcacgataag 
1701  ataaagtccc catccatttt actcctctca gccctggaga  aaggagaggc 
1751  caggtcccac  caccttccac  cagcatggac  ccccagtcca gaccccacgc 
1801  cttttctcag catcctcaga ccagcaggac  ttgcagcaat ggggaattag 
1851  gcacctgact tctccttcat ctacctttgg ctgggggcct  ccagccttga 
1901  ccttcgctct gagagtctca ggcaggtcca gagccagttc  tcccatgacg 
1951  tgatatgttt ccagagcagg ttcctgggtg agataaaagg atttgggctg 
2001  aacagggtgg  agggagcatt  ggaATGGCAC  TCAGGGCAAA  GGCAGAGGTG  Exl 
2051  TGCGTGGCAG  CGCCCTGGCT  GTCCCTGCAA  AGGGCACGGG  CACTGGGCAC 
253 2101  TAGAGCCGCT  CGGGCCCCTA  GGACGGTGCT  GCCGTTTGAA  GCCATGCCCC 
2151  AGCATCCAGG  CAACAGGTGG  CTGAGGCTGC  TGCAGATCTG  GAGGGAGCAG 
2201  GGTTATGAGC  ACCTGCACCT  GGAGATGCAC  CAGACCTTCC  AGGAGCTGGG 
2251  GCCCATTTTC  AGgtaaagcc  ctccctggcc  ctcgctggga acacccagat 
2301  ccctgcccct  gctgcccagg accctgccag gcactcagca ctgccattcc 
2351  cagcaggtcc  cggcactctg catcctttgg aggatgggga  aggagtgcag 
2401  cacatgctgg tctgtggtgc  tgccagggca  ggggatagtg  cagagaaaac 
2451  cccagctcac  tgcagagagg  gcaggactca gaagcactaa  agttgaaagg 
2501  ttccagggag  ccagcaggag ggctttagct  gtgaagccgc  taatccagga 
2551  gcagggaggg  tggacaggag acactttgga ttgggactgc  agggtggggc 
2601  cacgagggac  atgaccccgt  ccagcagggc  ctcctgcttg gccccacagG 
2651  TACAACTTGG  GAGGACCACG  CATGGTGTGT  GTGATGCTGC  CGGAGGATGT  Ex2 
2701  GGAGAAGCTG  CAACAGGTGG  ACAGCCTGCA  TCCCTGCAGG  ATGATCCTGG 
2751  AGCCCTGGGT  GGCCTACAGA  CAACATCGTG  GGCACAAATG  TGGCGTGTTC 
2801  TTGTTgtaag  cggcgagttg ggagctgaga gctgggagca gggtgggcag 
2851  cctgggtgta  ggggggaggc  gagagaggta ggacccaaaa gcacatctgc 
2901  cctgggcccc  tgtggtgggc  agtgagggtg agcacccggc  ccagaggacg 
2951  gccatcctgt  ggggtcgcgt  ctgcactgtg ggttggggaa  gcagggcggt 
3001  ggtggagaaa  tgggcacggg  cacctctgca gagaagacgc  agagcaatga 
3051  gcccttctgt gtagtgagaa  cccgctctgc  accaacctcg gcggctgctt 
3101  tctcttgcgg tctggggact  gtccttccca taggtcagaa aactgaggcc 
3151  ctgagaaggg gacttccact  ggcccaggtc  acaggctgag tgctgagcct 
3201  ggtgttcgcc  ggggccgcag  cctccctcag ggcgctcagg gtccctgcag 
3251  tcctggcaaa ccttcctgat ggggacagtc  cggggcagga  ggcaggtggg 
3301  gacgcaggtg gctggtggtt ccgttgttct cagaagcaag gcacaaggtg 
3351  gggcggttga  tggcactggg gaggatgttt cctggcccgt  ggagagggtg 
3401  gcgcctggtc  aggtgggcag  ggagaggctg atgcttggag tcggtcacct 
3451  gcagggatgt  tgtcattagg acgggggaag  gactggatga ggatgtcaca 
3501  gtggtgacag  cccccactcc  atggtaggaa  gggaacgcta  ttgggaatag 
254 3551  tggggtttag gtaaaagggc  acccgtgggt  cggggccttc  actgaggctg 
3601  gcctatagat gacatctggg agagagtcag gacccaggaa ggcaggtcca 
3651  ggaggctggg  tgcgcataat  ggaaggaagg  ggagcgctcc  tgtctgtgtg 
3701  tgtgtcttgc atctgtgcac  atgctgtgtg tttctctgta cctgcattgc 
3751  acatgtgtag tgtgtgcacg tgtcgtgtgt gaatgtatgt gtggtgtgtg 
3801  tgcacaagtg tctgtgtgtg tgcatgtgca ggtgccggca tgggtgtagt 
3851  gtttgtgcac acatgcacat gcgtctcttc acacatggtg ttgaggtctt 
3901  gcatgggcgc  acgtgtgcat gtgcatcttc tgcctgtcat  cactgtcaac 
3951  agctcacagc  agccagctgg acataaataa aggagttttg caggaatgtg 
4001  gctgacaggg gaaattcctc  cccaccattc  cctgggggca  tccatggagc 
4051  ccccacgcac  tctggctgtg ggtaggatgg catgaagcac  aaagcttggt 
4101  ttctgtcctg cagaagatat agatgcttca cagagacagc  agagcagatg 
4151  ccccagaggc  actgtgccca  gggcggggaa  gggtggggag  gagagggcag 
4201  ccaggggctc  tcccctcagg acactgtgtg ggtgaggtgg gcaaagcttg 
4251  acaacagggg  tcacctcctt  tcttggagaa aagccctacc  ctgttactac 
4301  agggagggcc  cgcatgggtg aggtggtgcc  agacttgggt  cgccaggtcc 
4351  cgggaatgac  ctcagttacc ctgtcagcac  ctgtgggcag aagctaccat 
4401  ctcatccctg cttagacctg agtggccttt gcccagcacc  tggaggccgc 
4451  tctgagaaaa ggctgcagct  cgaacacaaa  caggcagctt  ctaccagggc 
4501  ccccagtcag ctccctgcag gccgattccc  cttggggaca aggaggatgg 
4551  gatacgggtc  agggcctgtg  tcttgctggg gcggcctcac  aagctctgcc 
4601  ctggcctctg  tagGAATGGG  CCTGAATGGC  GCTTCAACCG  ATTGCGGCTG  Ex3 
4651  AACCCAGATG  TGCTGTCGCC  CAAGGCCGTG  CAGAGGTTCC  TCCCGATGGT 
4701  GGATGCAGTG  GCCAGGGACT  TCTCCCAGGC  CCTGAAGAAG  AAGGTGCTGC 
4751  AGAACGCCCG  GGGGAGCCTG  ACCCTGGACG  TCCAGCCCAG  CATCTTCCAC 
4801  TACACCATAG  AAGgtgtggg  ccatgcggga  aggtccagcc  ccagagaccc 
4851  tggagtggcc  agggatgggg  atggaggact  gaagggagtg  tggggaggca 
4901  gccaggaggc  ctggggctgc  cttgtgctca gcagtgcatc  ctccccgcag 
4951  CCAGCAACTT  AGCTCTTTTT  GGAGAGCGGC  TGGGCCTGGT  TGGCCACAGC  Ex4 
255 5001  CCCAGTTCTG  CCAGCCTGAA  CTTCCTCCAT  GCCCTGGAGG  TCATGTTCAA 
5051  ATCCACCGTC  CAGCTCATGT  TCATGCCCAG  GAGCCTGTCT  CGCTGGATCA 
5101  GCCCCAAGGT  GTGGAAGGAG  CACTTTGAGG  CCTGGGACTG  CATCTTCCAG 
5151  TACGgtgagg  ccagggaccc  gggcagtgct  atggggaagg gacaccatgg 
<  F33915 
5201  gggcccaatt tctccttctc caccacccag  tggggaatgg  aggccacagg 
5251  gaggggtcgg ggattcctca ccttcctgcc ggggagattg gtgcgaggct 
5301  ggggctgggc  tgggctgatc  cggagaattt gggatgagag  cagggagatt 
T2138  > 
5351  tgggtgtcgg ggcagtctgg  gcaggaggag  gacactgaag gatgcttccc 
5401  agcaccaaga  tctgagggct gtcccctgct  ccctggacag  GTGACAACTG  ExS 
5451  TATCCAGAAA  ATCTACCAGG  AACTGGCCTT  CAACCGCCCT  CAACACTACA 
5501  CAGGCATCGT  GGCGGAGCTC  CTGTTGAAGG  CGGAACTGTC  ACTAGAAGCC 
5551  ATCAAGGCCA  ACTCTATGGA  ACTCACTGCA  GGGAGCGTGG  ACACGgtcag 
5601  gccagcaacc  agccccaccc  agagagggtg  atgccaagcc  tgcctcccag 
5651  gcactgcctg ccaatgccac  acggcaccca  cgttccccat  ccccaggcta 
5701  caggccccac atttctgttg ccctcagcct  tccccctcct ttgttaaggg 
5751  atgagatttg  caggggaggg  gaaatgtgag ctccccctca catgagactg 
5801  agtttgcagt  tacctgtgtg gggatccatg  ctccaggctg gaagaaagtt 
5851  ggatgaggcc  ctggacacac  agcagctctg tccccactgg aaagctctgg 
5901  gtgtacaagg agaaggaggg  ttgagaggca  gctggaggac  tccactgggc 
5951  acccttccca gtgtgcccgg tcaccttggg ccagaaatgt  agatgcatgg 
6001  gagggcaggg  ttgtggggaa gacagcagca  caggctccag ccagtgcaga 
6051  ggggcctgtg ggtgcacagt ggggagaact  caatggaagc  agagggagct 
6101  ggggctccag  aactccctgg atgatgctga ggtgtggccc  cctgccctaa 
6151  tggtggctgt  gagaacccgc  cctgaagagg  ctgcagggga cctgggcctt 
6201  ggtggagatg ggggtcacct  ttccctgaag aagtcaggga  atctggccca 
6251  agtggtcatc  aaggtttcag atccggggtc  ccagggctct gtttttgctc 
6301  agggcatgga  tgtctccacc  cctcagaggg aggttgtcct gggaggggtg 
6351  tcccgggggc  tgagtcctcc  tgtgcaaggt  ctgaccctgc  agacatggct 
6401  tctgtagACA  GCGTTTCCCT  TGCTGATGAC  GCTCTTTGAG  CTGGCTCGGA  Ex6 
256 6451  ACCCCGACGT  GCAGCAGATC  CTGCGCCAGG  AGAGCCTGGC  CGCCGCAGCC 
6501  AGCATCAGTG  AACATCCCCA  GAAGGCAACC  ACCGAGCTGC  CCTTGCTGCG 
6551  GGCGGCCCTC  AAGGAGACCT  TGAGgtgggt  gctggctgag gcctccctgt 
6601  ggccctggcc  ccctgctgga gagcagcccc  cactgggtgg tggcagacag 
6651  aatctggggc  tgataaacag cgtcacccag cagcccattc ccctgcacct 
6701  gctcttcctc cccctcaagg acagggagct  cttcttcctc tggaatccct 
6751  cttcaacgcc  ctggggatta acgtggggca tgtccttctg cgctcggggc 
6801  tgcttaagtt aggggaggtt  tggctgggct  cagcaggtgc  aaggaagcac 
6851  ttcctacgac  ctgggcttcc  catggatctg ggacctctgc  ggggtcttcg 
6901  gtaggaaggg  tgctgagagc  acagggagcc  ccatccagct  gaggaccctt 
6951  tctgtggatg cccccacctc  cagGCTCTAC  CCTGTGGGTC  TGTTTTTGGA  Ex7 
7001  GCGAGTGGTG  AGCTCAGACT  TGGTGCTTCA  GAACTACCAC  ATCCCAGCTG 
7051  GGgtgagtga  gccccacacc  cctcgagctg agaacctccc  tccccagtca 
7101  ttccctgatc cctgctctgc  accgtccgca  gACATTGGTA  CAGGTTTTCC  Ex8 
7151  TCTACTCGCT  GGGTCGCAAT  GCCGCCTTGT  TCCCGAGGCC  TGAGCGGTAT 
7201  AATCCCCAGC  GCTGGCTAGA  CATCAGGGGC  TCCGGCAGGA  ACTTCCACCA 
7251  CGTGCCCTTT  GGCTTTGGCA  TGCGCCAGTG  CCTCGGGCGG  CGCCTGGCAG 
7301  AGGCAGAGAT  GCTGCTGCTG  CTGCACCACG  TAAGCAGGCC  TGGGGGCGGG 
7351  GGCGGGACCT  GGGCAGCAGA  GGCGGGACCT  GCACACTGGG  GGCGGGGCTT 
7401  GCATGGTGTg  attgacacct gggaacagtg gatggggcct  tggttggttg 
7451  aggtcggcgt  gaccagggag gatctgtgct  gagcaagaca gggtaggatc 
7501  tgggtgaggt  tgcttctaaa cattgaaatg gggactaggg gagtggggtg 
7551  gagcctgtac  agaataatgg ggcttgggca agacctgggc  aggattcagt 
7601  ctgggcctgg  tccgcaaggt  ggggctggtc  agaaatggga  taggttgggg 
7651  cccaggctgc  tgctccccct tcagcataat  tgttgcacct gggacgatgg 
7701  gaggaagctg  ccccaggtcc  atgggctact  gaccaggcca  gatggaaacc 
7751  cagcctctgt  cctagGTGCT  GAAGCACTTC  CTGGTGGAGA  CACTAACTCA  Ex9 
B2  3'UTR  > 
7801  AGAGGACATA  AAGATGGTCT  ACAGCTTCAT  ATTGAGGCCT  GGCACGTCCC 
7851  CCCTCCTCAC  TTTCAGAGCG  ATTAACTAGt  cttgcatctg cacccagggt 
257 7901  cccagcctgg ccaccagctt  ccctctgcct gaccccaggc  cacctgtctt 
<  M6641 
7951  ct.ctcccacg tgcacagctt  cctgagtcac ccctctgtcc agccagctcc 
8001  tgcacaaatg gaactcccca gggcctccag gactggggct  tgccaggctt 
8051  gtcaaatagc  aaggccaggg  cacagctgga gacgatcttg ctggcagggc 
8101  ctggccttgt  ccccagcccc  acctggcccc  ttctccagca agcagtgccc 
8151  tctggacagc  ttgactctac tcctcccagc gctggctcca ggctcctcat 
8201  gaggccatgc  aagggtgctg tgattttgtc ccttgccttc ctgcctagtc 
8251  tcacatgtcc ctgtccctct  cgccctggcc  agggcctctg  tgcagacagt 
8301  gtcagagtca  ttaagcggga tcccagcatc  tcagagtcca gtcaagttcc 
8351  ctcctgcagc  ctgaccccag gcagctcgag catgccctga gctctctgaa 
8401  agttgtcacc  cagaaatacg atcctgcagg gtagactaaa aaggcccctg 
8451  tggtcactta tactgacaca ttttaagtga tacaactgag  tctcgagggg 
8501  cgtgtgttcc  ccagctgatc  atgtcagcct  catgccccag gcctcgtctt 
8551  tcatggacca ggtcttgttc aagcagcgag  tgttgggtcc  tctgcttcct 
8601  gagctgtccc  ctggaaaagg  tcccgaggat  gctgtcagga gatggaagag 
8651  tcatgtgggg tgggaacctg gggtgtggtt  ccagaaatgt  ttttggcaac 
8701  aggagagaca ggattgggcc  aacaaggact  cagatgagtt  tattgactca 
<  B2  3'UTR 
8751  ttcctctgga agatacgcag  c ........................  ctcccct 
9251  agtcagcaca tc 
258 Appendix 2:  Sequences of oligonucleotide primers 
In each case (s) indicated the sense primer and (as) indicated the antisense primer 
Ex on  SSCP Primer Sequence  Amp  Rest.  Fragment 
Size  Enzyme  Sizes (bp) 
(bp) 
s  5'-AATGAGTCCCTGCCTCCAGC-3' 
1  473  Xho11  49,260,164 
AS  5'-GAATGGCAGTGCTGAGTGCC-3' 
s  5'-TTTGGATTGGGACTGCAGGG-3' 
2  260  Hha1  77,183 
AS  5'-CCCACCCTGCTCCCAGCTTC-3' 
s  5'-TGGCCACTCCAGGGTCTCTG-3' 
3  349  Hha1  115' 234 
AS  5'-CTGCAGGCCGATTCCCCTTG-3' 
s  5'-CCTTGTGCTCAGCAGTGCAT-3' 
4  306  Stu1  210,96 
AS  5'-GTGGTGGAGAGGGAGAAATT-3' 
s  5'-AGGAGGACACTGAAGGATGTT-3' 
5  312  Rsa1  183,189 
AS  5'-GACACGTGGGCGCCGTGTGAC-3' 
s  5'-TCTGACCCTGCAGCTGTGTCT-3' 
6  224  N/A  224 
AS  5'-AGGGCCACAGGGAGGCCTCA-3' 
s  5'-AATGACTGGGGAGGGAGGTT-3' 
7  147  N/A  147 
AS  5'-TGGATGCCCCCACCTCCAGG-3' 
s  5'-CCCTCGAGCTGAGAACCTCC-3' 
8  262  Hae111  119,143 
AS  5'-CCAGTCCCACATTGCTCAAG-3' 
s  5'-CTGTTCCCCCTTCAGCATAAT-3' 
9  5'-GAGACGTGATTAGTTGATGGC-3'  224  N/A  224 
AS 
Table 1.  SSCP sense (S)  and  antisense (AS)  primer sequences, amplicon  sizes 
(Amp size) and restriction digests 
259 CYP11B1 MUTATIONS 
Amino 
Sequence  Ex  on  acid 
Change 
1  R43Q  Sense  5'-GAA.  GCC  ATG  CCC  CAG  CGT  CCA  GGC  AA.C-3' 
Antisense  5'-GTT  GCC  TGG  ACG  CTG  GGG  CAT  GGC  TTC-3' 
2  L83S  Sense  5'-CAG  GTA  CGA  TTC  GGG  AGG  AGC  AGG  CAT  G-3' 
Antisense  5'-CAT  GCC  TGC  TCC  TCC  CGA  ATC  GTA  CCT  G-3' 
2  H125R  Sense  5'-GAC  ACC  ATC  GTG  GGC  GCA  AA.T  GTG  GCG  TGC-3' 
Antisense  5'-GCA  CGC  CAC  ATT  TGC  GCC  CAC  GAT  GTT  GTC-3' 
3  P135S  Sense  5'-CTT  GTT  GAA.  TGG  GTC  TGA  ATG  GCG  CTT  C-3' 
Antisense  5'-GAA.  GCG  CCA  TTC  AGA  CCC  ATT  CAA.  CAA.  G-3' 
3  Fl39L  Sense  5'-GGC  CTG  AA.T  GGC  GCC  TCA  ACC  GAT  TGC  G-3' 
Antisense  5'-CGC  AA.T  CGG  TTG  AGG  CGC  CAT  TCA  GGC  C-3' 
3  L158P  Sense  5'-GTG  CAG  AGG  TTC  CCC  CCG  ATG  GTG  GAT  G-3' 
Antisense  5'-CAT  CCA  CCA  TCG  GGG  GGA  ACC  TCT  GCA  C-3' 
3  L186V  Sense  5'-GGG  GAG  CCT  GAC  CGT  GGA  CGT  CCA  GCC-3' 
Antisense  5'-GGC  TGG  ACG  TCC  ACG  GTC  AGG  CTC  CCC-3' 
3  T196A  Sense  5'-CAG  CAT  CTT  CCA  CTA  CGC  CAT  AGA  AGC  CAG  C-3' 
Antisense  5'-GCT  GGC  TTC  TAT  GGC  GTA  GTG  GAA.  GAT  GCT  G-3' 
Table 2.  Primers for site-directed mutagenesis 
SEQUENCING PRIMERS 
Name  Ex  on  Sequence 
V6776  pCMV4 (s)*  5'TAG  TGA  ACC  GTC  AGA  ATT  G  3' 
V6777  pCMV4 (as)*  5'TAG  AGG  ACA  CTA  GTC  AGA  C  3' 
N4019  Exon 2 (s)  5'AGA  CAA.  CAT  CGT  GGG  CAC  AAA.  TG  3' 
* pnmers flankmg either side of  the pCMV  4 clomng site 
Table 3.  Sequencing primers for pCMV4-Bl wildtype and mutant constructs 
260 Oligonucleotide Seq (5' -3') 
HBl sense  TGC  GCG  TGT  TCC  TCT  ACT  CT 
HB 1 antisense  GTG  CAG  AGA  CGT  GAT  TAG  TTG  ATG 
HUMBIFL  TAC  AGC  TTC  ATA  TTG  AGG  CCC  AGC  A-FL 
HUMBILC  LC-TTC  CCC  CTC  CTC  ACC  TTC  AGA  GC 
FL, Fluorescein; LC, LightCycler Red705 dye. 
Table 4:  Lightcycler primers and probes for QRT  -PCR 
Primer  Sequence  PCR 
B15'UTR (s)  5 ~ -TCC  TTC  GCA  TCC  CTT  GTA  GTA  AGT  T- 3~  Bl  5' 
B1Exon9 (as)  5 ~-TAG TTG  ATG  GCT  CTG  AAG  GTG  A- 3~  to  Ex9 
M6635 (s) 
5~-CTG TTC  CCC  CTT  CAG  CAT  AAT- 3~  Bl 
B13'UTR+500 (as) 
5~-CTA TTC  CAG  GGC  GAC  AAC  TTT- 3~  3'UTR 
T8303D (s) 
5~-GAA TTC  TGC  ATC  CTG  TGA  AAT  TAT  c- 3~  B2  5' 
F33915 (as)  5 ~ -GTG  GTG  GAG  AGG  GAG  AAA  TT- 3~  to  Int4 
T2138 (s)  5 ~ -ATT  TGG  GTG  TCG  GGG  CAG  TCT-3~  B2  Ex5 
M6641 (as) 
5~-CTG TGC  ACG  TGG  GAG  AGA  AGA-3~  to  Ex9 
B2 3'UTR (s)  5 ~-ATA TTG  AGG  CCT  GGC  ACG  TC- 3~  82 
B2 3'UTR (as) 
5~-GAT GTG  CTG  ACT  AGG  GGA  G- 3~  3'UTR 
Table  5.  Primer  pairs  for  PCR  amplification  of the  entire  CYPJJBJ  and 
CYPJJB2 genes 
261 CYPJJBJ SEQUENCING PRIMERS 
Primer  Ex  on  Sequence 5'  - 3' 
B 1Prom-1750(as)  5'  AAG  TCA  AAT  TGT  CTC  TGT  TTG 
F81092 (s)  5'  CAC  AGG  GAA  TGC  TTC  CAG  TTT  TTG 
F81093 (s)  5'  CCA  AGG  GAT  GAA  GCC  CAC  TTG  AT 
F81094 (s)  5'  AAT  GGT  ACC  AGT  TCC  TCC  TTG  TAC 
F81095 (s)  5'  CTC  TGA  TGG  TAG  TTT  GTA  TTT  CTG  T 
F81097 (s)  5'  TAA  TCC  TGA  GTT  CTA  GTT  TGA  TTG  C 
B9865 (as)  5'  CTG  CCT  TTG  CCC  TGA  GTG  cc 
F31463 (s)  1  AAT  GAG  TCC  CTG  CCT  CCA  GC 
Y6266 (as)  1  CCC  ACC  CTG  CTC  CCA  GCT  CT 
Y6265 (s)  2  TTT  GGA  TTG  GGA  CTG  CAG  GG 
Bllnt2 (3280) (s)  Int2  AGA  AGC  AAG  GCA  CGA  GGT  GG 
Bllnt2 (3580) (s)  Int2  GGA  CCC  AGG  AAG  GCA  AGT  CCA 
B1Int2 (3690) (s)  Int2  GGC  TGC  CAT  CAC  TGT  CAA  CA 
N4020 (as)  Int2  TTC  AGC  CGC  AAT  CGG  TTG  AAG 
Y6263 (s)  3  CTG  CAG  GCC  GAT  TCC  CCT  TG 
B4251 (as)  3  GTG  GTG  GAG  AGG  GAG  AAA  TT 
B4250 (s)  4  CCT  TGT  GCT  CAG  CAG  TGC  AT 
M6643 (as)  4  GAC  ACG  TGG  GCG  CCG  TGT  GAC 
M6642 (s)  5  AGG  AGG  ACA  CTG  AAG  GAT  GTT 
F42299 (as)  5  AGG  GCC  ACA  GGG  AGG  CCT  CA 
F42117 (s)  6  TCT  GAC  CCT  GCA  GCT  GTG  TCT 
Y6260 (as)  6  AAT  GAC  TGG  GGA  GGG  AGG  TT 
Y6259 (s)  7/8  TGG  ATG  CCC  CCA  CCT  CCA  GG 
M6635 (s)  9  CTG  TTC  CCC  CTT  CAG  CAT  AAT 
B1Ex9as (as)  9  TAG  TTG  ATG  GCT  CTG  AAG 
Bl3'UTR+500 (as)  3'  CTA  TTC  CAG  GGC  GAC  AAC  TTT 
Table 6.  Primers for the Sequencing of the entire CYPJJBJ gene 
262 Primer  Sequence 
Sense (B15'UTR)  5'-TCC  TTC  GCA  TCC  CTT  GTA  AGT  T-3' 
PCR 1  Antisense  (B 1  prom-260)  5'-CTT  GGA  TTA  TTC  ATC  TCC  TTG  CAA  GG-3' 
Sense (B15'7-32)  5'-GCA  TCC  CTT  GTA  AGT  TGG  ATT  CCT  AA-3' 
PCR2  Antisense (B 15'3 93-369)  5'-AAG  CAT  TCC  CTT  TGA  AAA  CTG  GTA  C-3' 
Table 7.  Nested PCR primers for amplifying the region surrounding the  -1889 
G/T and -1859 A/G polymorphisms 
The polymorphisms were then genotyped by sequencing using the primer B15'258-
238 (see table 5). 
Base 
Change  SequencePrimeSequence 
SNP 
-1889  (S)  5'-CTC  TGT  TTG  TCT  GTT  AAG  TGT  GTA  TAA  GAA  TGC 
Gto T  (AS)  5'-CAC  AAG  CAT  TCT  TAT  ACA  CAC  TTA  ACA  GAC 
-1859  (S)  5'-GCT  TGT  GAT  TTT  TGT  ACG  TTG  ATT  TTG  TAT 
A toG  (AS)  5'-GTC  TCA  GGA  TAC  AAA  ATC  AAC  GTA  CAA  AAA 
Table 8.  Site-directed mutagenesis primers for CYPJJBJ 5'UTR 
polymorphisms 
AAA 
CCT 
TCA 
TTG  TG-3' 
CAG  AG-3' 
GAG  AC-3' 
CAA  GC-3' 
263 Appendix 3:  Reagents 
Unless otherwise stated all standard chemicals and reagents were purchased from 
Sigma (Sigma-Aldrich Chemical Co. Ltd, Poole, Dorset, UK). 
Bacterial media and plates 
LB medium  lOg tryptone, 5g yeast extract, lOg NaCl to a final litre with 
deionised water, adjust to pH 7.0 with NaOH. Autoclave 
LB agar  1  Og NaCl, 1  Og Tryptone, 5g yeast extract, 20g of agar, adjust 
to pH 7.0 with NaOH. Autoclave 
LB-amp plates  1 litre of  LB agar, add 400 Ill of  filter-sterilized ampicillin 
Buffers 
lOmM Tris-HCl, lmM EDTA, pH 7.5 
40mM Tris-acetate, lmM EDTA, pH 8.0 
TE buffer 
TAE buffer 
Loading dye  1.5g Ficoll, 25mg Bromophenol Blue, 25mg Xylene Cyanol 
Site directed mutagenesis 
Quick change site-directed mutagenesis kit (Stratagene) 
Pfu DNA polymerase (2.5U/!ll) 
1  OX reaction buffer 
Dpn I restriction enzyme (1 OU/Ill) 
Reagents not supplied in the kit: 
Primers (see table 2 and 8, appendix 2) 
NZY+broth  16g ofNZM broth, 5g of  yeast extract, 12.5ml 
of 1M MgC12, 12.5ml of 1M MgS04, lOml of 
2M filter-sterilized glucose solution per litre. 
LB-amp agar plates  (see above). 
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